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The mu opioid receptor (MOPr), a G protein-coupled receptor (GPCR), is the 
pharmacological site of action of morphine and related opioid narcotic agonists that bind to the 
orthosteric site on MOPr, evolutionarily developed to accommodate the endogenous opioid 
peptides.  MOPr activation results in analgesia but also causes a number of unwanted effects 
including constipation, respiratory depression, tolerance, and euphoria leading to a high addictive 
liability. In contrast, small molecule positive allosteric modulators of MOPr (MOPr-PAMs) bind 
to alternative sites on the protein to modulate receptor function. MOPr PAMs represent a 
potential avenue for pain relief with a better therapeutic profile.  
Studies described in this thesis seek to understand the mechanism of action of MOPr 
PAMs. The results show that MOPr-PAMs promote an active state of MOPr by disruption of the 
Na
+
 binding site on the receptor, a mechanism that may be applicable to other GPCRs. 
Furthermore,this active state can be captured and measured by the camelid antibody Nb39 
providing a novel method for quantifying orthosteric and allosteric agonist efficacy.  The work 
also demonstrates that the allosteric site on MOPr can accommodate structurally diverse ligands, 
and is somewhat conserved on the related delta opioid receptor.  Lastly, this thesis explores the 
effects of chronic allosteric enhancement of MOPr signaling on the downstream processes of 












Opium, the dried latex obtained from the papaver somniferum plant, has been used by 
humans for spiritual and medical uses for thousands of years (Brownstein, 1993) and contains 
dozens of active alkaloids, including codeine, thebaine, and morphine (Kalant, 1997). Morphine, 
the primary molecule responsible for opium’s actions, makes up at least 10% of opium by weight 
and the first reported extraction of morphine occurred in the early 1800’s by Friedrich 
Sertürner.(Sertürner,1805; Frick et al., 2005). Presently, medical use of opioid ligands exceeds 
250 million prescriptions per year in the United States (Paulozzi et al., 2014). The most 
commonly prescribed opioids include morphine and its semisynthetic analogues oxycodone and 
hydrocodone (IMS 2011). Though these drugs are effective at causing analgesia, they have a 
number of unwanted side effects including respiratory depression, suppression of gastric 
motility, and nausea (Kromer, 1988; Dhawan et al., 1996; Yaksh TL et al., 2011). In addition, 
long-term administrations of opioids results in tolerance and dependence, with drug cessation 
causing a withdrawal syndrome.   Appreciation for the pharmacological effects of morphine led 
to in depth research about how and where morphine acts. Over 150 years after the isolation of 
morphine, the endogenous opioids and their receptors were discovered, opening the door for 
further structure-activity-relationship (SAR) studies of opioid ligands (Hughes et al., 1975; 
Mains et al., 1977; Goldstein et al., 1979; Chavkin and Goldstein, 1981). 
 
Opioid receptors   
Clinically used opioids exert their analgesic and side effects by activating the mu opioid 
receptor (MOPr), a class A G protein-coupled receptor (GPCR) (Matthes et al., 1996). There are 
three other members of the opioid receptor family: delta (DOPr), kappa (KOPr) and the 





review see (Waldhoer et al., 2004)). In particular, MOPr is expressed throughout the central 
nervous system with enrichment in the periaqueductal gray region, nucleus accumbens, cerebral 
cortex, amygdala, and the nucleus of the solitary tract and is also highly expressed in the 
gastrointestinal tract. All clinically used opioids bind to the site where the endogenous opioid 
peptides bind, known as the orthosteric site (Fig 1.1). In addition to small morphine-like 
molecules from opium and their derivatives, MOPr binds endogenous peptide ligands that range 
from 5 amino acids (aa) (leucine-enkephalin and methionine-enkephalin) to the 31-aa peptide β-
endorphin (Fig 1.1).  
 
MOPr Structure 
The orthosteric site of MOPr has been well-characterized by X-ray crystallography, 
mutagenesis, and a rich structure-activity relationship library. The MOPr has been crystallized in 
both an inactive state in complex with the irreversible antagonist β-funaltrexamine (β-FNA) as 
well as in an active form in complex with the high efficacy agonist BU72 and the G protein 
mimetic Nb39 ((Manglik et al., 2012; Huang et al., 2015); Appendix A).  
To accommodate such a wide range of structurally dissimilar ligands, the binding pocket 
for MOPr is large in contrast to aminergic receptors like β2- adrenergic (β2AR) and muscarinic 
receptors (Rasmussen, DeVree, et al., 2011; Kruse et al., 2013). The binding of opioids involves 
a phenolic hydroxyl group that engages in a water-mediated interaction with H297
6.52
 
(superscript indicates Ballesteros-Weistein nomenclature (Ballesteros and Weinstein, 1995)) and 
the interaction of the morphinan tertiary amine with D147
3.32 
(Fig 1.1). The importance of this 
phenolic hydroxyl has been established by SAR. While no crystal structure of a peptide-bound 
MOPr has been determined, mutagenesis studies probing the binding of the synthetic peptide full 






]-enkephalin) show that there are extensive 















Figure 1.1: Structures of various opioid ligands and crystal structures of inactive and active 
MOPr. Structures of A) Leu-Enk, B) DAMGO, C) morphine, D) etorphine, and E) methadone.  
F) Overlay of the inactive (PDB 4DKL; purple) and the active (PDB 5C1M; green) crystal 
structure of MOPr. G) The orthosteric binding pocket of active MOPr with the agonist BU72 







Receptor theory  
GPCRs are allosteric machines that convey information from the extracellular side of a 
cell to the intracellular side. This propagation of signal occurs through conformational changes 
initiated by ligand binding that promotes G protein binding and nucleotide exchange. Receptor 
equilibrium can be simply thought of in terms of R (inactive) and R* (active receptor capable of 
signal transduction) populations. Although this model was originally proposed for ion channels 
that are either open or closed, it can also be generally applied to GPCRs (Del Castillo and Katz, 
1957). Ligand-free receptors sample conformational space, with ligand-free sampling of R* 
being reflective of constitutive, or basal, receptor activity. By definition, agonists stabilize R* 
with the proportion of R* reflective of their intrinsic efficacy, neutral antagonists bind the 
receptor but do not perturb this equilibrium, and inverse agonists stabilize R, decreasing basal 
activity (Kofuku et al., 2012). 
Pharmacological characterization of novel ligands involves determining both their 
affinity and efficacy. These parameters can be considered largely independent and one does not 
predict the other. The affinity, or the strength of interaction between two molecules, is based 
upon the changes in free energy that occur following interaction (i.e. ligand and receptor) 
compared to the free energy of the entities in isolation and is often determined through the use of 
radiolabeled ligands. Affinity between a receptor and a ligand can change based upon the buffers 
and specifics of an assay, but is considered independent of tissue type and receptor expression.  
Efficacy, on the other hand, has been an ever evolving concept that can be measured and thought 
of in a multitude of ways.  
 
History of pharmacological efficacy  
The earliest ideas of efficacy derived from initial observations that some ligands caused a 
response in a tissue while others did not, and could only block the activity of another ligand. This 
was first described by Ariens and de Groot with the concept of “intrinsic activity” of a ligand 
(Ariens and De Groot, 1954).  The word “efficacy” was first defined by Stephenson in 1956 by 
the following: “Different drugs may have varying capacities to initiate a response and 
consequently occupy different proportions of the receptors when producing equal response. This 
property will be referred to as the efficacy of the drug.” In the same paper, Stephenson defined 





between agonists and antagonists (Stephenson, 1956).” Later, a method to analyze the relative 
ability of agonists to produce a response based on a given receptor occupancy was described by 
Furchgott (intrinsic efficacy; (Furchgott, 1967). 
Stephenson’s definition allows for characterization of ligands on the basis of activity, but 
it was soon appreciated that the maximal response of a ligand depends greatly on the signaling 
output analyzed, degree of signal amplification, cell-type, and receptor expression level, in 
addition to many other factors. Partial agonists can display full agonist activity if signaling 
outputs far from the receptor, including physiological effects, are analyzed This makes 
translation from in vitro to in vivo efficacy hard to predict. Due to this, many sought to determine 
a value for an “intrinsic efficacy,” or value reflective of the interaction of the specific ligand with 
a receptor that was less prone to differing between systems, much like affinity. Currently, the 
most well-accepted method for calculating the intrinsic efficacy of a ligand is the Black-Leff 
operational model (Black and Leff, 1983). This model was built to analyze an agonist-
concentration response curve that obeyed the Law of Mass Action. In it, a ‘transducer function,’ 
tau (τ), is proposed that ‘transduces’ an agonist-occupied receptor into a pharmacological effect 
and defines the operational efficacy of a ligand. This model explicitly links receptor occupancy 
with functional response and for agonists, a τ value and KA (agonist-receptor dissociation 
constant) can be calculated (Black and Leff, 1983) and be used to compare agonists and to 
calculate agonist bias (Kenakin et al., 2012). 
 
Role of sodium in receptor equilibrium and agonist activity 
While receptor equilibrium between active and inactive states is readily perturbed by 
agonists in proportion to their efficacy, other factors can alter this equilibrium. In particular, Na
+
 
ions have been shown to alter the equilibrium between R and R* for many GPCRs, including 
MOPr (Pert et al., 1973; Pert and Snyder, 1974; Motulsky and Insel, 1983; Carroll et al., 1988; 
Emmerson et al., 2004; Selent et al., 2010; Liu et al., 2012). Sodium ions bind in the central 
portion of the heptahelical bundle forming important water-mediated coordinations with residues 
in transmembrane 3 (TM3), TM7, and TM2 among others as seen in the four crystal structures of 
GPCRs so far obtained with Na
+
 visible (A2A adenosine receptor, β1 adrenergic receptor, DOPr, 





Miller-Gallacher et al., 2014). In particular, a highly conserved aspartate residue (D2.50) in TM2 
is shown to be required for Na
+
 to regulate receptor function.   
Sodium regulates receptor function by stabilization of the inactive-state of the receptor. 
Na
+
 binding shifts receptor equilibrium to R and thereby causes a decrease in the basal activity of 
the receptor and a decrease in the affinity of agonists to bind. Inverse agonists are compounds 
that decrease basal binding and therefore show an increase in the affinity in the presence of Na
+
 
ion (Appelmans et al., 1986). Molecular dynamics simulations suggest that activation of the 
receptor causes conformational changes that restrict accessibility and space for the water, 
therefore driving it out of the Na
+
 ion binding pocket. Analyses performed by the Stevens group 
(Katritch et al., 2014) have shown that the Na
+
/water pocket collapses in size from ~200 Å
3
 to 70 
Å
3
 due to activation-related movement of the TM helices as seen in crystal structures (Fig 1.2). It 
is theorized that Na
+
 is then driven through the receptor and exits out the intracellular face, down 
its concentration gradient (Katritch et al., 2014), although the fate of Na
+
 following receptor 
activation is not completely understood. The incompatibility of Na
+
 and active-states of GPCRs 
has been confirmed by the lack of Na
+
 found in GPCR structures, including the crystal structure 
of MOPr which shows occlusion of the sodium-binding site. These data, and others, support the 
hypothesis that sodium stabilizes R and that removal of Na
+
 either drives R* or destabilizes the 
receptor, much like an agonist, allowing for transition to R*. In support of this, sodium ions 
enhance the thermal stability of the A2A adenosine receptor (Liu et al., 2012) as well as the β1 
adrenergic receptor (Miller-Gallacher et al., 2014). 
 
Cellular consequences of MOPr activation  
Agonist occupation of MOPr leads to activation of heterotrimeric G proteins of the Gαi/o 
class including Gαi1, Gαi2, Gαi3, Gα0, and Gαz. Nucleotide exchange on the alpha subunit leads to 
an active GTP-bound Gα and an activated Gβγ that interact with effector enzymes and second 
messengers including: adenylate cyclase (AC), G protein-coupled inwardly rectifying potassium 
channel (GIRK), mitogen-activated protein kinase (MAPK), N-type calcium channels, and 
phospholipase C (PLC).  Termination of G protein signaling occurs when GTP is hydrolyzed by 
the intrinsic GTPase activity of the Gα subunit, which can be accelerated by regulators of G 















Figure 1.2: Sodium binding site collapses in active state of A2AAR. A) Na
+
 (blue sphere) in 
the middle of the transmembrane bundle of the A2AAR receptor structure with water molecules 
as red spheres. B) The sodium-pocket collapses in the active-like state of A2AAR which disables 
sodium from binding. C) The conservation of the sodium-binding site in a number of Class A 
GPCRs (A2AAR- cyan, chemokine receptor type 4- green, rhodopsin- magenta, and all other 
(β2AR, histamine 1 receptor, dopamine D3 receptor, kappa opioid receptor, sphingosine-1 







Signal transduction from the receptor terminates through various forms of homologous or 
heterologous desensitization. Homologous desensitization occurs when kinases recruited by 
activated G proteins, namely G protein-coupled receptor kinase 2 and 3 (GRK2/3), recognize and 
bind to agonist-bound receptor to phosphorylate residues on the intracellular loops and C-
terminal tail of MOPr. Heterologous desensitization occurs when kinases, including protein 
kinase C (PKC) and Ca
2+
/calmodulin-dependent protein kinase II (CaMKII) phosphorylate 
intracellular residues of MOPr, independent of agonist occupancy. Phosphorylation enhances the 
binding of arrestin-2 and arrestin-3 to MOPr (Zhang et al., 1998; McPherson et al., 2010). 
Arrestin-binding leads to clathrin-mediated endocytosis of MOPr which results in the majority of 
MOPr being degraded, with a small percentage being returned to the plasma membrane once 
phosphatases remove and resensitize the receptor. Desensitization and downregulation occurs 
through prolonged administration of opioid ligands (Williams et al., 2001, 2013).  
 
Biased agonism and implications for novel opioid therapeutics 
The concept of intrinsic efficacy became more complicated when inconsistencies arose as 
newer methods of measuring signal outputs were developed. Studies moved from measuring 
physiological responses in animal tissues (i.e. contraction) to detection of second messenger 
production in immortalized cell lines expressing high levels of receptors. Many levels of the 
signal transduction pathway may now be measured and quantified. In addition to the G protein 
mediated pathways, both the Gα and Gβγ arms, G protein-independent signaling pathways have 
also been elucidated. The activation of these latter pathways, mainly mediated by arrestin, can 
now also be quantified. It has been shown for many GPCRs that a ligand may not signal through 
each arm (G protein or arrestin) to the same extent and as such may exhibit varying intrinsic 
efficacies depending upon the pathway. For example, binding of parathyroid hormone (PTH1-
34) results in full activation of both Gs and Gq/11 at the parathyroid 1 (PTH1) receptor. In 
contrast, a synthetic derivative PTH-barr is an inverse agonist of G protein signaling at this 
receptor but induces arrestin-dependent ERK activation (Gesty-Palmer et al., 2006). Indeed, 
signaling by this ligand is abrogated in arrestin-3 knockout mice (Gesty-Palmer et al., 2009). 
Another example is the activation of GPR109A by niacin, also known as vitamin B3.  Niacin 
administration has the clinical benefit of increasing high-density lipoproteins and reducing 





arrestin-2 and subsequent binding to activated cystolic phospholipase A2 (cPLA2) generates 
arachidonate, resulting in the uncomfortable flushing associated with niacin administration  
(Walters et al., 2009). As such, the GPR109A agonist MK-0354 has been developed that has a G 
protein bias and shows therapeutic benefits without the flushing (Semple et al., 2008). 
At MOPr, it has been proposed that G protein-privileged ligands would be the most 
clinically beneficial with decreased tolerance and respiratory depression, but robust analgesia. 
This hypothesis is supported by experiments conducted with arrestin-3 knockout mice (Bohn et 
al., 1999, 2002; Raehal et al., 2005). These mice are resistant to both acute tolerance following 
one administration of a high dose of the opioid agonist morphine (100 mg/kg) and also show a 
lack of tolerance formation following 9 days of morphine administration (10 mg/kg once a day) 
or after morphine-pellet implantations which slowly release morphine continuously over the 
course of 3 days (Bohn et al., 2000).  
Based on data like these, there has been an effort to develop MOPr agonists that are G 
protein-biased. One of the first such ligands was herkinorin, a derivate of the kappa opioid 
receptor agonist salvinorin A, which was shown to activate G protein mediated ERK1/2 
phosphorylation. But, herkinorin administration failed to cause robust phosphorylation of MOPr, 
arrestin recruitment, and arrestin-mediated internalization of MOPr in cultured HEK293 cells 
stably expressing MOPr (Groer et al., 2007). Another ligand, TRV130, has also been purported 
to be a G protein-biased ligand capable of potent antinociception with reduced gastrointestinal 
and respiratory depression as compared to the traditional ligand morphine (Dewire et al., 2013).  
The degree of this ligand’s bias has been questioned, though. It may be that TRV130 is not 
biased, but is actually a balanced, but low efficacy partial agonist when the Black-Leff 
operational model is applied to analysis of TRV130 signaling (Thompson et al., 2015). 
Nonetheless, TRV130 has recently moved into Phase 3 clinical trials for the treatment of 
moderate to severe pain, with a focus on acute postoperative pain (www.trevenainc.com). 
 
Allostery at opioid receptors 
A recent avenue of research in the pharmacology of GPCRs is the study of allosteric 
ligands (Conn et al., 2009; Wootten et al., 2013). Allosteric ligands bind to regions on GPCRs 
spatially distinct from the orthosteric site and can alter affinity, potency, and efficacy of a ligand 





agonist binding and activity while negative allosteric modulators (NAMs) decrease such features.  
Muscarinic receptors have the most well studied allosteric ligands. A crystal structure of the 
human M2 muscarinic acetylcholine receptor (M2R) in complex with an agonist and a positive 
allosteric modulator was recently reported (Kruse et al., 2013). The structure reveals that the 
allosteric site of the M2 receptor lies directly above the orthosteric site. When an agonist binds, a 
‘shelf’ is created by the rotation of residues over the orthosteric site. This ‘shelf’ provides a 
pocket for allosteric ligands to bind and has direct consequences on the association and 
dissociation kinetics of orthosteric ligand binding. In addition, the structure provided a molecular 
basis for the cooperativity seen between allosteric and orthosteric ligands. The binding site for 
the allosteric ligand was only present when the receptor was occupied by an agonist and in an 
active-like state.  
Allosteric ligands offer many advantages over orthosteric ligands including preservation 
of spatial/temporal regulation and specificity. First, due to their mechanism of action, these 
ligands often have no activity in the absence of an orthosteric ligand. This means that activity is 
dependent upon endogenous ligands being synthesized and released, allowing for signal timing 
and distribution to more closely mimic the body’s natural timing and endogenous ligand release. 
Secondly, it is often difficult to create a selective drug that targets one receptor subtype of a 
family (muscarinic for example) due to the endogenous orthosteric ligand(s) they share. In 
contrast, in the absence of an endogenous allosteric ligand there is no evolutionary pressure to 
conserve other potential pockets on the receptor. Consequently, selective M1 and M4 allosteric 
ligands have been discovered and represent novel ways to treat certain diseases such as 
schizophrenia (Felder et al., 2000; Seager et al., 2009; Farrell and Roth, 2010). 
Allostery at opioid receptors remains a relatively unexplored avenue of research. 
Cannabidiol (CBD) and the closely related cannabidiol receptor 1 agonist (CB1) (-)-Δ9-
tetrahydrocannabinol (THC) have been postulated to be negative allosteric modulations (NAMs) 
at both MOPr and DOPr (Kathmann et al., 2006). In rat brain homogenates, the dissociation of 
the MOPr selective agonist 
3
H-DAMGO was shown to be 12-fold faster in the presence of 100 
µM CBD and 2-fold faster in the presence of 100 µM THC. In addition, they were both shown to 
accelerate the dissociation of the DOPr selective antagonist naltrindole (NTI). But, allosteric 
modulation by THC and CBD was not confirmed to be mediated by direct binding to MOPr. The 





targets of CBD including CB1, GPR55, the serotonin 1A (5-HT1A) receptor, and peroxisome 
proliferator-activated receptor (PPAR)-gamma receptors (Russo et al., 2005; Campos et al., 
2012; Hegde et al., 2015; Walsh et al., 2015).  As such, the effects of CBD and THC may not be 
through a direct allosteric interaction at MOPr, but instead indirectly through the interactions of 
another receptor with MOPr. There are reports of heterodimer formation between MOPr with 
both CB1 and 5-HT1A receptors and it is also possible that CBD has allosteric effects across this 
heteromeric interface as has been seen with the dopamine receptor allosteric ligand SB269652 
that acts as a NAM of dopamine D2 receptor (D2R) dimers (Kathmann et al., 2006; Hojo et al., 
2008; Cussac et al., 2012; Lane et al., 2014). The description of CBD and THC as NAMs at 
MOPr is also in contrast to the numerous studies showing synergism between cannabinoids and 
opioids in causing antinociception and analgesia in rodents and humans, respectively (for review 
see (Cichewicz, 2004)). 
In collaboration with Bristol-Myers Squibb, our lab discovered several small molecule 
PAMs of MOPr (Burford et al., 2013) from a 1.2 million compound library using a DiscoveRx® 
high-throughput screen to measure agonist-mediated arrestin recruitment. Specifically, 
compounds were screened alone and in the presence of an EC20 concentration of the MOPr 
agonist endomorphin-1. Those compounds that selectively enhanced agonist-response while 
having no response alone were evaluated further. This screen yielded several PAMs as well as 
several ‘silent’ (neutral) allosteric molecules (SAMs) that show no activity but instead bind 
competitively to displace the PAMs. The lead compound, BMS-986122, was then shown to 
enhance the affinity and potency of several opioids agonists to bind MOPr and cause G protein 
activation as measured by GTPγ
35
S binding (Burford et al., 2013). 
 
Hypothesis and Aims 
The overall goal of the work described in this thesis is to further explore allosteric 
modulation of MOPr. Specifically, the goals are to determine the mechanism of allosteric 
modulation of this receptor, to probe the interaction between allosteric modulator and MOPr, and 
to understand the acute and chronic effects of allosteric modulation at the cellular level. Given 
that allosteric modulators of GPCRs are a possible drug avenue; this work will provide the in 






Chapter 2: Investigate the probe dependence and mechanism of action of BMS-986122. 
Chapter 2 investigates the probe dependence of the MOPr PAM BMS-986122. Probe 
dependence, or the variance of allosteric action based on the orthosteric ‘probe’ used, is a well-
known phenomenon for allosteric modulators (Valant et al., 2012). Though it is known that 
BMS-986122 enhances the affinity of MOPr agonists DAMGO and endomorphin-1, it is 
unknown if BMS-986122 can enhance the binding and activity of endogenous peptides or 
commonly used opioid drugs, such as morphine and methadone. The studies in this chapter 
utilize radioligand binding assays and functional assays using GTPγ
35
S in cultured cells 
expressing rat MOPr to understand which orthosteric ligands are cooperative with BMS-986122 
In analyzing the probe dependence of BMS-986122, an understanding of the mechanism of 
action of this mu-PAM, namely an allosteric interaction with the Na
+
 binding site was uncovered 
and will be explored.  
 
Chapter 3: Investigate the action of BMS-98618 and the possibility of a conserved opioid 
binding site across MOPr and DOPr. 
Chapter 3 focuses on the recently discovered DOPr PAM, BMS-986187. Although 
discovered as a high affinity and high efficacy DOPr PAM, BMS-986187 was found to have 
allosteric activity at MOPr. In this chapter, we investigated if BMS-986187 has the same 
mechanism of action as BMS-986122 at both MOPr and DOPr. Furthermore, we tested if BMS-
986122 and BMS-986187 bind at the same site on MOPr or if they target different allosteric sites 
on the receptor.  
 
Chapter 4: Investigate the ability of orthosteric and allosteric ligands to stabilize active-state 
MOPr 
Chapter 4 investigates the minimal functional unit required to observe allosteric 
modulation of MOPr. All previous characterization of MOPr PAMs was performed in cell 
membranes and it is as of yet unknown if BMS-986122 or BMS-986187 bind directly to the 
receptor. In this chapter, purified MOPr reconstituted into high-density lipoproteins (MOPr-
rHDL) and radioligand binding as well as interferometry was used to monitor ligand binding as 





active-state biosensor of MOPr. These tools were used to further probe the mechanism of MOPr-
PAM activity and to create a novel assay for measuring both allosteric and orthosteric efficacy. 
 
Chapter 5: Investigate the consequences of long-term exposure to BMS-986122 on cellular 
tolerance and desensitization. 
The final data chapter focuses on the consequences of allosteric modulation on processes 
of cellular tolerance and desensitization which have direct relevance to the potential clinical 
benefit of these compounds. Using cultured cell lines expressing MOPr, the loss in signal 
transduction following chronic agonist exposure was measured in the absence or presence of 
BMS-986122 with the hypothesis that the MOPr PAM should enhance these processes. 
Furthermore, the ability of BMS-986122 to enhance MOPr phosphorylation and internalization 
was also measured. Lastly, these studies explored if BMS-986122 showed a bias in the signaling 
outputs that it potentiated. 
 
The appendices contain studies related to the investigation of slowly dissociating ligands 
of MOPr for use in crystallography (Appendix A), the discovery of allosteric modulators of the 
delta opioid receptor (Appendix B), and the use of molecular dynamics simulations to find novel 









Disruption of the Na
+
-Ion Binding Site as a Mechanism for Positive Allosteric Modulation 




Positive allosteric modulation of the mu opioid receptor (MOPr), the site of action of all 
clinically used opioids, represents a novel approach for the management of pain. We recently 
reported on positive allosteric modulators of MOPr (mu-PAMs), a class A G-protein coupled 
receptor (GPCR). This study was designed to examine the mechanism of allostery by comparing 
the degree to which opioid ligand structure governs modulation. To do this we examined the 
interaction of the mu-PAM, BMS-986122, with a chemically diverse range of MOPr orthosteric 
ligands.  Generally, for full agonists BMS-986122 enhanced the binding affinity and potency to 
activate G protein with no alteration in the maximal effect. In contrast, lower efficacy agonists 
including morphine were insensitive to alterations in binding affinity and showed little to no 
change in potency to stimulate G protein. Instead, there was an increase in maximal G protein 
stimulation. Antagonists were unresponsive to the modulatory effects of BMS-986122. Sodium 
is a known endogenous allosteric modulator of MOPr and alters orthosteric agonist affinity and 
efficacy. The sensitivity of an orthosteric ligand to BMS-986122 was strongly correlated with its 
sensitivity to NaCl. In addition, BMS-986122 decreased the ability of NaCl to modulate agonist 
binding in an allosteric fashion. Overall, BMS-986122 displayed marked probe dependence that 
was based upon the efficacy of the orthosteric ligand and can be explained using the Monod-
Wyman-Changeux two-state model of allostery. Furthermore, disruption of the Na
+
 ion binding 
site may represent a common mechanism for allosteric modulation of class A GPCRs.  
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The mu opioid receptor (MOPr) is the site of action of all clinically used opioid drugs. 
MOPr is a class A G protein-coupled receptor (GPCR) that couples to heterotrimeric Gi/o 
proteins. Clinically used opioid agonists bind to the orthosteric site on MOPr and though they are 
efficacious at causing pain relief, have a number of unwanted side effects resulting from direct 
MOPr activation. We have recently discovered and presented a preliminary characterization of 
positive allosteric modulators of MOPr (mu-PAMs) and are currently pursuing the idea that mu-
PAMs could be a viable way to manage pain (Burford et al., 2013; N Burford et al., 2015). In 
particular, the ligand BMS-986122 (Fig 2.1) represents the most active mu-PAM currently 
identified. It was discovered in a high-throughput screen for its ability to enhance the recruitment 
of β-arrestin to MOPr by the agonist endomorphin-1. Though having little agonist activity on its 
own, this modulator has the ability to enhance the affinity, potency, and/or maximal response of 
MOPr agonists. In the same systems, BMS-986122 has no activity when the delta opioid receptor 
(DOPr) is expressed, indicating the importance of MOPr for BMS-986122 activity.  
 
 




The study of allosteric modulation of GPCRs has recently gained momentum (Luttrell 
and Kenakin, 2011) and represents a novel avenue for drug development (Wootten et al., 2013; 
Nickols et al., 2014). Allosteric modulators have been discovered for several GPCRs including 
the muscarinic, cannabinoid, and metabotropic glutamate receptors (O’Brien et al., 2004; Price et 
al., 2005; May, Avlani, et al., 2007) with a growing body of in vitro and in vivo literature 
describing allostery at GPCRs (Seager et al., 2009; Kruse et al., 2013; Byun et al., 2014). In 






Allosteric modulators exhibit probe dependence, meaning they show disparate effects 
depending on the agonist bound to the orthosteric site (Keov et al., 2011). A striking example of 
this is LY2033298, a PAM of the muscarinic acetylcholine receptors M2 and M4.  LY2033298 
increases the affinity of the agonist oxotremorine, while having no effect on the binding of the 
agonists pilocarpine and McN-A-343 (Valant et al., 2012). Currently, it is not known if all opioid 
agonists are equally sensitive to the PAM effect of BMS-986122, nor the mechanism underlying 
the allosteric modulation.  Our initial characterization showed that BMS-986122 causes a shift in 




, Gly-ol]-enkephalin), but increases the 
maximal stimulation of G protein by morphine (Burford et al., 2013). Opioid ligands are 
extremely diverse, ranging from the 31-amino acid endogenous peptide β-endorphin to small 
alkaloids like morphine. Therefore, this study sought to answer two questions: a) does BMS-
986122 show probe dependence for the orthosteric ligand? and b) if probe dependence is seen, 
what is the mechanistic basis for this? 
To address these questions we examined the effect of BMS-986122 on the MOPr 
properties of a wide range of opioid ligands from endogenous peptides to small molecules (Fig. 
2.2). The results reveal that the PAM effects of BMS-986122 are dependent on the efficacy of 
the orthosteric ligand and not on the structure per se. We find a strong correlation between the 
positive action of BMS-986122 and the negative action of Na
+
 ions to inhibit agonist binding. 
Moreover, we also show that BMS-986122 allosterically inhibits the ability of Na
+
 ions to reduce 
agonist binding. The PAM effect of BMS-986122 can consequently be explained by an 
inhibition of the ability of Na
+
 ions to stabilize the inactive state of the receptor, thereby allowing 
the receptor to shift to an active conformation.  Thus, the mechanism of positive allosteric 
modulation can be simply explained by the two-state Monod-Wyman-Changeux model of 
allosterism (Monod et al., 1965). 
Results: 
We first investigated the effects of a maximally effective concentration (10 μM; (Burford 
et al., 2013)) of BMS-986122 on the MOPr activity of a range of endogenous opioid peptides 
(Fig. 2.2). Using cell membrane homogenates prepared from C6 glioma cells stably expressing 
MOPr (C6MOPr, (Clark et al., 2003)), we performed radioligand competition binding assays 
using 
3





generate an inactive receptor state known to predominate in native membranes (Carroll et al., 
1988; Lee et al., 1999). As shown in Fig. 2.3A and Table 2.1, BMS-986122 caused an 
approximate six-fold enhancement in the affinity of both methionine-enkephalin (Met-Enk) and 
leucine- enkephalin (Leu-Enk). A similar increase in affinity was seen for the smaller putative 
endogenous peptide endomorphin-1 (Zadina et al., 1997). In addition to enhancing its affinity to 
bind MOPr, BMS-986122 caused a leftward shift in the concentration-response for Met-Enk to 
activate G protein, with no alteration in the maximal response (Emax), as measured by GTPγ
35
S 
binding in membrane homogenates (Fig. 2.3C, Table 2.2); an effect also seen with Leu-Enk and 
endomorphin-1 (Table 2.2). The endogenous opioid β-endorphin, a much larger 31-amino acid 
peptide, was also modulated by BMS-986122 with leftward shifts in both the affinity (fourfold; 
Table 2.1) and potency (six-fold; Table 2.2) to activate G protein.  
Because we had previously seen that BMS-986122 increased the maximal G protein 
activation by morphine (Burford et al., 2013), we determined the modulation of opioid affinity, 
potency, and maximal agonist effect of this small molecule MOPr agonist. There was no shift in 
the affinity of morphine to bind MOPr in the presence of BMS-986122 (Fig 2.3B and Table 2.1). 
Even at 30 μM BMS-986122, a concentration approaching the limits of solubility, there was still 
no enhancement of morphine affinity (Fig 2.4; Ki (veh) = 163 ± 18 nM, Ki (BMS-986122; 30 
µM) = 250 ± 110 nM)). In contrast to this lack of effect on affinity, BMS-986122 did alter the 
ability of morphine to activate G protein. There was a small 2.9-fold decrease in the potency 
(EC50), but the most striking effect was a significant increase in the degree of maximal 
activation. In the presence of BMS-986122, morphine was able to activate G protein to nearly 
the same extent as the full agonist DAMGO (Fig. 2.3D and Table 2.2). Moreover, the rate at 
which DAMGO activated G protein was unchanged in the presence of 10 µM BMS-986122 







Figure 2.2: Structures of opioid ligands 
A) Peptides: (1) DAMGO, (2) β-endorphin, (3) endomorphin-1, (4) leucine-enkephalin, (5) 
methionine-enkephalin. 
B) Small molecules: (6) buprenorphine, (7) diprenorphine, (8) etorphine, (9) fentanyl,  (10)  







Figure 2.3: Comparison of the effect of BMS-986122 on Met-Enk and morphine. 
3
H-DPN 
binding to MOPr was determined in membranes from C6MOPr cells in the presence of 
increasing concentrations of Met-Enk (A) or morphine (C) in the presence of vehicle (●) or 10 
µM BMS-986122 (○).  The ability of increasing concentrations of Met-Enk (B) or morphine (D) 
to elicit GTPγ
35
S binding in C6MOPr cell membranes was measured in the absence (●) or 
presence (○) of 10 µM BMS-986122 as described in the methods. Data are presented as % 
stimulation of a maximal concentration (10 µM) of the full agonist standard DAMGO. E) Rate of 
G protein activation by DAMGO (dotted line, circles) or morphine (solid line, squares) was 
measured in the presence of vehicle (closed symbols) or 10 µM BMS-986122 (open symbols). 
The rate of DAMGO-stimulated GTPγ
35
S was unchanged (vehicle: 21.5 ± 1.0 cpm/min; BMS-
986122: 20.8 ± 0.7 cpm/min), while the rate of morphine- stimulated GTPγ
35
S was enhanced 
from 11.5 ± 0.7 cpm/min (vehicle) to 18.1 ± 0.5 cpm/min in the presence of BMS-986122. All 





Table 2.1: Binding affinity of MOPr ligands in the presence or absence of BMS-86122 
 
 
Affinity (Ki values) were determined by competitive displacement of 
3
H-DPN binding from 
C6MOPr cell membranes in a buffer containing 10 µM GTPγS and 100 mM NaCl as described 
in the methods, in the absence or presence of 10 µM BMS-986122. * p < 0.05, ** p < 0.01, *** 
p< 0.001 compared to control (vehicle) data by Student’s t test. Data shown are means ± SEM of 
3-5 independent experiments each in duplicate. 
  
Ligand  Ki (Vehicle, nM)  Ki (BMS-986122, nM) Ki (Veh)/Ki (BMS) 
Peptides     
β-Endorphin 194 ± 13  47 ± 8 ***  4.1 
Endomorphin 1 104 ± 32  17 ± 8 *  6.1 
Leu-Enk 664 ± 67  100 ± 15**  6.6 
Met-Enk 423 ± 133  63 ± 16 *  6.7 
Small molecules    
Buprenorphine 0.5 ± 0.1 0.4 ± 0.2 1.3 
Etorphine 2.4 ± 0.3  1.5 ± 0.8  1.6 
Fentanyl 222 ± 34  89 ± 25* 2.5 
Loperamide 215 ± 54  14 ± 2 * 15.4 
(RS)-Methadone 1076 ±  85  100 ± 4 *** 10.7 
(R)-Methadone 382 ± 10 36 ± 10 *** 10.6 
(S)-Methadone 6358 ±  2065 896 ±  35*  7.1 
Morphine 163 ± 18  143 ± 42  1.1 





Table 2.2: Stimulation of GTPγ
35






S assay was performed as described in the methods. 
a
Maximal values relative to the 
stimulation observed with 10 µM DAMGO.  * p < 0.05, ** p < 0.01, *** p< 0.001 compared to 
control (vehicle) data by Student’s t test. Data shown are means ± SEM of 3-5 independent 




Ligand Vehicle BMS-986122 (10 µM) EC50 (veh)/ 
EC50(BMS) 
Peptides EC50 (nM) Max (%)
a
 EC50 (nM) Max (%)
a
  
β-endorphin 167 ± 21 90 ± 6 28 ± 5 **  88 ± 6        6.0 
DAMGO 104 ± 39  100 19 ± 7 100        5.5  
Leu-Enk 116 ± 21 106 ± 4 27 ± 9 ** 98 ± 6        4.3 
Met-Enk 169 ± 16 103 ± 2 49 ± 7 ** 107 ± 1        3.5 
Endomorphin 1  70 ± 4  94 ± 8 21 ± 3 * 93 ± 5        3.3 
Small molecules      
Buprenorphine 0.5 ± 0.2  21 ± 3 0.5 ± 0.2 52 ± 1 ***        1.0 
Etorphine  0.28 ± 0.04  99 ± 2  0.17 ±  0.05  102 ± 5         1.6 
Fentanyl  459 ± 173  61 ± 3  156 ± 24  85 ± 1***         2.9 
Loperamide  37 ± 1  86 ±  2  3.9 ± 0.6***  91 ±  1        9.5 
(RS)-Methadone  542 ± 149  85 ± 1  47 ± 6*  85 ± 3         11.5 
(R)-Methadone  273  ±  12  95 ± 4  31 ± 0.6 ***  87 ± 3         8.8 
(S)-Methadone  7737 ± 854  70 ± 4  1275 ± 216** 85 ± 3*          6.1 
Morphine  292 ± 59  61 ± 2  100 ± 11 *  85 ± 1***         2.9 












Figure 2.4: Affinity of morphine to bind MOPr is unaltered, even in the presence of 30 µM 
BMS-986122. Competition binding was performed in the absence (●), or presence (○) of 30 µM 







We hypothesized that the disparate effects on orthosteric ligand binding seen with BMS-
986122 might be explained by the structure of the ligand: peptides versus small molecules. All of 
the endogenous ligands tested are large, flexible peptides while morphine is a small, rigid 
molecule. To address this possibility, we measured the effect of BMS-986122 on additional 
small molecule MOPr agonists that are structurally distinct from morphine, namely 
buprenorphine, fentanyl, methadone, and loperamide as well as the antagonist naloxone (Tables 
2.1 and 2.2, Fig 2.2B). Buprenorphine behaved like morphine, showing no increase in binding 
affinity for MOPr or potency in the GTPγ
35
S assay, but a marked concentration-dependent 
enhancement in maximal effect (Fig 2.5).  With fentanyl, there was a small (2.5-fold) increase in 
its affinity for MOPr, together with a 2.9-fold shift in potency and an increase in the maximal 
level of ligand-stimulated GTPγ
35
S binding.  Conversely, for the small molecule (RS)-
methadone, there was a 10.9-fold shift in the MOPr binding affinity (Fig. 2.6A; Table 2.1) and a 
large (11.5) fold shift in the potency of (RS)-methadone to activate G protein, with no increase in 
the maximal effect (Fig. 2.6B; Table 2.2). Hill slopes of binding and GTPγ
35
S assays for all 
compounds were not significantly different from 1.0. We further characterized the effect of 
BMS-986122 on (RS)-methadone-mediated G protein activation by performing a series of 
concentration-response curves in the presence of increasing levels of BMS-986122 (Fig. 2.6C). 
Analyses of these curves using the allosteric ternary complex model afforded an alpha (α) value 
for functional cooperativity between (RS)-methadone and BMS-986122 of 18.4 and an affinity 
(KB) of 1.7 µM. This contrasts with our previously published cooperativity value of 8 for the 
interaction between endomorphin-1 and BMS-986122 recruitment of β-arrestin (Burford et al., 
2013).  For loperamide, there was a similar 15-fold shift in affinity and a 9.5-fold shift in the 
potency (Tables 2.1 and 2.2).  
The above experiments used racemic methadone. The (R)-isomer has a higher affinity for 
MOPr and a higher analgesic potency than the (S)-isomer (Scott et al., 1948; Kristensen et al., 
1995). We therefore examined if the differential binding of the isomers to the MOPr affected the 
response to BMS-986122. The affinities of the individual isomers for MOPr as well as the 
racemate were all enhanced in the presence of BMS-986122 (Table 2.1). In the GTPγ
35
S assay 
for (R)-methadone, there was an 8.8-fold shift in potency in the presence of BMS-986122, with 
no change in maximal G protein stimulation. In contrast (S)-methadone, which is a partial 










Figure 2.5: Buprenorphine stimulation of G protein is concentration-dependently increased 
by BMS-986122. GTPγ
35
S binding experiments were performed in C6MOPr cell membranes 
using 10 μM buprenorphine in the presence of increasing concentrations of BMS-986122. Data 
are normalized to stimulation occurring from 10 μM DAMGO. Data shown are means ± SEM of 












Figure 2.6: BMS-986122 enhances the affinity and potency of (RS)-methadone.  A) 
Displacement of 
3
H-DPN in C6MOPr membranes was measured in the presence of increasing 
concentrations of (RS)-methadone in the presence of vehicle (●) or 10 µM BMS-986122 (○). B) 
The ability of increasing concentrations of (RS)-methadone to elicit GTPγ
35
S binding in 
C6MOPr cell membranes was measured in the absence (●) or presence (○) of 10 µM BMS-
986122. Experiments were performed as described in Fig 1.  C) Stimulation of GTPγ
35
S binding 
by (RS)-methadone was performed in the presence of increasing concentrations (0.3-10 µM) of 
BMS-986122. Data were analyzed using the allosteric ternary complex model as described in the 







enhancement of the maximal stimulation.  There was no effect of BMS-986122 on the affinity of 
the antagonist naloxone for MOPr (Table 2.1), nor did BMS-986122 impart any agonist activity 
to naloxone (Table 2.2). 
The above findings suggest that it is the degree of agonist efficacy of the orthosteric 
ligands rather than their chemical structure that governs the response to BMS-986122 and so the 
observed probe dependence.  Sodium ions are known to reduce the affinity of agonists to bind to 
GPCRs, including the MOPr (Pert et al., 1973; Simon and Groth, 1975; Selley et al., 2000), by 
stabilizing an inactive state of the receptor (Gutiérrez-de-Terán et al., 2013; Fenalti et al., 2014; 
Katritch et al., 2014). Agonists vary in their response to Na
+
 ions such that sensitivity to Na
+
 ions 
generally correlates with the degree of intrinsic activity, with a continuum from antagonists that 
are insensitive to Na
+
 ions to full agonists that are the most sensitive. Since this matches the 
responsiveness to BMS-986122, we hypothesized that there would be a correlation between the 
sensitivity of a ligand to the mu-PAM and the sensitivity of a ligand to the presence of Na
+
 ions. 
Competition binding curves for orthosteric ligands were performed in Tris buffer in the absence 
or presence of NaCl/GTPγS to calculate the ratio of binding affinity (as pKi values) to active and 
inactive states of MOPr. Under both conditions competition binding curves with Hill slopes not 
significantly different from one were obtained for all compounds (Fig 2.7). pKi values under the 
two conditions were then compared to the shift in affinity (Fig 2.8A) or potency (Fig 2.8B) of the 
orthosteric ligand caused by 10 μM of BMS-986122.  We observed a strong correlation between 
an orthosteric ligand’s loss of binding affinity in the presence of Na
+
/GTPγS and its increased 
affinity or potency in the presence of BMS-986122.  As expected, there was a relationship 
between the shift in potency and affinity of orthosteric ligands caused by BMS-986122 (Fig 2.9). 
To analyze whether Na
+
 ions and BMS-986122 were antagonistic, we investigated the 
ability of BMS-986122 to inhibit the effect of Na
+
 ions on agonist binding.  As expected NaCl 
showed a concentration-dependent inhibition of DAMGO binding, determined as the inhibition 
of an EC60 concentration of DAMGO (10 nM) to displace 
3
H-DPN (0.2 nM) (Fig. 2.8C). This 
gave an inhibitory concentration 50 (IC50) value for NaCl of 6 ± 1 mM.  Addition of BMS-
986122 resulted in a concentration-dependent rightward shift of the IC50 of NaCl to 16 ± 2 mM 









Figure 2.7: Competition binding of orthosteric ligands in the absence (A) or presence (B) of 
100 mM NaCl and 10 µM GTPγS. Competition binding was performed using a variety of 
orthosteric ligands in C6MOPr cell membrane preparations. Nonlinear regression analysis fit all 








Figure 2.8: Relationship between BMS-986122 and Na+ ions. A) pKi values were obtained 
for each ligand in the presence and absence of 100 mM NaCl and 10 µM GTPγS with or without 
10 µM BMS-986122. The ratio of the calculated pKi values is plotted. B) pEC50 values were 
obtained for each ligand in the absence or presence of 10 µM BMS-986122. The ratio of these 
values is plotted compared to the ratio of pKi values with and without BMS-986122 obtained 
from A. C) Using C6MOPr membranes, DAMGO (10 nM) was incubated with 0.2 nM 
3
H-DPN 
and increasing concentrations of NaCl with 10 µM GTPγS in the presence of vehicle (●), 3 µM 
BMS-986122 (triangles with dashed line), 10 µM BMS-986122 (○), or 30 µM BMS-986122 (■). 
Data shown are means ± SEM of 3-10 independent experiments each in duplicate. (Legend for 
A/B: 1.β-endorphin 2.Buprenorphine 3.DAMGO 4.Endomorphin1 5.Etorphine 6.Fentanyl 7.Leu-












Figure 2.9: Correlation between the degree of shift in affinity caused by the addition of 
BMS-986122 and the shift in potency at activating G protein. pKi values were obtained for 
various orthosteric ligand in the absence or presence of 10 µM BMS-986122. The ratio of these 
pKi is plotted against the ratio of pEC50 values obtained for the orthosteric ligands in the absence 








This effect was saturable as the curve failed to shift any further right in the presence of 30 µM 
BMS-986122 (Fig 2.8C). 
Finally, to confirm a role for Na
+
 ions we examined the ability of BMS-986122 to alter 
etorphine binding and activity. Etorphine (Fig. 2.10) is a potent full agonist at MOPr, but is 
relatively insensitive to Na
+
/GTP (Ki = 0.18 ± 0.03 nM in Tris and Ki = 2.4 ± 0.3 nM with 
Na
+
/GTPγS) (see also (Lee et al., 1999)) compared to other full agonists. We therefore 
hypothesized that etorphine would be less sensitive to BMS-986122. Indeed, BMS-986122 
caused no shift in the affinity of etorphine (Table 2.1). In GTPγ
35
S binding assays, there was also 
no significant shift in potency and no alteration in the level of maximal stimulation (Table 2.2).  
Discussion 
In this study we show that the mu-PAM BMS-986122 exhibits marked probe dependence 
across a variety of structurally diverse agonists acting at the orthosteric site on MOPr. The 
sensitivity of orthosteric ligands to BMS-986122 correlated with the ratio of agonist affinities for 
active and inactive states of the receptor defined by the absence or presence of Na
+
 ions and 
guanine nucleotide and was consistent with the hypothesis that probe dependence of BMS-
986122 is defined by the efficacy of the orthosteric agonist. The effects of BMS-986122 are in 
line with the Monod-Wyman-Changeux two-state model of allosterism (Monod et al., 1965; 
Canals et al., 2012) involving a single active state, bound to G protein, and single inactive 
receptor state, uncoupled from G-protein and stabilized by Na
+
 ions. BMS-986122 favors the 
active state, opposes the action of Na
+
 ions, and therefore positively modulates the properties of 
the orthosteric agonist.  
Though the degree of effect varied, BMS-986122 enhanced the affinity and potency of all 
endogenous opioid peptides tested and none showed any enhancement of maximal G protein 
activation. We initially hypothesized that the 31-amino acid β-endorphin may be a bitopic ligand, 
capable of binding to both the orthosteric site as well as the allosteric site (for review see (Lane 
et al., 2013)). Thus, we predicted that β-endorphin would compete with BMS-986122 as well as 
with 
3
H-DPN for binding to MOPr. However, BMS-986122 affected β-endorphin in a manner 
similar to other endogenous ligands, suggesting that it is not bitopic, at least for the allosteric site 












Figure 2.10: BMS-986122 fails to stimulate GTPγ
35
S binding over basal levels, even with 
decreased (10 mM) NaCl. GTPγ
35
S binding was performed with 30 µM concentrations of 
DAMGO or BMS-986122. While DAMGO stimulated GTPγ
35
S over basal, BMS-9896122 
failed to show any detectable stimulation. Data shown are means ± SEM of 3 independent 







In contrast to the peptides, there were differences seen with small molecule MOPr 
agonists, indicating orthosteric probe dependence.  Morphine, buprenorphine, and fentanyl 
showed an increase in maximal ability to stimulate GTPγ
35
S binding with little or no change in 
potency or affinity in the presence of BMS-986122. Opioid peptides have a message and address 
sequence (Chavkin and Goldstein, 1981; Schwyzer et al., 1981) and occupy more of the MOPr 
binding pocket than smaller organic molecules (Manglik et al., 2012) which could explain their 
different sensitivities to BMS-986122. However, our findings are not simply a matter of 
chemical structural differences in terms of peptide versus small molecules since (R)-methadone 
and loperamide were sensitive to BMS-986122 in the same ways as the endogenous peptides. 
Indeed, the allosteric action of BMS-986122 on these compounds was much greater than for the 
peptides. 
Morphine, as well as fentanyl, buprenorphine, and (S)-methadone have reduced efficacy 
as compared to the endogenous peptides and (R)-methadone or loperamide. We have previously 
reported that binding of the opioid antagonist DPN was unaffected by BMS-986122 (Burford et 
al., 2013) and have now demonstrated a lack of modulation of the opioid antagonist naloxone. 
Thus, a rational explanation for our findings is that the observed probe selectivity is dependent 
on agonist efficacy. Table 2.3 lists the intrinsic efficacy of the opioid compounds examined, 
determined by the method of Ehlert (Ehlert, 1985) using values for agonist affinity determined in 
the presence or absence of NaCl/GTPγS and agonist potency in the GTPγ
35
S assay. The 
compounds with efficacy greater than or equal to β-endorphin (namely etorphine, Leu-Enk, 
loperamide, Met-Enk, (RS) - and (R)-methadone, endomorphin 1), all behaved similarly in their 
response to BMS-986122 with an increase in potency and ligand affinity, but no change in 
maximal response. In contrast, the lower efficacy agonists showed an increase in maximal effect 
with minimal alteration in potency or affinity, resulting in an increase in intrinsic efficacy (Table 
2.3). With morphine we also demonstrated an increase in the rate of G protein activation, a 
property associated with ligand efficacy (Alt et al., 2001).  Finally (S)-methadone, that has an 
efficacy value between that of morphine and DAMGO, showed a shift in potency and an increase 
in maximal effect. 
In a simple two-state model of GPCR activation, receptors are hypothesized to exist in 





Table 2.3: Efficacy of MOPr agonists
a
 
              Efficacy
a
 
Ligand Vehicle BMS-986122 
Etorphine 4.7 5.0 
Leu-Enk 3.6 2.3 
Loperamide 2.9 2.1 
DAMGO 2.1 2.0 
Met-Enk 1.8 1.2 
(RS)-Methadone 1.3 1.3 
Endomorphin 1 1.2 0.8 
(R)-Methadone 1.1 0.9 
β-endorphin 1.0 1.2 
(S)-Methadone 0.6 0.7 
Fentanyl 0.5 0.7 
Morphine 0.5 1.0 
Buprenorphine 0.2 0.5 
Naloxone 0 0 
Ligands are listed in order of decreasing efficacy (vehicle). 
a
Efficacy values were calculated 
from the ligand affinity and GTPγ
35
S data in Tables 2.1 and 2.2 according to the method of 





have higher affinity for the active, G-protein bound state and preferentially stabilize this 
conformation, thus propelling agonist-induced activation of G protein and downstream cellular 
responses (Chung et al., 2011; Kenakin, 2013). The inactive receptor state has lower affinity for 
orthosteric agonists and is stabilized in the presence of Na
+
 ions as well as guanine nucleotides 
that drive uncoupling of receptor and G-protein.  The differential affinity of orthosteric agonists 
employed in this study for inactive and active MOPr states varied, but showed a strong 
correlation with their relative sensitivity to BMS-986122 and with their potency to stimulate 
GTPγ
35
S binding.  Thus, BMS-986122 appears to shift the equilibrium towards the active 
receptor state thereby modulating the activity of the orthosteric agonists differentially, depending 
on their efficacy, an action that is opposite to the effects of Na
+
 ions (Selley et al., 2000). The 
action of BMS-986122 on maximal response of the lower efficacy agonists is also in line with a 
two-state model of GPCR function. Utilizing the idea that efficacy is based upon an agonist’s 
ability to shift the equilibrium of receptors towards an active state we would expect BMS-
986122, by stabilizing an active receptor state, to enhance the efficacy of partial agonists. The 
appropriateness of the two-state model of allosterism to explain the  probe dependence of BMS-
986122 at MOPr mirrors the action of the M1 muscarinic acetylcholine receptor modulator 
BQCA (benzylquinone carboxylic acid), which enhances the potency of orthosteric ligands or 
their maximal response depending on the efficacy requirements of the signaling assay (Canals et 
al., 2012).  
If a two-state model does explain the action of BMS-986122 then we should expect to see 
agonist activity of the modulator even in the absence of orthosteric agonist (Canals et al., 2012). 
BMS-986122 alone fails to activate G protein to a detectable level as measured by the GTPγ
35
S 
assay, even with a lowered Na
+
 concentration to increase apparent efficacy (Fig 2.10;(Szekeres 
and Traynor, 1997)). Downstream of G proteins, MOPr orthosteric agonists inhibit adenylate 
cyclase (AC), a response that is more sensitive to lower efficacy compounds, due to increased 
amplification (Clark et al., 2008).  At high concentrations, BMS-986122 does inhibit AC 
(Burford et al., 2013), thus confirming the appropriateness of the two-state model.  In addition, 
we would predict BMS-986122 to have activity at even more amplified downstream signaling 





An apparent anomaly to the hypothesis that probe dependence is based on orthosteric 
ligand efficacy and can be explained by a two-state model is that etorphine shows no 
cooperativity with BMS-986122, and is relatively insensitive to Na
+
 ions, yet this compound is a 
highly efficacious MOPr agonist (Table 2.3).  Biophysical studies with the β2-adrenergic 
receptor have shown that agonists destabilize the receptor, but the receptor exists in a variety of 
conformationally heterogeneous states that are not fully stabilized unless G protein is bound 
(Nygaard et al., 2013).  Thus, it is feasible that etorphine promotes a state that has very high 
affinity for G protein, but enriches this population to a lesser extent than other agonists.  
Further support for the two-state model comes from the relationship between BMS-
986122 and Na
+ 
ions.  High resolution X-ray structures of several class A GPCRs (Gutiérrez-de-
Terán et al., 2013), including the DOPr (Fenalti et al., 2014),  have identified the Na
+
 site as a 
Na
+
-H2O cluster in a cavity in the middle of the 7-transmembrane (TM) helices. This cavity in 
the DOPr is formed by side chains of 16 residues distributed across TM domains 2, 3, 6 and 7 
and is fully conserved in the MOPr (Fenalti et al., 2014). Comparison of inactive and active 
GPCR structures and molecular dynamics simulations performed with the adenosine A2A 
receptor show that agonist binding causes molecular rearrangements that are not compatible with 
concurrent Na
+
 binding (Gutiérrez-de-Terán et al., 2013). In particular, the addition of agonist 
dramatically reduces the size of the binding pocket for the Na
+
-H2O cluster.  BMS-986122 
decreased the potency of Na
+
 ions to inhibit binding of the agonist DAMGO and there was a 
strong correlation between the opposite effects of the BMS-986122 and Na
+
/GTP on opioid 
ligands.  Thus, the binding of both BMS-986122 and Na
+
 to MOPr is incompatible. We conclude 
that BMS-986122 favors the active receptor conformation with disruption of the Na
+
-H2O cluster 
binding pocket and this explains its PAM activity. The interaction between Na
+
 and BMS-
986122 could be through direct competition, for example as with the diuretic amiloride (Gao and 
Ijzerman, 2000), or indirectly through an allosteric interaction. However, the evidence favors an 
allosteric mechanism for several reasons.  Firstly, BMS-986122 does cause a small increase in 
agonist affinity in the absence of Na
+
 ions (Burford et al., 2013) suggesting it can stabilize an 
active receptor conformation. Secondly the same degree of shift in the inhibitory effect of NaCl 
on DAMGO binding is seen with both 10 µM and 30 µM BMS-986122, suggesting saturation is 
reached as expected for allosterism, rather than the surmountable parallel shifts expected if the 







binding pocket is conserved between MOPr and DOPr (Fenalti et al., 2014) and indeed across all 
Class A GPCRs (Katritch et al., 2014), yet the PAM activity of BMS-986122 is selective for 
MOPr over DOPr (Burford et al., 2013). Current work is in progress to identify the allosteric site 
on MOPr. 
In conclusion, this study further confirms the use of the Monad-Wyman-Changeux two-
state model of allosterism as the simplest mechanism to explain PAM activity at GPCRs (Canals 
et al., 2012). Furthermore, the results directly relate the action of a small molecule PAM to 
interfere with Na
+
 binding at a GPCR. Disruption of the Na
+ 
binding pocket during receptor 
activation may be a general mechanism for allosteric modulation across many class A GPCRs 
that have a conserved Na
+
-H2O cluster binding pocket (Chapter 3). For example, the CB1 
receptor PAM ORG27569 and the M1 receptor PAM BQCA both enhance the high affinity state 
of their respective receptors (Ahn et al., 2012; Canals et al., 2012). This may, however, not be 
true for all agonists, in particular, those whose affinity is less sensitive to Na
+
 ions such as 
etorphine, or receptors such as the β1 adrenergic receptor where Na
+
 does not appear to be 
involved in the transition from inactive to active states (Miller-Gallacher et al., 2014).  
Nonetheless interference with the stability of the Na
+
-H2O binding pocket of GPCRs may be a 
generally applicable mechanism that provides a basis for the discovery of novel modulators and 
the identification of potential endogenous modulators (for review see (Christopoulos, 2014)).  





S]GTPγS were from PerkinElmer Life Sciences. Cell 
culture materials were from Invitrogen (Carlsbad, CA).  BMS-986122 (2-(3-Bromo-4-
methoxyphenyl)-3-[(4-chlorophenyl)sulfonyl]-thiazolidine) was a gift from Bristol-Myers 
Squibb (Wallingford, CT). Morphine sulfate, leucine-enkephalin, methionine-enkephalin, β-
endorphin, DAMGO, nalbuphine, and endomorphin-1 were from Sigma-Aldrich.  All other 
chemicals, unless otherwise specified, were purchased from Sigma. All other opioids were from 
the Opioid Basic Research Center at the University of Michigan.  
Cell lines and membrane preparation: Generation of C6 rat glioma cells heterologously 
expressing only the mu-opioid receptor (C6MOPr; Bmax = 2.1 pmol/mg protein) and membrane 






H-DPN assays: Assays were performed using C6MOPr membranes by the method as described 
(Clark et al., 2003). Competitive displacement of 0.2 nM 
3
H-DPN was measured using 
increasing concentrations of orthosteric ligand in the presence of vehicle (1% DMSO) or BMS-
986122 at the indicated concentration.  
GTPγ
35
S assays: Assays were performed using C6MOPr membranes as described (Clark et al., 
2003). Orthosteric and allosteric ligands were included where appropriate.  For the rate 
experiments (Fig. 2.3E) maximal (10 µM) concentrations of DAMGO or morphine were 
preincubated in the above buffer with C6MOPr membranes and vehicle or 10 µM BMS-986122. 
After 1 h, 0.1 nM GTPγ
35
S was added and aliquots of the reaction were analyzed at various time 
points. 
Data analysis: Data were analyzed using GraphPad Prism version 6 (GraphPad, San Diego, CA, 
USA). Ki values and EC50 values were determined using nonlinear regression. The method of 
Ehlert (Ehlert, 1985) was used to calculate agonist efficacy based in the ability to stimulate 
GTPγ
35
S according to the equation: efficacy = 0.5 x (Emax,A /Emax) x (1 + Ki/EC50), where 
Emax,A is the maximum stimulation by agonist A, Emax is the maximum stimulation by 
DAMGO, Ki is the affinity of agonist A, and EC50 is the potency of agonist A. Hill slopes for all 
the binding and functional data were not significantly different from one (Fig 2.7), allowing use 
of the Ehlert equation. Functional cooperativity (α) between BMS-986122 and methadone, that 
describes the degree of change in ligand affinity between two separate but linked site both bound 
with appropriate ligand, and the affinity (KB) value for BMS-986122 were obtained using an 
allosteric ternary complex model (Christopoulos and Kenakin, 2002) in GraphPad Prism, 









Two Chemically Distinct Allosteric Modulators Bind to a Conserved Site on Mu and Delta 
Opioid Receptors  
Summary  
The mu and delta opioid receptors (MOPr and DOPr, respectively) are G protein-coupled 
receptors (GPCRs) that display a high degree of homology and share many endogenous peptide 
ligands. Even so, the recently described positive allosteric modulator (PAM) of MOPr (BMS-
986122) is inactive at DOPr while the structurally unrelated delta-PAM, BMS-986187, exhibits 
PAM activity at both receptors, though shows a 100-fold higher potency at DOPr. Allosteric 
binding sites are generally not conserved due to a lack of evolutionary pressure and 
consequently, there may be more than one allosteric binding site on any given GPCR. Here we 
test the hypothesis that chemically distinct allosteric ligands, BMS-986122 and BMS-986187, 
bind to different allosteric sites on MOPr and may therefore possess different mechanisms of 
action.  We compared the activity of BMS-986122 and BMS-986187 as PAMs at MOPr and 
DOPr expressed in C6 glioma and CHO cells. The results confirm the BMS-986187 is a highly 
efficacious, but low affinity, mu-PAM. Moreover, we demonstrate that the PAM activity of 
BMS-986187 at both MOPr and DOPr is due to disruption of the Na
+
 binding site, thus driving 
an active receptor state, in the same way as BMS-986122. Finally, a silent allosteric modulator 
(SAM) of MOPr blocks the action of BMS-986187 at both MOPr and DOPr and BMS-986122 
acts as a SAM at DOPr, indicating that they may actually bind at the same site. Overall, the 
results are consistent with a hypothesis that there is a single allosteric binding site on MOPr that 
is able to accommodate a number of chemotypes and shows some degree of conservation with an 








The mu opioid receptor (MOPr) represents the main pharmacological target of current 
pain-relieving agents including morphine and oxycodone. Such opioid drugs compete with the 
endogenous opioid peptides for binding and activation of MOPr and are therefore termed 
‘orthosteric’ ligands.  However, in addition to pain relief, orthosteric agonist activation of MOPr 
has unwanted effects including nausea, constipation, tolerance, and addiction, thus making 
separation of beneficial and unwanted effects very difficult. One approach that could result in 
analgesics with better therapeutic profiles is to target allosteric sites on MOPr with positive 
allosteric modulators (PAMs) (Burford et al., 2015). Ideally, these ligands would have no 
activity alone and would instead serve to enhance signaling of endogenous opioid peptides, 
thereby preserving the spatial and temporal aspects of endogenous signaling. To help test this 
hypothesis, allosteric modulators of MOPr have been discovered and characterized (Burford et 
al., 2013; Livingston and Traynor, 2014; Chapter 2). These ligands, as exemplified by BMS-
986122, bind allosterically to MOPr and enhance the affinity, potency, and/or efficacy of various 
orthosteric ligands in an agonist-dependent manner, described as probe dependence.  
 Allosteric modulation of G protein-coupled receptors (GPCRs) has the potential for 
additional clinical benefits. The characteristic of probe dependence, which is the phenomenon in 
which an allosteric ligand will have distinct cooperativity with different orthosteric ligands, or 
probes, could be very beneficial in the clinical setting. For instance, a PAM displaying selective 
cooperativity with certain orthosteric ligands (e.g. endogenous peptides) over abused ligands 
(e.g. heroin) would help avoid overdoses and minimize abuse potential. Furthermore, the 
allosteric ligand-bound receptor can be thought of as an entirely new receptor with different 
sensitivities to activation and different patterns of second-messenger engagement. This gives the 
possibility of inducing biased signaling by initiating pathway-specific signal transduction.  For 
MOPr, the ideal PAM would enhance analgesia without enhancing constipation, respiratory 
depression, or abuse liability (Raehal et al., 2011). Lastly, there is the possibility of enhanced 
GPCR selectivity. In theory, allosteric sites on proteins face less evolutionary pressure to be 
conserved and therefore even closely related receptors can have different allosteric binding 
pockets (For review see Conn et al., 2009). This has been demonstrated with the development of 
allosteric modulators selective for different muscarinic receptor subtypes (For review see 





 At the opioid receptors, BMS-986122 is selective for MOPr and has no detectable 
activity at the closely related delta opioid receptor (DOPr; (Burford et al., 2013)) which shares 
over 64% identity and also shares endogenous ligands (Chen et al., 1993). But, this notion of 
allosteric specificity is not absolute. The muscarinic receptor (mAChR) allosteric modulator 
C7/3-phth acts at all subtypes of mAchRs, although it has the highest affinity for the M2 mAChR 
(Christopoulos et al., 1999). SCH-202676 is a sulfhydryl reactive compound that acts as an 
‘allosteric’ modulator of a variety of GPCRs, including MOPr and DOPr (Fawzi et al., 2001; 
Gao et al., 2004; Lewandowicz et al., 2006). Finally, the recently discovered DOPr PAM, BMS-
986187, has 100-fold binding selectivity for DOPr over MOPr, but initial studies suggested it 
retains efficacious mu-PAM activity (Appendix B; (Burford et al., 2015)). In previous work we 
have demonstrated the mechanism of BMS-986122 action at MOPr is to allosterically disrupt the 
binding of Na
+
 ions (Chapter 2). Na
+
 ions modulate the activity of many class A GPCRs, 
including the opioid receptors (For review see Katritch et al., 2014). The Na
+
 ion binds at a well-
described site within the 7-transmembrane bundle and helps to stabilize the receptor in an 
inactive state with reduced affinity for agonists (Pert et al., 1973; Pert and Snyder, 1974; Liu et 
al., 2012). We hypothesized in Chapter 2 that allosteric disruption of Na
+
 binding may be a 
common mechanism for PAMs of class A GPCRs.  
 BMS-986187 is structurally different from the mu-PAM BMS-986122 (Fig 3.1). Here we 
confirm that BMS-986187 has PAM activity at MOPr and test our hypothesis of a general 
mechanism of action of allosteric modulation of GPCRs by studying whether the binding of 
BMS-986187 and Na
+
 ions are mutually incompatible at DOPr. Moreover, we assess whether the 
allosteric action of BMS-986187 at MOPr exhibits the same sodium-ion dependent mechanism. 
Finally, because BMS-986122 and BMS-986187 are structurally different we assess, if the 
binding sites for the two drugs at the MOPr and DOPr are conserved.    
 
 
Figure 3.1: Structure of BMS-986187 (A) 








Mu-PAM activity of the delta-PAM, BMS-986187 
BMS-986187 shows 100-fold binding selectivity for DOPr as compared to MOPr, but, 
initial data suggest that BMS-986187 is an efficacious, but low affinity, PAM at MOPr 
(Appendix A; (Burford et al., 2015)). To further examine PAM activity of BMS-986187 at 
MOPr, we studied the allosteric effect of BMS-986187 using cell membrane preparations from 
C6 rat glioma cells stably expressing rat MOPr (C6MOPr). We verified that BMS-986187 does 
not compete with the antagonist 
3
H-diprenorphine (DPN, Fig 3.2A) for the orthosteric site on 
MOPr. However, BMS-986187 was able to increase the affinity (Ki) of agonists for MOPr as 
measured by competition binding consistent with a positive allosteric ligand. Thus, in the 
presence of 10 µM BMS-986187 the affinity of the prototypic MOPr agonist DAMGO was 
enhanced 10-fold from 730 ± 40 nM to 70 ± 20 nM, while the affinity of methadone was 
increased 26-fold from 620 ± 100 nM to 25 ± 2 nM. In contrast, the affinity of morphine, a 
partial agonist, was enhanced to a much lesser extent from 230 ± 14 nM to 72 ± 9 nM (Fig 3.2). 
BMS-986187 is an ago-PAM at DOPr, meaning that it can activate certain downstream 
signaling pathways in the absence of orthosteric agonist (Burford et al., 2015) in addition to 
allosterically enhancing agonist affinity. In contrast, at MOPr, BMS-986187 alone (up to 30 µM; 
the solubility limit) was unable to significantly activate G protein as measured by GTPγ
35
S 
binding (Fig 3.2B) in C6MOPr membranes.  Though not an ago-PAM at MOPr, at a 





, Gly-ol]-enkephalin) 5-fold (130 ± 23 nM to 20 ± 6 nM), methadone, by 6-fold (200 ± 
33 nM to 30 ± 15 nM), and morphine by 3-fold (120 ± 9 nM to 40 ± 12 nM). There was also an 
increase in the maximal effect of morphine, from 70 ± 1 % to 90 ± 2 % of the DAMGO response 
(Fig 3.2).  Performing GTPγ
35
S binding of methadone in the presence of increasing 
concentrations of BMS-986187 allowed for the generation of a series of concentration-response 
curves that, when analyzed using the allosteric ternary complex model, resulted in an alpha value 
of cooperativity between methadone and BMS-986187 of 28.8. The KB, or affinity of BMS-
986187 for the unoccupied MOPr, was determined to be 2.2 µM (Fig 3.3).  Thus overall, BMS-






Figure 3.2: BMS-986187 is an allosteric ligand and can enhance the affinity, potency, and 
maximal stimulation of several opioid ligands at MOPr. A) The ability of BMS-986122 alone 
(A) or orthosteric ligands (DAMGO (C), methadone (E), and morphine (G)) in the absence (■) 
or presence (□) or 10 µM BMS-986122 to displace 
3
H-DPN binding in C6MOPr cell membranes 
was measured. Concentrations response curves of BMS-986122 alone (B) or the orthosteric 
ligands DAMGO (D), methadone (F), and morphine (H) in the absence (■) or presence (□) or 1 
µM BMS-986122 were performed to measure stimulation of GTPγ
35
S binding. The stimulation 
at 10 µM BMS-986187 alone was not significant. Data are presented as % stimulation of a 
maximal concentration (10 µM) of the full agonist standard DAMGO.  Nonlinear regression 
analysis fit all curves to one-site.  Data shown are means ± SEM of 3-4 independent experiments 














Figure 3.3: BMS-986187 has a concentration-dependent effect on the potency of methadone 
to activate G protein. Stimulation of GTPγ
35
S binding in C6MOPr cell membranes by 
methadone was performed in the presence of increasing concentrations (0.3-10 µM) of BMS-
986187. Data were analyzed using the allosteric ternary complex model as described in the 








qualitatively the same as that seen with BMS-986122 at MOPr. The determined affinity of BMS-
986187 was similar to that of BMS-986122 (KB = 1.7 µM, Chapter 2) but BMS-986187 showed 
a higher cooperativity with methadone compared to BMS-986122 which has an alpha value of 
18.4 (Chapter 2). 
BMS-986187 has agonist effects at MOPr in the absence of orthosteric agonist 
Although at MOPr, BMS-986187 was unable to increase GTPγ
35
S binding in the absence 
of orthosteric agonist it is possible that BMS-986187 may display agonist activity at a more 
amplified downstream pathway. We investigated the ability of BMS-986187 to inhibit adenylate 
cyclase using CHO cells expressing human MOPr. In these cells, BMS-986187 alone inhibited 
forskolin-stimulated cAMP accumulation to almost the extent seen with DAMGO giving an EC50 
value of 380 nM (Fig 3.4A), thus acting as an “ago-PAM” (Schwartz and Holst, 2007). BMS-
986187 also enhanced the inhibitory effect of DAMGO in the cAMP accumulation assay by a 
maximum of 10-fold (from 66 pM with vehicle to 7 pM) (Fig 3.4B). If BMS-986187 shows any 
signaling bias this would not be evident by measuring G protein signaling so we also determined 
if BMS-986187 alone could produce arrestin-3 recruitment. For these studies we employed CHO 
PathHunter cells expressing enzyme-acceptor tagged arrestin-3 and PK-tagged human MOPr 
from DiscoveRx to investigate arrestin-3 recruitment. BMS-986187 alone failed to recruit 
arrestin-3 up to the highest concentration (30 µM) tested (Fig 3.4C). In contrast, DAMGO was 
an efficient agonist in this assay with an EC50 of 170 nM. BMS-986187 enhanced the potency of 
DAMGO in a concentration-dependent manner to 3 nM, representing a 58-fold shift (Fig 3.4D).  
BMS-986187 acts to disrupt Na
+
 binding at both MOPr and DOPr 
We have previously proposed that the original MOPr PAM, BMS-986122, acts to 
allosterically disrupt the Na
+
 ion binding site on MOPr. Na
+
 ion binding contributes to 
stabilization of an inactive state of the receptor and disruption of this leads to an increased level 
of active-state MOPr with cooperativity with agonist binding and activity. We therefore tested if 
BMS-986187 has the same mechanism of action at DOPr. We performed a Schild analysis of the 
ability of NaCl to inhibit basal GTPγ
35
S binding in membranes prepared from CHO cells 











Figure 3.4: Effects of BMS-986187 on adenylate cyclase inhibition (AC) and arrestin 
recruitment. Using CHO-MOPr cells, the ability of BMS-986187 alone to inhibit AC was 
measured (A). Concentration-response curves of the full MOPr agonist DAMGO were 
performed in the presence of vehicle (black) or in the presence of increasing concentrations of 
BMS-986187 (B). Using CHO cells, the ability of BMS-986187 to cause arrestin recruitment 
alone was measured (C). In addition, concentration-response curves of DAMGO were performed 
in the presence of vehicle (black) or of increasing concentrations of BMS-986187. (D) These 
data were fit using the allosteric ternary complex model as described in the methods. All data 
were analyzed GraphPad Prism and data shown are means ± SEM of 3 independent experiments 







were used instead of C6DOPr cells because we have previously shown that BMS-986187 has 
greater agonist activity in the CHO line. In contrast to parallel rightward shifts with the addition 
of increasing BMS-986187, which is indicative of competitive antagonism, we observed 
rightward shifts that saturated, revealing a negative allosteric interaction between Na
+
 ions and 
BMS-986187. Analysis of this set of curves using the allosteric ternary complex model resulted 
in a KB of BMS-986122 for the Na
+
 ion-free receptor of 110 nM [95% CI 48 nM to 230 nM] and 
an alpha value of cooperativity of 0.16, indicative of negative cooperativity (Fig 3.5).  
Furthermore, we investigated if BMS-986187 would also inhibit the effects of Na
+
 ions at 
MOPr. Using C6MOPr membranes, we found that BMS-986187 reduced the potency of NaCl to 
inhibit the binding of leucine-enkephalin (Leu-Enk) at MOPr. The potency of NaCl was 
decreased 4-fold in the presence of BMS-986187, suggesting the mechanism of allosteric 
disruption of Na
+
 binding is not unique to molecules structurally related to BMS-986122 and is 
also not unique for MOPr. 
BMS-986122 and BMS-986187 bind to the same site on MOPr and DOPr 
BMS-986122 and BMS-986187 have the same probe dependence and mechanism of 
action at MOPr. To determine if they bind at the same site on MOPr we used the mu-silent 
allosteric modulator (mu-SAM) BMS-986123. BMS-986123 has been previously shown to 
displace BMS-986122 from MOPr while having no effects alone (Burford et al., 2013). We 
therefore tested if BMS-986123 could also displace BMS-986187 at MOPr. BMS-986187 at 10 
µM produced a 5-fold increase in the EC50 of DAMGO to stimulate GTPγ
35
S binding in 
C6MOPr cell membranes. The addition of increasing amounts of the mu-SAM concentration-
dependently decreased the EC50 of DAMGO such that the positive allosteric effects of BMS-
986187 were no longer observed (Fig 3.6).  We used DAMGO for this experiment because 
although previously designated as a mu-SAM BMS-986123 showed a low degree of positive 
allosteric cooperativity with methadone, increasing methadone’s affinity for MOPr by 3-fold 
(from 620 ± 100 nM with vehicle to 200 ± 20 nM with 10 µM BMS-986123; data not shown), 
indicating that it is not truly silent.  
We then sought to determine if BMS-986123 was also a SAM at DOPr. GTPγ
35
S binding 










Figure 3.5 Negative cooperativity between NaCl and BMS-986187 at DOPr.  The ability of 
increasing concentrations of NaCl to decrease basal GTPγ
35
S binding the presence of increasing 
concentrations of BMS-986187 was measured using CHO cells expressing human DOPr. Data 
were fitted using an allosteric ternary complex model and the KB of BMS-986187 to the sodium-
free receptor to be 110 nM [95% CI 48 nM to 130 nM]. The log(alpha) value of cooperativity 
between sodium and BMS-986187 is -0.79 [95% CI -0.93 to -0.64]. Data shown are mean ± 













Fig 3.6: The mu-SAM BMS-986123 blocks the action of BMS-986187 at MOPr. Using 
C6MOPr cell membranes, the ability of 10 µM BMS-986187 to enhance the potency of 
DAMGO-mediated GTPγ
35
S stimulation was measured in the presence or absence of 30 µM of 
the mu-SAM BMS-986123. An intermediate concentration of 10 µM mu-SAM was also tested 







with the orthosteric ligand Leu-Enk. BMS-986187 (300 nM) displayed no agonism alone but 
enhanced the potency of Leu-Enk to stimulate GTPγ
35
S by 4-fold. This effect was absent in the 
presence of BMS-986123 (Fig 3.7).  
Finally, since BMS-986123 blocks the action of BMS-986122 at MOPr and BMS-986187 
at DOPr, we predicted that BMS-986122 would be a SAM at DOPr. To test this, we measured 
the ability of Leu-Enk to stimulate GTPγ
35
S in C6DOPr cell membranes. This gave an EC50 for 
Leu-Enk of 650 nM. The presence of BMS-986187 (300 nM) shifted the dose response 5-fold 




Here, we confirmed that BMS-986187, initially described as a delta-PAM, is also a 
highly efficacious PAM for MOPr and likely has the same mechanism of action, allosteric 
disruption of the Na
+
 binding site, at both MOPr and DOPr as the previously described, yet 
structurally distinct, BMS-986122. Finally, we show that the known mu-SAM (BMS-986123) 
acts to reverse the activity of BMS-986187 at both MOPr and DOPr.  Together, our data are 
consistent with an allosteric binding site on both MOPr and DOPr that is conserved enough to 
recognize the same ligands and sufficiently promiscuous to recognize structurally diverse 
compounds.  
At DOPr, BMS-986187 is an ago-PAM ligand capable of both allosteric activity and 
direct agonist activity as measured by G protein activation, AC inhibition, and ERK activation 
(Appendix A; (Burford et al., 2015)), even though it does not bind to the orthosteric site. In 
contrast, the agonist activity of BMS-986187 at MOPr cannot be observed at the G protein level 
but can be seen as amplified AC inhibition, consistent with a low efficacy (Traynor and 
Nahorski, 1995). In addition, DOPr is known to have a higher constitutive activity compared to 
MOPr (Polastron et al., 1992; Neilan et al., 1999) and so is less constrained in the inactive state. 
It therefore should be easier for a PAM to drive the receptor to an active state.  
BMS-986187 has the ability to enhance the affinity of DAMGO to bind MOPr by 10-
fold. We also tested if BMS-986187 was cooperative with methadone, which we had previously 















Figure 3.7: mu-SAM reverses activity of BMS-987187 at DOPr, implying a conserved 
opioid allosteric binding site. Using C6DOPr cell membranes, the ability of 300 nM BMS-
986187 to enhance the potency of Leu-Enk-mediated GTPγ
35
S stimulation was measured in the 
presence or absence of 30 µM of the mu-SAM BMS-986123. Data shown are mean ± SEM from 
three experiments in duplicate. Potency values were obtained from fitting the data by linear 












Figure 3.8: mu-PAM BMS-986182 is weak PAM at DOPr capable of reversing BMS-
986187 activity. Using C6DOPr cell membranes, the ability of 300 nM BMS-986187 to enhance 
the potency of Leu-Enk-mediated GTPγ
35
S stimulation was measured in the presence or absence 
of 30 µM of the mu-PAM BMS-986122. Data shown are mean ± SEM from three experiments in 
duplicate. Potency values were obtained from fitting the data by linear regression with Hill 






Indeed, BMS-986187 caused a 28-fold shift in the affinity of methadone to bind MOPr. This 
means that for BMS-986187, BMS-986122, and the recently reported mu-PAM MS1 (Appendix 
B; (Bisignano et al., 2015)), methadone is more sensitive to modulation relative to DAMGO. 
Methadone is also more sensitive to the inhibitory effects of Na
+
 (Chapter 2), suggesting 
increased sensitivity to both positive and negative modulators that is presumably driven by the 
way in which methadone binds to the orthosteric site of MOPr. Molecular dynamics simulations 
recently performed with methadone, Na
+
, and BMS-986122 at MOPr may also provide insight 
into this sensitivity (Bartuzi et al., 2016). In this paper, the authors found several poses that 
methadone could adopt- one more reflective of a full agonist than the other and that the presence 
of BMS-986122 in the simulations shifted the methadone to preferring the full-agonist specific 
position. 
BMS-986187 appears to display the same efficacy-based probe dependence as we 
reported with the mu-PAM BMS-986122 (Chapter 2). For full agonists such as DAMGO and 
methadone, BMS-986187 causes an enhancement in both the affinity to bind MOPr as well as 
the potency to activate G protein. For the partial agonist morphine, BMS-986187 causes a small 
shift in affinity but significantly increases the level of maximal activation. This efficacy-based 
probe dependence falls in line with the Monod-Wyman-Changeux theory of allostery (Monod et 
al., 1965), and has also been reported with the M2 mAChR PAM benzyl quinolone carboxylic 
acid (Canals et al., 2012) which demonstrates a probe selectivity reflective of a two-state model 
of GPCR signaling.  
The KB, or affinity of BMS-986187 for MOPr, was found to be 2.2 µM which is not 
different than the KB of BMS-986122 for MOPr (1.7 µM; Chapter 2). The alpha value (α) of 
cooperativity between BMS-986187 and methadone was found to be 29; this is higher than the 
alpha value between BMS-986122 and methadone of 18 showing improved allosteric 
cooperativity of BMS-986187. Similarly, single concentrations of BMS-986187 showed larger 
shifts in the DAMGO affinity and potency to stimulate GTPγ
35
S binding than BMS-986122 and 
whereas both BMS compounds caused an increase in the maximal response to morphine, BMS-
986187 also afforded an increase in morphine potency. We are currently testing the hypothesis 
that these efficacy differences are due to variation in the ability of the two BMS compounds to 





Opioid receptor bias has been implicated in the selection of specific physiological effects 
resulting from MOPr activation. For instance, β-arrestin signaling is heavily implicated in the 
development of opioid tolerance (Bohn et al., 2000, 2002; Raehal and Bohn, 2011). 
Consequently, we analyzed the ability of BMS-986187 to alter both G-protein signaling (through 
GTPγ
35
S binding and AC inhibition assays) as well as arrestin-3 recruitment. Using the 
prototypic MOPr agonist DAMGO, it was found that BMS-986187 was able to enhance the 
potency of DAMGO in all pathways tested. There was enhanced cooperativity seen in the 
arrestin recruitment assay but this difference may be due to differences in the assay kinetics, 
ceiling, and lack of amplification. There seems to be no obvious bias, though there could well be 
a probe dependence to any bias. For example endomorphin-2 was shown to be biased (Rivero et 
al., 2012) and BMS compounds could potentially alter this bias. It was noted that BMS-986187 
alone was unable to cause arrestin-3 recruitment. The arrestin assay relies on enzyme 
complementation with no amplification and is therefore a high efficacy requiring system which 
could account for the lack of BMS-986187 agonist activity in this assay. A more amplified 
arrestin-mediated pathway, like ERK, may be more sensitive (Chapter 5).  
One of the proposed advantages of allosteric ligands is thought to lie in their selectivity 
as they target regions of proteins that faced little to no evolutionary pressure to remain 
conserved. However, both BMS-986187 and BMS-96122 bind to MOPr and both are 
antagonized by the mu-SAM BMS-986122. Indeed both the mu-SAM and BMS-986122 act as 
SAMs against the delta-PAM activity of BMS-986187. Although it is feasible that there could be 
negative allosteric interference between modulators, our data are consistent with a competitive 
interaction suggesting some form of a common site. Given the diversity in structure between 
BMS-986187 and BMS-986122 the specific amino-acid contacts are however, likely to be 
different. Based on two recent molecular dynamics studies, the proposed binding of BMS-
986122 at MOPr and BMS-986187 at DOPr rely upon residues that are conserved. In particular 
both studies emphasize the importance of residues Asn2.63, Tyr2.64, Trp7.35, and His7.36, 
which are conserved across MOPr and DOPr (Bartuzi et al., 2016; Shang et al., 2016). MOPr 
and DOPr share a high degree of homology, especially in the transmembrane domains and the 
orthosteric ligand binding pockets (Fenalti et al., 2014; Huang et al., 2015), which has evolved to 
bind the same ligands, including β-endorphin and the enkephalins. Because our data suggest a 





modulator that binds to MOPr and DOPr. There are very few examples reported thus far of 
endogenous allosteric modulators (for review see (van der Westhuizen et al., 2015)) including 
dynorphin A, a putative allosteric modulator of M2 acetylcholine receptor (Hu and El-Fakahany, 
1993), and glutathione, an allosteric ligand at the calcium sensing receptor (CaSR) (Wang et al., 
2006; Broadhead et al., 2011). 
In conclusion we have provided evidence that a common allosteric binding site exists on 
MOPr and DOPr, although this does not rule out the presence of other, as yet unidentified, 
allosteric sites on these receptors. Our support for a common allosteric site is based on several 
arguments. First, BMS-986187 and BMS-986122 are structurally very different yet both are 
effective PAMs for MOPr and the previously “selective” mu-PAM BMS-986122 is actually a 
SAM for DOPr. Secondly, the mechanism of allostery of both BMS compounds at MOPr and 
DOPr involves disruption of the Na
+
 binding site thereby driving formation of active receptor 
conformations. Finally, data from molecular dynamics simulations suggests that involvement of 
similar residues in MOPr and DOPr. However, the difference in chemical structure between 
BMS-986122 and BMS-986187 suggests this site is capable of accommodating a wide range of 
structures. 
 





S]GTPγS were from PerkinElmer Life Sciences. All tissue 
culture medium, penicillin-streptomycin, geneticin (G148), trypsin, and fetal bovine serum were 
from Invitrogen (Carlsbad, CA). DAMGO, naloxone, and morphine sulfate were from Sigma-
Aldrich. PathHunter detection reagents were from DiscoveRx (Freemont, CA).  Lance-Ultra 
cAMP detection reagents were from PerkinElmer Life Sciences (Cambridge, MA). BMS-
986122, BMS-986123, and BMS-986187 were gifts from Bristol Myers Squibb. Methadone was 
from the Opioid Basic Research Center at the University of Michigan. All other chemicals, 
unless otherwise specified, were purchased from Sigma (St. Louis, MO).  
Cell Lines and Membrane Preparation: The generation and maintenance of C6 rat glioma cells 
stably transfected with rat mu opioid receptor (MOPr) or rat delta opioid receptor (DOPr) were 
performed as described (Clark et al., 2008). FlpIn Chinese Hamster Ovary (CHO) expressing 





binding assays as described (Burford et al., 2015). Briefly, cells were grown to confluence and 
washed twice with 37 ºC phosphate-buffered saline (pH 7.4). Cells were detached in harvesting 
buffer (20 mM HEPES, 150 mM NaCl, 0.68 mM EDTA, pH7.4) and pelleted by centrifugation 
at 200 x g for 3 min at room temperature. The pellet was resuspended in ice-cold 50mM Tris (pH 
7.4) and homogenized using a Tissue Tearor (Dremel). This homogenate was centrifuged at 
20000 x g at 4 ºC for 20 min. The pellet was then resuspended, homogenized, and centrifuged 
once more. The final pellet was resuspended in 50 mM Tris (pH 7.4) using a glass dounce 
homogenizer and aliquots were flash frozen in liquid nitrogen. Aliquots were stored at -80 ºC 
until use. Concentration was determined using BCA quantification method with bovine serum 
albumin as the standard.  
CHO PathHunter cells expressing enzyme acceptor (EA)-tagged β-arrestin 2 and ProLink (PK)-
tagged MOPr receptor (CHO-OPRM1) were from DiscoveRx (Freemont, CA).  Cells were 
grown in F-12 media (Invitrogen 11765), containing Hyclone FBS 10%, Hygromycin 300 
µg/mL, Geneticin (G418) 800 µg/mL and maintained at 37 °C in a humidified incubator 
containing 5% CO2.  These cells were used for β-arrestin recruitment assays and inhibition of 
forskolin-stimulated cAMP accumulation assays described below. 
Radioligand Binding Assays: Ligand binding assays were performed using the cell membrane 
homogenates described above. Competition binding assays were performed as previously 
described (Livingston and Traynor, 2014). Briefly, displacement of 
3
H-diprenorphine (DPN; 0.2-
0.3 nM) was incubated in assay buffer (50 mM Tris pH 7.4, 100 mM NaCl, 5 mM MgCl2, 1 mM 
EDTA, 10 µM GTPγS) with 10 µg membrane protein, orthosteric ligand, and allosteric ligand 
(or vehicle). Nonspecific binding as determined in the presence of 10 µM naloxone. Assays were 
incubated for 75 minutes to reach equilibrium and then terminated and counted as described 





S binding experiments were performed as described (Livingston and 
Traynor, 2014) using cell membrane homogenates prepared as described above. Briefly, 10 µg of 
membrane proteins were incubated for 1 h at 25ºC in buffer [50 mM Tris pH 7.4, 100 mM NaCl, 
5 mM MgCl2, 1 mM EDTA] with 0.1 nM GTPγ
35
S (guanosine-5’-O(3-thio)triphosphate), 30 μM 
GDP (guanosine 5’-diphosphate), orthosteric ligand, and allosteric ligand (or vehicle). An 










diethylbenzamide] for DOPr) was used to define maximal activation and water/vehicle defined 
basal binding. The assays were terminated and counted as described above. 
PathHunter β-Arrestin Assay: Confluent flasks of CHO-OPRM1 cells were harvested with 
TrypLE Express, and resuspended in F-12 media supplemented with 10 % FBS and 25 mM 
HEPES, at a density of 6.67 x 10
5
 cells /mL and plated (3 µL / well) into white solid TC-treated 
1536-well plates (Corning, NY).  Plates were incubated overnight at 37 
o
C in a 5% CO2 
humidified incubator.  The next day, increasing concentrations of BMS-986187 (40 nL of 100 x 
final concentration in 100% DMSO) were added to separate rows of the assay plates by acoustic 
dispense using an Echo-550 (Labcyte, Sunnyvale, CA) from Echo-qualified 1536-well source 
plates (Labcyte).  Next, 1 µL of increasing concentrations of DAMGO (4 x final concentration in 
assay buffer) were added to separate columns of the assay plates containing cells. Plates were 
covered with a lid and incubated at room temperature for 90 min.  Incubations were terminated 
by the addition of 2 µL PathHunter Reagent (DiscoveRx).  One hour later luminescence was 
detected using a Viewlux imaging plate reader (PerkinElmer). 
Inhibition of Forskolin-Stimulated cAMP Accumulation Assays: CHO-OPRM1 cells were 
grown to confluence then harvested and resuspended at 10
6
 cells / mL in assay buffer (HBSS + 
25 mM HEPES, + 0.05% BSA).  Increasing concentrations of BMS-986187 (30 nL of 100 x 
final concentration in 100% DMSO) were added to separate rows of 1536-well white solid NT 
plates by acoustic dispense using an Echo-550 (Labcyte, CA). Next, 1 µl of increasing 
concentrations of DAMGO (at 3 x final concentration in assay buffer) were added to separate 
columns of the plates. Next, 1 µL of cells (1000 cells / well) were added to all wells followed by 
1 µL of forskolin (3 x final concentration in assay buffer).  Plates were lidded and incubated for 
45 min at RT.  Incubations were terminated by the addition of Lance-Ultra cAMP detection 
reagent (Perkin Elmer) (1.5 µL of Eu-cryptate-labelled cAMP tracer in lysis buffer, followed by 
1.5 µL of U-light conjugated anti-cAMP antibody in lysis buffer).  After a 1 h incubation at room 
temperature, time-resolved fluorescence (TRF) was detected on a Viewlux or Envision plate 
reader (PerkinElmer) with excitation at 337 nm and emission reads at 615 nm and 665 nm.  The 





on a standard curve for cAMP (replacing the cell addition step) run at the same time and under 
identical conditions to the assay. 
Data Analysis: Data were analyzed using GraphPad Prism version 6 (GraphPad, San Diego, CA, 
USA). Ki values and EC50 values were determined using nonlinear regression. The method of 
Ehlert (Ehlert, 1985) was used to calculate agonist efficacy based in the ability to stimulate 
GTPγ
35
S according to the equation: efficacy = 0.5 x (Emax,A /Emax) x (1 + Ki/EC50), where 
Emax,A is the maximum stimulation by agonist A, Emax is the maximum stimulation by 
DAMGO, Ki is the affinity of agonist A, and EC50 is the potency of agonist A. Hill slopes for all 
the binding and functional data were not significantly different from one, allowing use of the 
Ehlert equation. Functional cooperativity (α) and the affinity (KB) value for allosteric modulators 
were obtained using an allosteric ternary complex model (Christopoulos and Kenakin, 2002) in 











Stabilization of Active-State Mu Opioid Receptor by Orthosteric and Allosteric Ligands: 
Implications for Agonist Efficacy 
Summary 
 The mu opioid receptor (MOPr) represents one of the most pharmacologically targeted G 
protein-coupled receptors (GPCRs). Activation by an orthosteric agonist such as morphine 
causes robust pain relief, but also results in unwanted effects including respiratory depression, 
constipation, and addiction. However, these actions have different agonist efficacy requirements. 
Consequently, an understanding of the factors governing efficacy and a quantitative way to 
measure efficacy is needed. Utilizing purified MOPr reconstituted into high density lipoprotein 
(rHDL) particles we studied binding of the MOPr state-sensitive sensor nanobody39 (Nb39) by 
interferometry to monitor abundance of the MOPr active state following agonist binding. 
Differences in orthosteric ligand efficacy were shown to correlate with different kinetics of Nb39 
association and dissociation. In addition, we have recently described a series of positive 
allosteric modulators (PAMs), exemplified by BMS-986122 and BMS-986187, that enhance the 
affinity and/or efficacy of orthosteric MOPr ligands. BMS-986122 and BMS-986187 enhanced 
the on-rates of Nb39 in the absence of orthosteric ligand and they also showed cooperativity with 
agonist to promote Nb39 binding, but differences were seen in the allosteric efficacies. Finally, 
we show that allosteric cooperativity between agonist and BMS-986187 is the same in 
membrane systems containing G protein and in the MOPr rHDL system without G protein, 
suggesting that the allosteric modulators alone are able to stabilize of an active state of MOPr 
and induce of high-affinity agonist binding. 
Introduction  
Pain is an unavoidable condition for which millions of people worldwide seek medical 





ligands such as morphine and oxycodone. These drugs bind and activate the mu opioid receptor 
(MOPr), a G protein-coupled receptor (GPCR), at its orthosteric site and compete with the 
endogenous opioid peptides. Though efficacious at causing pain relief, MOPr activation at the 
orthosteric site also results in constipation, respiratory depression, and euphoria which enhances 
the addictive liability of opioid agonists. We are currently pursuing the idea that allosteric 
modulation of MOPr could represent a better method of pain relief with the potential for an 
improved therapeutic profile. In contrast to traditional activation by orthosteric agonists, 
allosteric enhancement of the actions of endogenous opioid peptides would preserve the spatial 
and temporal regulation of opioid peptide release (Burford et al., 2015). This may allow for 
analgesia while avoiding long-term adaptations that manifest as tolerance and dependence. In 
addition, allosteric ligands have been known to alter or promote the bias of orthosteric agonists 
(Leach et al., 2007; Ahn et al., 2012; Baillie et al., 2013). Induction of a bias of MOPr signaling 
could potentially result in analgesia with reduced adverse effects. For example, G protein biased 
signaling has been suggested to promote analgesia while decreasing the potential for tolerance 
and dependence (Bohn et al., 1999, 2000; Raehal et al., 2011). 
Positive allosteric modulators (PAMs) of MOPr, exemplified by BMS-986122 (Burford 
et al., 2013), enhance the affinity and/or efficacy of orthosteric ligands for MOPr, but show a 
distinct dependence on which orthosteric ligand is used to probe the allosteric interaction 
((Burford et al., 2013; Livingston and Traynor, 2014); Chapter 2). We have shown that BMS-
986122 allosterically disrupts the binding of the endogenous negative allosteric modulator Na
+
 
and promotes formation of active state MOPr with the degree of agonist cooperativity dependent 
upon the intrinsic efficacy of the ligand ((Livingston and Traynor, 2014); Chapter 2). In order to 
fully validate the hypothesis that BMS-986122 promotes active-state MOPr, we sought to design 
and implement a method to investigate the formation and stabilization of active state MOPr in 
response to various orthosteric and allosteric ligands.  
The side effects of opioid agonists result from on-target activation of MOPr (Matthes et 
al., 1996), although it is known that the initiation of these physiological effects requires different 
degrees of efficacy. Evidence exists that the discriminative stimulus of opioid agonists varies 
depending on efficacy (Walker et al., 2004), suggesting that opioid agonist efficacy is a 
determinant of abuse potential. Indeed, it has been show that higher efficacy ligands carry more 










), both carry lower addictive liability, but exhibit robust pain relief in 
humans indicating that the efficacy requirements for euphoria and pain relief are different. 
Indeed, extremely high efficacy opioid agonists including etorphine, have shown limits in their 
clinical value due to propensity to cause severe respiratory depression in addition to analgesia 
(Blane et al., 1967) and have a narrow therapeutic index. In order to be able to predict the ability 
of MOPr agonists to cause various physiological effects, an understanding of their intrinsic 
efficacy is required.  
The majority of approaches to determine intrinsic efficacy rely upon cell-based systems 
and the measurement of signaling downstream of the receptor. Despite best efforts, the 
calculated intrinsic efficacy of ligands can vary based on the signaling output measured due to 
signal amplification, ligand bias, kinetics of the assay, and the species of the cell system used 
(Kenakin, 2002; Kenakin and Christopoulos, 2011; Luttrell and Kenakin, 2011; Herenbrink et 
al., 2016). For example, using the same cellular background, the putatively biased ligand 
TRV130 initiates robust arrestin recruitment (74% of standard) downstream of mouse MOPr, 
less with human MOPr (14% of standard), and shows undetectable levels using rat MOPr 
(Dewire et al., 2013). Complications such as these make correlations of physiological effects to 
values of efficacy and bias difficult to interpret. In this study we sought to establish a method to 
evaluate the intrinsic efficacy of opioid ligands utilizing a cell-free assay independent of 
signaling outputs and signal amplification. We then sought to utilize this method to further probe 
the mechanism by which small molecule PAMs alter the efficacy of ligands at MOPr.  
The recent crystal structure of MOPr in complex with the highly efficacious agonist 
BU72 utilized nanobody 39 (Nb39), a camelid antibody, to stabilize active MOPr (Huang et al., 
2015). Nb39 enhances the affinity of agonists to bind MOPr and stabilizes conformational 
changes in MOPr associated with an active-like state, including an outward movement of 
transmembrane helix 6. Nanobodies are small, monomeric proteins that can be utilized as 
conformational biosensors. Nanobodies have recently been used as tools to monitor formation of 
active-state β2 adrenergic receptors (β2AR) in live cells (Irannejad et al., 2013). Consequently, 
we sought to use Nb39 as a probe to detect active-state conformation of MOPr using a variety of 
orthosteric and allosteric ligands in a cell-free setting. We predicted that the intrinsic efficacy of 







Measure of orthosteric agonist efficacy using interferometry-based technique 
Nb39 enhances the affinity of agonists such as BU72 to bind MOPr ((Huang et al., 2015), 
Appendix A) by stabilizing active (R*) states of MOPr. Because agonists shift the equilibrium of 
receptor to R* in proportion to their efficacy to activate downstream signaling, we predicted that 
agonists should enhance the binding of Nb39 in an efficacy-dependent manner.  To test this, we 
implemented an interferometry-based technique to study the association and dissociation kinetics 
of Nb39 binding to monomeric MOPr in reconstituted high-density lipoproteins (rHDL). Briefly, 
MOPr rHDL particles are immobilized on a probe which is dipped in buffers containing ligands 
and Nb39. As shown in Figure 4.1, there was no detectable binding of Nb39 to MOPr in the 
absence of ligand. This indicates there is no spontaneous formation of active MOPr even with 
Nb39 present. Indeed, published research indicate very low levels of constitutive activity of 
MOPr (Divin et al., 2009; Connor and Traynor, 2010). In contrast, a wide range of agonists 
caused binding of Nb39, although to varying degrees (Table 4.1). In particular, the presence of a 
saturating concentration (30 µM) of BU72 drives robust and rapid binding of Nb39 (Fig 4.1, 
Table 4.1).  The high-efficacy peptide agonist DAMGO displayed a similar association rate, but 
drove less overall binding of Nb39. In contrast, the partial agonist morphine led to slower Nb39 
association and less overall binding of Nb39 (Fig 4.1, Table 4.1). Neither of the orthosteric 
antagonists naloxone or diprenorphine promoted MOPr:Nb39 interaction (Table 4.1).   
To determine if the association rates of Nb39 to agonist-bound receptor reflect the 
efficacy of the agonist, we compared Nb39 association with three methods of efficacy 
measurement. In particular we studied the i) maximal efficacy to stimulate G protein signaling 
(Strange, 2008), ii) intrinsic efficacy as defined by Ehlert’s equation (Ehlert, 1985), and iii) 
reduction in agonist affinity in the presence of Na
+
 ions and GTP nucleotide (Lee et al., 1999). 
These complimentary methods of efficacy determination generally agree with one another, but 













Figure 4.1: Orthosteric ligand-mediated Nb39 association and dissociation in MOPr-rHDL. 
As described in the methods, the association and dissociation of Nb39 (1 µM) was measured 
using OctetRed
®







First, we compared the Nb39 association half-time (t1/2) and the ability to stimulate G 
protein activation for each ligand. The GTPγ
35
S response elicited (taken from Chapter 2; 
(Livingston and Traynor, 2014)) by a saturating (10 µM) concentration of ligand correlated with 
the t1/2 for Nb39 recruitment. (r
2
 = 0.75, p<0.0001 Fig 4.2A). Next, we correlated these 
association data with the intrinsic efficacy of the various orthosteric ligands. Intrinsic efficacy 
was calculated using the Ehlert equation ((Ehlert, 1985); see Methods) with potency and 
maximal response obtained from GTPγ
35
S binding assays and affinity values obtained using 
radioligand competition binding in the same buffer as the GTPγ
35
S assays. There was a 
statistically significant correlation. For instance, both etorphine and BU72 have equivalent Ehlert 
values (4.7) and both ligands show the same association rate for Nb39 (t1/2 = 3.5 sec for BU72, 
3.9 sec for etorphine). The correlation was weaker than the comparison with the GTPγ
35
S 
maximum stimulation, but was still significant (r
2
= 0.44, p=0.02 Fig 4.2B). For this analysis, we 
had to exclude nalbuphine as an EC50 value could not be determined due to its extremely low 
efficacy to activate G protein. 
To avoid the use of a signaling measure, we used an additional readout of intrinsic 
efficacy, specifically the Na
+
/GTP shift. It is known that addition of Na
+
 and guanine nucleotide 
decreases the affinity of agonists to bind MOPr and that this effect is larger for higher efficacy 
ligands (Lee et al., 1999). Using previously published data (Chapter 2), we plotted the shift in 
affinity of the orthosteric ligands by the addition of NaCl/GTP (100 mM and 10 µM 
respectively) versus the calculated t1/2 of Nb39 association to ligand-bound MOPr. This 
correlation was significant (Fig 4.2C, r
2
 = 0.73, p= 0.002). Of note, the ligands BU72 and 
etorphine were excluded from this analysis due to their paradoxical lack of Na
+
/GTP shift 
(Chapter 2; Appendix A).   
Our interferometry technique also allows for measurement of the dissociation of Nb39 
from ligand-bound MOPr. In contrast to the association rates observed, the dissociation of Nb39 
was fairly constant across the various ligands (Table 4.1). As an example, the Nb39 dissociation 
rate was the same from both morphine-bound MOPr (0.033 ± 0.001 min
-1
) and BU72-bound 
MOPr (0.031 ± 0.001 min
-1
), despite their markedly different efficacies. In contrast, L-






Figure 4.2: Correlation of association times of Nb39 with various measures of agonist 
efficacy. The t1/2 of association of Nb39 in the presence of saturating agonist was measured and 
is plotted against A) maximal stimulation of GTPγ
35
S binding by agonist (r
2
 = 0.75, p<0.0001), 
B) the calculated Ehlert efficacy (Ehlert, 1985) values for each agonist to activate G protein (r
2
= 
0.44, p=0.02),  and C) the shift in affinity of the agonist as measured by radioligand competition 




 = 0.73, p= 0.002). The ligands are: 1) BU72, 
2) DAMGO, 3) Leu-Enk, 4) L-methadone, 5) Morphine, 6) Nalbuphine, 7) Endomorphin2, 8) 
Loperamide, 9) Oxycodone, 10) Etorphine 11) Fentanyl, 12) Met-Enk, 13) Hypdrocodone, and 





Table 4.1: Association and dissociation kinetics of Nb39 to MOPr rHDL in the presence of 
various agonists.  
 
kobs and koff were fit for each independent experiment (3-10 individual experiments) and 
averaged. One-phase association and single-phase exponential decay models were used. Half-
time values (t1/2) numbers were calculated from the respective K values (t1/2 = 0.693/k).  
  









BU72 0.20 ± 0.01 3.5 0.031 ± 0.001 22 
DAMGO 0.179 ± 0.008 3.9 0.030 ± 0.001 23 
Leu-Enk 0.098 ± 0.02 7.1 0.031 ± 0.001 23 
L-Methadone 0.19 ± 0.02 3.6 0.052 ± 0.003 13 
Morphine 0.08 ± 0.01 8.5 0.033 ± 0.003 21 
Nalbuphine 0.023 ± 0.008 30 0.036 ± 0.004 19 
Endomorphin 2 0.101 ± 0.002 6.9 0.036 ± 0.002 19 
Loperamide 0.208 ± 0.009 3.2 0.044 ± 0.003 16 
Oxycodone 0.044 ± 0.001 16 0.028 ± 0.001 25 
Etorphine 0.180 ± 0.007 3.9 0.026 ± 0.001 27 
Fentanyl 0.075 ± 0.005 9.2 0.035 ± 0.002 20 
Met-Enk 0.131 ± 0.004 5.3 0.027 ± 0.001 26 
Hydrocodone 0.042 ± 0.004 17 0.029 ± 0.001 24 
Buprenorphine 0.058 ± 0.009 12 0.025 ± 0.001 27 
Naloxone n/a ---- n/a ---- 
Diprenorphine n/a ---- n/a ---- 
BMS-986122 0.012 ± 0.001 56 0.027 ± 0.003 25 





ligands (t1/2 of dissociation of 13 and 16 sec for L-methadone and loperamide, respectively; see 
Table 4.1). This difference can be interpreted as a distinct methadone-(or loperamide-) bound 
MOPr with decreased affinity for Nb39 as compared to other ligands. 
 
Allosteric modulation of MOPr rHDL by small molecule PAMs and measurement of allosteric 
efficacy 
Previously, we have shown that the MOPr PAM, BMS-986122, enhances agonist affinity 
and efficacy by stabilizing the active state of MOPr. To test this hypothesis using the 
interferometry method, we first wanted to validate that BMS-986122 had detectible allosteric 
activity in monomeric MOPr rHDL, as all previous work was done in cell membranes. The 
affinity of L-methadone was measured using competition binding with 
3
H-diprenorphine in the 
presence or absence of 10 µM BMS-986122.  The affinity of L-methadone was enhanced 3-fold 
in the presence of 10 µM BMS-986122 (Fig 4.3). This shift is much smaller than seen in 
membranes prepared from C6 rat glioma cells stably expressing MOPr (C6MOPr; Chapter 2; 
(Livingston and Traynor, 2014)). In order to determine if this diminished BMS-986122 activity 
in the MOPr rHDL system was a property of BMS-986122 or a property of purified MOPr, we 
investigated BMS-986187, another PAM that is structurally distinct from BMS-986122 (Fig 4.3). 
Though initially discovered as a PAM of the closely related delta opioid receptor (DOPr) we 
have shown it is a low affinity PAM of MOPr that binds at the same site on the receptor as BMS-
986122 (Chapter 3; (Burford et al., 2015)). In contrast to BMS-986122, BMS-986187 enhanced 
the affinity of L-methadone to bind MOPr by over 10-fold in the rHDL system (Fig 4.3). By 
performing competition assays in the presence of increasing concentrations of BMS-986187, the 
allosteric ternary complex model was used to calculate an α value of cooperativity (58) and KB 
(4.5 µM), representing the affinity of BMS-986187 for the unoccupied MOPr in rHDL, similar to 
that seen for MOPr in C6 membranes (Chapter 3).  From this we determined the affinity of 
BMS-986187 for the methadone-bound MOPr in rHDL (KB/α) to be 77 nM. 
The discrepancy in BMS-986122 and BMS-986187 activity in MOPr rHDL was 
surprising as we have previously shown that both ligands have the same probe dependence, same 







Figure 4.3: Allosteric modulation of MOPr rHDL by small molecule PAMs. Structures of 
BMS-986187 (A) and BMS-986122 (B).  The ability of increasing concentrations of BMS-
986122 (C) or BMS-986187 (D) to enhance the binding affinity of methadone was measured 
using displacement of 
3
H-diprenorphine. The effect of BMS-986187 on methadone affinity is 
plotted in (E) and these data were analyzed using the allosteric ternary complex model to 
calculate KB and alpha value of cooperativity. The ability of 10 µM BMS-986122 to enhance the 
affinity of DAMGO (F) or morphine (G) is also shown. All plotted points are means ± SEM of 







dependence of BMS-986187 we had previously seen (Chapter 3) was based upon direct 
ligand:receptor interaction and not due to the cellular membrane environment, we studied the 
ability of BMS-986187 to enhance affinity of three orthosteric ligands in rHDL-MOPr. The 
probe dependence was the same in the rHDL-MOPr system as in the C6MOPr membranes; 
BMS-986187 was able to enhance the affinity of DAMGO by six-fold (logKi (veh) = -5.8 [95% 
C.I. -6.1 to -5.5] and logKi (BMS-986187) = -6.6 [95% C.I. -6.7 to -6.4]) and methadone, but 
failed to alter that of morphine (logKi (veh) = -6.2 [95% C.I. -6.4 to -6.0 and logKi (BMS-
986187) = -6.3 [95% C.I. -6.7 to -5.9])  (Fig 4.3). Furthermore, this probe dependence matches 
that seen for BMS-986122 and can be most simply explained by a two-state model of GPCR 
function ((Monod et al., 1965; Livingston and Traynor, 2014), Chapter 2) in which BMS-986187 
drives R*. 
We hypothesized that both PAMs stabilize active-states of MOPr but that BMS-986187 
has a higher allosteric efficacy compared to BMS-986122 as seen by the enhanced cooperativity 
with L-methadone in the MOPr rHDL. Therefore we hypothesized that both ligands alone would 
result in the binding of Nb39 but BMS-986187 would do so to a greater extent and at a more 
rapid rate. We found that both allosteric ligands were able to cause Nb39 binding but that it was 
quite slow (Fig 4.4, Table 4.1) compared to orthosteric agonists. In addition, the koff of Nb39 
from the BMS-986122-bound or BMS-986187-bound MOPr showed the same kinetics as the 
orthosteric agonists. This suggests that the active state stabilized by these PAMs is similar to 
those stabilized by traditional orthosteric agonists.  
In addition to stabilizing active-state alone, we were interested to investigate the effect of 
the allosteric ligands on the ability of orthosteric agonists to promote Nb39 binding. Since both 
allosteric ligands have the ability to increase the efficacy of various orthosteric ligands in cell-
based signaling assays, we hypothesized that this increase in efficacy would manifest as an 
increase in the observed on rate of Nb39 and that BMS-986187 would have a larger effect on 
Nb39 association than BMS-986122. Shown in Fig 4.5 is the ability of the two MOPr PAMs to 
enhance morphine-driven recruitment of Nb39. As predicted, both allosteric ligands enhanced 
the rate of Nb39 association and also enhanced maximal Nb39 binding.  We did the same 
experiments with the orthosteric ligands L-methadone and DAMGO. Both PAMs enhanced the 










Two-way ANOVA with a Tukey post-hoc test was performed. * indicated statistically 
significance compared to vehicle condition for each orthosteric ligand. (* p < 0.05, ** p < 0.01, 
*** p< 0.001). 
++
 indicates p < 0.01 as compared to L-methadone/BMS-986187 combination. 
§ 
indicates p < 0.01 as compared to morphine/vehicle combination. 
¥
 indicates p < 0.01 as 
compared to DAMGO/vehicle combination.  
 
 
Morphine (1 µM Nb39) 
   
 
kobs (min
-1) t1/2 Assoc (sec) koff (min
-1) t1/2 diss (sec) 
Vehicle 0.08 ± 0.01 8.5 0.033 ± 0.001 21 
BMS-986122 0.11 ± 0.001 6.4 0.032 ± 0.0002 22 
BMS-986187 0.13 ± 0.01 *** 5.3 0.024 ± 0.0004 29 
     L-Methadone (100 nM Nb39) 
   
 
kobs (min
-1) t1/2 Assoc (sec) koff (min
-1) t1/2 diss (sec) 
Vehicle 0.087 ± 0.009 8.0 0.050 ± 0.004 § 14 
BMS-986122 0.077 ± 0.007 9.0 0.047 ± 0.004 ++ 15 
BMS-986187 0.055 ± 0.004 * 13 0.033 ± 0.002 ** 21 
     DAMGO (100 nM Nb39) 
   
 
kobs (min
-1) t1/2 Assoc (sec) koff (min
-1) t1/2 diss (sec) 
Vehicle 0.051 ± 0.003 14 0.035 ± 0.003 ¥ 20 
BMS-986122 0.05 ± 0.01 13 0.029 ± 0.003 24 












Figure 4.4: Binding kinetics of Nb39 driven by allosteric ligands. The association and 
dissociation of Nb39 (1 µM) was measured using OctetRed®. Shown is a representative 






MOPr with BMS-986187 having a larger effect. Unexpectedly, the association of Nb39 to L-
methadone bound MOPr was actually slowed in the presence of either BMS-986122 or BMS-
986187. Additionally, the dissociation of L-methadone is unchanged by BMS-986122 but is 
slowed significantly by BMS-986187 (Table 4.2) 
 
Discussion  
We have described a novel method for examining the efficacy of both orthosteric and 
allosteric ligands of a prototypic class A GPCR, MOPr, which relies upon the ability of Nb39 to 
recognize the active state of the receptor.  The ability of a ligand to stabilize active states (R*) of 
a GPCR is the first requirement in displaying physiological agonist effects. For MOPr, activation 
results in a variety of effects depending on the efficacy and bias of the ligand as well as the 
location of the receptor. Understanding the actions of ligands at this first step is crucial in 
predicting their activity downstream and in vivo. The technique presented here is a way of 
quantitatively examining the efficacy of both orthosteric and allosteric ligands at MOPr and 
should readily be applied to other GPCRs. This technique is independent of signaling and does 
not depend upon calculations of efficacy derived in the operational model from Black and Leff 
(Black and Leff, 1983) or the method of Ehlert (Ehlert, 1985). Measurement of Nb39 binding has 
no amplification and is dependent upon only receptor:ligand interaction. This enables fine-tune 
detection of ligand differences that may be masked when measuring an amplified signaling 
output. Indeed, if we were to perform the same correlation analysis presented in Fig 4.2 with a 
more amplified output (adenylate cyclase), the correlation falls dramatically (data not shown). 
As predicted based on data from previous studies with Nb39 and Nb80 (Rasmussen, 
Choi, et al., 2011; Irannejad et al., 2013; Huang et al., 2015), the presence of an agonist resulted 
in robust Nb39 binding while the antagonists naloxone or diprenorphine failed to promote 
detectable Nb39 binding. Our findings show that the ability of an agonist to promote Nb39 
binding is well-correlated with its ability to promote signal transduction through G protein as 
measured by GTPγ
35
S binding. In fact, this technique was more sensitive as some of the ligands 
were able to promote Nb39, but failed to show measurable G protein activity using the GTPγ
35
S 













Figure 4.5: Effects of mu-PAMs on morphine-mediated association and dissociation of 
Nb39 from MOPr-rHDL. As described in the methods, the association and dissociation of 
Nb39 (1 µM) was measured using OctetRed
®
. Shown is a representative experiment comparing 
the kinetics in the presence of morphine plus vehicle (black), BMS-986122 (green), or BMS-





While theoretically measuring the same process (active-state promotion) the GTPγ
35
S assay can 
vary dramatically based upon nucleotide concentration, receptor:G protein ratios, MgCl2 
concentration, NaCl concentrations, time, and temperature (Traynor and Nahorski, 1995; 
Szekeres and Traynor, 1997; Remmers et al., 2000; Heusler et al., 2016). Indeed, it may be 
possible for there to be initiation of R*:G complexes that do not result in nucleotide exchange 
and GTPγ
35
S binding and therefore would not be detectable by this method. In contrast, Nb39 
binding is not an enzymatic process like nucleotide exchange and instead represents a 
bimolecular binding event. 
It is important to note that the range of active MOPr conformations recognized by Nb39 
is, as of yet, unknown but it is known that Nb39 stabilizes an active state of MOPr displaying the 
prototypic outward movement of TM6 associated with active GPCRs.  Also, the affinity of the 
agonist BU72 for Nb39-bound MOPr and Gi-bound MOPr is the same, suggesting the states of 
MOPr are similar (Huang et al., 2015). The correlation experiments leave room for interpretation 
of the nature of states that Nb39 can bind.  If Nb39 was an active state sensor capable of 
recognizing and binding all active-like conformations capable of initiating downstream signal 
transduction, there should theoretically be perfect correlations in Fig 4.2. As evidenced, the 
correlation with Ehlert efficacy values shows this is not the case. Though a well-accepted 
method for determining intrinsic efficacy, Ehlert’s measure still relies upon data collected from a 
signaling assay which means that if a ligand is biased the results may differ depending on which 
signaling output is chosen. The Ehlert equation relies upon an EC50, affinity value, and an Emax 
that is relative to a chosen standard. The EC50 of an assay will be heavily reliant on the system: 
receptor reserve, time of incubation, and inherent system maximum and is therefore not an 
absolute number (Strange, 2008). It is possible that there are active states recognized by Nb39 
that are not as efficient as others at activating G protein.  
Data from the interferometry experiments correlated more strongly with the Na
+
/GTP 
shift of orthosteric agonists. This is likely because affinity is ideally system-independent and so 
the Na
+
/GTP shift appears to be more reflective of true intrinsic efficacy of a ligand with no 
dependence on selection and measurement of a signaling output. Of note, etorphine and BU72 
are unique ligands in that they exhibit no Na
+
/GTP shift despite their high efficacy. This high 
efficacy and induction of rapid Nb39 binding is not predicted by their lack of sensitivity to 
Na
+







, but perhaps a decrease in the potency of sodium to alter etorphine’s affinity 
compared to other agonists and that a higher concentration of Na
+
 could further shift the affinity 
of BU72 and etorphine. The lack of the ability of Na
+
/GTP to alter affinity is in agreement with 
the lack of allosteric effects of the PAMs on these ligands (Chapter 2), suggesting that their 
affinity may be too high to be altered by allosteric ligands/ions. It is also possible that etorphine 
and BU72 promote a distinct state of the receptor that is not negatively cooperative with sodium. 
Indeed, recent NMR work has suggested that BU72 is a superagonist capable of stabilizing 
MOPr in an active-state without G protein and etorphine may be similar (Sounier et al., 2015). 
Generally most orthosteric ligands examined, as well as the allosteric ligands, induced a 
conformation of MOPr that displayed the same dissociation rate of Nb39. There were two 
outliers though: L-methadone and loperamide. The dissociation rates of Nb39 from the 
methadone-bound and loperamide-bound MOPr were statistically much faster than with other 
agonists as well as the allosteric ligands.  This difference could arise for various reasons. 
Presumably, dissociation of Nb39 is driven by the relaxation of the R* to inactive R 
conformation; this could indicate that the methadone-bound MOPr produces an active state with 
a shorter lifetime than other agonists, despite L-methadone being present in concentrations ten-
fold greater than its affinity. In contrast, if we take the dissociation to be a product of the affinity 
of Nb39 for a methadone-bound receptor, this indicates that the methadone-bound receptor has 
decreased affinity for Nb39. The same can be said for loperamide, though to a lesser extent. 
Although the dissociation of Nb39 from the methadone-occupied receptor was faster than 
the other ligands, it was still sensitive to the PAMs in the same way (Table 4.2) in that the 
dissociation was slowed by the PAMs. In contrast to the other orthosteric ligands tested however, 
BMS-986122 and BMS-986187 both slowed association of Nb39 in the presence of methadone, 
indicating a negative cooperativity. This is in sharp contrast to both of these PAMs increasing 
potency and affinity of L-methadone to bind and activate MOPr (Fig 4.3, (Livingston and 
Traynor, 2014), Chapter 2, Chapter 3), but fits with a decrease in the Ehlert efficacy of L-
Methadone that was seen in the presence of BMS-986122 (Chapter 2). One plausible explanation 
is that Nb39 recognizes only a subset of all possible conformations that are capable of activating 
G protein such that the efficiency of MOPr to activate nucleotide exchange may not be reflected 
in differences in Nb39 binding. In addition, methadone is the most sensitive orthosteric ligand 





and MS1 (Appendix C; (Bisignano et al., 2015)). It is suggestive that methadone engages with 
MOPr in distinct ways that can be seen both in Nb39 binding characteristics as well as in 
sensitivity to allosteric modulation.  
The differences in the efficacy of BMS-986122 and BMS-986187 are intriguing. Both 
ligands exhibit the same probe dependence, same mechanism of action, and appear to bind at the 
same site. Both are capable of driving Nb39 binding alone, but BMS-986187 does so to a greater 
extent at a faster rate. In line with this enhanced allosteric efficacy, only BMS-986187 is capable 
of driving high-affinity agonist binding alone (Fig 4.3). In addition, the dissociation rate of Nb39 
from allosteric ligand-bound receptors is the same as that of agonist-bound receptors suggesting 
that they are similar active states that recognize Nb39 in the same manner (Table 4.1). Indeed, 
this is an example of a G protein-independent high affinity state. It would be interesting to 
determine if a BMS-986187:Receptor:Agonist complex adopts the same conformation as a 
Receptor:Agonist:G protein complex. Crystallographic work is underway to determine the mode 
of BMS-986187 binding and to determine the structural features that govern allosteric 
modulation of MOPr. 
In summary, these data show a novel method for the quantitative evaluation of efficacy of 
both orthosteric and allosteric ligands using purified MOPr in rHDL particles and demonstrate 
that allosteric modulators of MOPr that work by displacement of Na
+
 ions are capable of forming 
active state receptor and of driving G protein-independent high affinity agonist binding. This 
technique is more sensitive than traditional measures of efficacy and is not reliant upon signal 
amplification. In the future, the methodology could also be applied to other GPCRs and other 
interacting proteins, such as arrestin, in order to determine a ligands’ bias at the purely receptor 
level, independent of second messengers and cell type. 
 
Materials and Methods 
Purification of MOPr: Full length Mus musculus MOPr bearing an amino-terminal Flag epitope 
tag and a carboxy-terminal 6xHis tag was expressed in Sf9 insect cells using the BestBac 
baculovirus system (Expression Systems). A tobacco etch virus (TEV) protease recognition 
sequence was inserted after residue 51 and a rhinovirus 3C protease recognition sequence was 





baculovirus encoding MOPr 48–60h at 27 ºC. Receptor was solubilized and purified in a final 
buffer comprised of 25 mM HEPES pH 7.4, 100 mM NaCl, 0.01% MNG (Anatrace), and 
0.001% cholesterol hemisuccinate (CHS), as previously described (Manglik et al., 2012). 
Purification of Nb39: Nb39 was purified as described (Huang et al., 2015). Briefly, Nb39 
bearing a carboxy-terminal His tag were expressed in the periplasm of Escherichia coli strain 
WK6 grown in Terrific Broth medium containing 0.1% glucose, 2 mM MgCl2, and 50 mg/ml 
ampicillin and induced with 0.5 mM isopropyl-b-D-thiogalactoside (IPTG). Cells were harvested 
after overnight growth at 25 °C and incubated in a buffer containing 200 mM Tris, pH 8.0, 0.5 
mM EDTA, 500 mM sucrose and 0.5 mg/ml lysozyme for 1 h at 25 ºC. Bacteria were 
osmotically lysed by rapid dilution in water. The periplasmic fraction was isolated by 
centrifugation of cell debris, and was supplemented with NaCl (150 mM final) and imidazole (25 
mM final). Nb39 was isolated from the periplasmic fraction by nickel affinity chromatography, 
and subsequently purified by size-exclusion chromatography in a buffer comprised of 25 mM 
HEPES pH7.5 and 100 mM NaCl. Peak fractions were pooled and concentrated to approximately 
5mM. 
Apolipoprotein purification and biotinylation: Apolipoprotein-AI (Apo-AI) was purified as 
described previously (Whorton et al., 2007). Apo-A1 was biotinylated using NHS-PEG4-biotin 
(Pierce Biotechnology) at a 1:1 molar ratio. Following a 30-min biotinylation reaction at room 
temperature, the sample was dialyzed to remove free biotin.  
MOPr rHDL Reconstitution: Purified MOPr was reconstituted into high-density lipoprotein 
(HDL) particles comprised of the lipids POPC and POPG (Avanti Polar Lipids) in a 3:2 molar 
ratio as previously described (Whorton et al., 2007). For OctetRed® experiments, rHDL 
particles containing receptor were isolated from empty rHDL by FLAG affinity chromotography 
and elution fractions positive for 
3
H-diprenorphine binding were pooled. 
Nb39 Kinetic Assays: Nb39 binding to MOPr in the presence or orthosteric and/or allosteric 
ligands was measured using the OctetRED biolayer interferometry system (Pall Forte Bio). In 
this assay, biotinylated apolipoprotein-containing rHDL-MOPr sample is immobilized on a 
streptavidin-coated fiber optic probe that is incubated into buffers containing ligands in the 





buffer containing ligands but no Nb39. Specifically, biosensors (Pall Forte ´Bio) were loaded 
with biotinylated MOPr-rHDL particles for 15 min at room temperature and the biosensors were 
transferred to the OctetRED instrument. Sensors were placed into assay buffer (20 mM HEPES, 
pH 7.7, 100 mM NaCl, 1 mM EDTA, 0.05% (w/v) BSA) with vehicle or various 
orthosteric/allosteric ligands for 10 min to reach equilibrium. To measure Nb39 association, the 
probe was transferred to assay buffer with Nb39 (at indicated concentrations) for 5min, followed 
by a 10 min dissociation step in assay buffer (preliminary studies showed that dissociation of 
Nb39 was quite rapid). All ligands (orthosteric and allosteric), once introduced to the probe 
remained in each subsequent buffer during association and dissociation. All experiments were 
carried out at 25 ºC with the assay plate shaking at 2,000 r.p.m. Nonspecific binding was 
measured using a vehicle control with no ligands and this was subtracted to account for baseline 
drift. Raw data were processed to remove baseline using Octet Data Analysis 7.0 software (Pall 
Forte Bio) and exported to GraphPad Prism 6.0 for curve fitting. Association and dissociation 
curves were fit using a single-phase exponential association or decay curves, respectively.  





H-DPN) was incubated with varying concentrations of 
agonist in a binding buffer comprised of 25 mM HEPES pH 7.4, 100 mM NaCl, and 0.1% BSA 
in the presence or absence of 3 µM Nb39. For assays performed using cell membranes, 
conditions listed were kept the same except for exclusion of BSA and inclusion of 10µg protein 
per well. Binding reactions were incubated for 2 h at 25 °C. Free radioligand was separated from 
bound radioligand by rapid filtration onto a Whatman GF/C filter pretreated with 0.1% 
polyethylenimine using a 24-well harvester (Brandel). Nonspecific binding was measured in the 
presence of 10µM naloxone, an opioid antagonist. Radioligand activity was measured by liquid 
scintillation counting using a Wallac 1450 MicroBeta counter (Perkin Elmer). Competition 




















Currently used opioid analgesics, in particular morphine, compete with endogenous 
opioid peptides by binding to the orthosteric site of the mu opioid receptor (MOPr), a G protein 
coupled receptor (GPCR). Activation of MOPr causes analgesia but also results in respiratory 
depression, sedation, constipation, and euphoria leading to a high addictive liability. 
Furthermore, long-term treatment with opioids leads to tolerance, or the requirement for larger 
doses to maintain adequate pain relief. Our lab is pursuing the idea that positive allosteric 
modulators (PAMs) of MOPr may represent a way to treat pain with a better therapeutic profile.  
Such compounds, including BMS-986122, enhance the affinity, potency, and/or efficacy or 
orthosteric opioid ligands, including morphine, to bind MOPr and activate G protein. Here, we 
sought to determine if the enhancement in the efficacy of morphine to activate G protein 
signaling by BMS-986122 also results in enhanced desensitization and tolerance. The results 
demonstrate that BMS-986122 alone did not cause any long-term adaptations in MOPr signaling 
and also fails to enhance morphine-induced desensitization as measured by receptor 
downregulation, receptor phosphorylation, and loss of receptor mediated signaling following 
long-term agonist exposure. Furthermore, we show that BMS-986122 initiates activation of 
extracellular signal-regulated kinase 1/2 in a pertussis-toxin insensitive manner supporting a G 
protein independent mechanism and demonstrates that BMS-986122 is a biased “ago-PAM.” 
Development of biased allosteric ligands at GPCRs represents a novel avenue for analgesic drug 
development and future work will determine the physiological consequences for this biased 







Pain is one of the leading causes of doctor visitations and is responsible for an estimated 
$600 billion per year in health costs and loss in work productivity in the United States (Debono 
et al., 2013). Currently used opioids, including the gold standard morphine, cause analgesia by 
activation of the mu opioid receptor (MOPr), a G protein-coupled receptor (GPCR). Though 
MOPr agonists are effective at managing moderate to severe pain, they cause undesirable on-
target effects including respiratory depression, constipation, dependence, and also have an 
addiction liability. Most prescription opioids, including buprenorphine, oxycodone, and 
morphine, are partial agonists that bind to the orthosteric site on MOPr, or the site where the 
endogenous opioid peptides bind.   
The use of opioid drugs for the management of chronic pain is problematic as long term 
administration produces tolerance with dose escalation being required to maintain adequate pain 
relief. Tolerance does not develop to all MOPr effects at equivalent rates (Jaffe, 1985; Roerig et 
al., 1987; Buntin-Mushock et al., 2005), leading to severe and dose-limiting constipation. 
Morphine, in particular, is known to cause robust tolerance in animal models as well as in 
humans (Huidobro et al., 1976; de Leon-Casasola et al., 1993; Buntin-Mushock et al., 2005) 
though it remains one of the most commonly used opioid agonists. Physiological tolerance 
initiates at the level of the receptor. Generally, exposure to MOPr agonists results in 
phosphorylation of the intracellular loops and C-terminal tail of the MOPr that enhances arrestin-
2/3 binding.  Arrestin-binding blocks subsequent G protein activation resulting in receptor 
desensitization and also initiates internalization of the receptor which can then be recycled or 
degraded. Indeed, chronic stimulation of MOPr, both in vitro and in vivo, leads to 
downregulation of MOPr (Stafford et al., 2001; Yoburn et al., 2003). In contrast to its robust 
physiological tolerance and desensitization, morphine generally does not induce robust 
internalization and phosphorylation of MOPr, but can do so in certain tissues or with particular 
alterations in cellular environment (Whistler and von Zastrow, 1998; Whistler et al., 1999; 
Rodríguez-Muñoz et al., 2007). For instance, if GRK2 is overexpressed, the ability of morphine 
to internalize is increased (Zhang et al., 1998). However, the effect of increased receptor 
internalization on physiological tolerance remains controversial. 
We are currently pursuing the idea that positive allosteric modulation of MOPr may 





development. Positive allosteric modulators (PAMs) bind to sites distinct from the orthosteric 
site, or the site where endogenous ligands and clinical opioids bind, and enhance the binding and 
activity of orthosteric ligands. A MOPr PAM could be given alone to cause pain relief by 
enhancement of endogenous opioid peptide activity, preserving spatial and kinetic peptide 
regulation, or be given in combination with a traditional opioid ligand, enhancing its activity 
while enabling a lower dose to be used (Burford et al., 2015).  
Another benefit of allosteric modulation of GPCR activity is the potential for the 
induction of signaling bias, or the preferential activation of one pathway (e.g. G protein-
mediated) over other pathways (e.g. arrestin-mediated). Allosteric ligands acting at other GPCRs 
have been shown to induce bias of orthosteric ligands in vitro, including ORG27569 at the 
cannabinoid CB1  receptor and PDC113.824 at the prostaglandin F2alpha (PGF2α) receptor 
(Goupil et al., 2010; Ahn et al., 2012; Baillie et al., 2013). Accumulating literature suggests that 
many of the detrimental effects of opioid agonists result from arrestin mediated signaling, 
including MOPr internalization. For example, arrestin-3 knockout mice display increased 
morphine-induced analgesia, decreased respiratory depression, and decreased constipation 
following acute morphine administration and also show decreases in tolerance development 
following chronic exposure to morphine (Bohn et al., 1999, 2000, 2002; Raehal et al., 2005). 
Therefore a MOPr PAM that enhances G protein signaling at the expense of arrestin-mediated 
signaling of traditional opioids would enhance the clinical value of opioid drugs. 
The first MOPr PAM discovered, BMS-986122 (Burford et al., 2013), increases the 
affinity of full agonists like the endogenous enkephalins and β-endorphin to bind MOPr and the 
potency of these full agonists to activate Gi/o protein as measured by GTPγ
35
S binding (Chapter 
2; Livingston and Traynor, 2014). In addition, the PAM enhances the efficacy of partial agonists 
such as morphine (Chapter 2, Chapter 4). Agonist efficacy is correlated with ability to cause 
phosphorylation and desensitization of MOPr (McPherson et al., 2010), therefore we 
hypothesized that BMS-986122 should enhance these events. To address this, we studied the 
effects of BMS-986122 on the action of morphine in cellular models of desensitization (Elliott et 
al., 1997). Results indicate that BMS-986122 does not enhance morphine-induced cellular 
desensitization or downregulation of MOPr despite enhancing the efficacy of morphine. 
Moreover during these studies we also found that BMS-986122 is biased and can activate 






To assess the ability of BMS-986122 to cause MOPr desensitization alone, membranes 
prepared from C6 glioma cells stably expressing rat MOPr (C6MOPr) were treated overnight 
with vehicle or 10 µM BMS-986122. The ability of MOPr to signal to G protein in a 
concentration-dependent manner when occupied by morphine was then assessed using GTPγ
35
S 
binding. The potency and maximal activity of morphine was unaltered by overnight pretreatment 
with BMS-986122 (Fig 5.1A).  
Next, as BMS-986122 has been shown to increase the efficacy of morphine as determine 
by the method of Ehlert (Ehlert, 1985; Chapter 2), we investigated if this also would result in an 
enhancement in desensitization. As a comparison, we studied the effect of BMS-986122 on the 







]-enkephalin  (DAMGO). C6MOPr cells were 
pretreated overnight (18 h) with 10 µM DAMGO in the presence or absence of 10 µM BMS-
986122. The membranes were challenged with DAMGO across several concentrations using a 
GTPγ
35
S binding assay. Results show that, as expected, pretreatment with DAMGO did cause a 
reduction in the ability of the challenge DAMGO to elicit G protein activation, indicative of 
desensitization. But, the presence of BMS-986122 did not enhance this desensitization (Fig 
5.1B). As DAMGO is a high efficacy ligand that may cause maximal desensitization, we needed 
to verify that an effect of BMS-986122 was not being masked so we also challenged these 
membranes with morphine, a lower efficacy partial agonist with a smaller receptor reserve. 
Results using a morphine challenge were the same: pretreatment of C6MOPr cells with DAMGO 
caused a reduction in the ability of morphine to signal but that this was not enhanced by co-
treatment with BMS-986122 (Fig 5.1C). Similarly, BMS-986122 did not enhance desensitization 
mediated by the partial agonist morphine (10 µM) (Fig 5.1D).  
We then examined whether BMS-986122 could ‘rescue’ MOPr coupling to G proteins, 
following desensitization with morphine, predicting that the PAM should enhance the activity of 
the remaining non-desensitized receptors or be capable of enhancing signal transduction through 







Figure 5.1: Desensitization of MOPr by various ligands in C6MOPr cell membranes as 
determined by loss of GTPγ
35
S binding. A) C6MOPr cells were treated with vehicle or 10 µM 
BMS-986122 for 18 h. The ability of morphine to initiate GTPγ
35
S binding was measured in both 
membranes. B) C6MOPr cells were treated overnight (18 h) with vehicle, BMS-986122 (10 
µM), DAMGO (10 µM), or DAMGO and BMS-986122 (both 10 µM).  Membranes prepared 
from each condition were challenged with increasing concentrations of DAMGO or morphine 
(C) for the ability to stimulate GTPγ
35
S binding. D) C6MOPr cells were pretreated with 
morphine (10 µM) with or without BMS-986122 (10 µM) for 18 h and then challenged with 
varying concentrations of morphine. E) Membranes were pretreated with morphine (10 µM) for 
18 h and then a morphine concentration-response GTPγ
35
S assay was performed in the presence 
of vehicle or BMS-986122 (10 µM). All data shown are means ± SEM of 2-4 individual 
experiments in duplicate. Data are expressed as percent over basal GTPγ
35
S binding calculated 















Table 5.1: Saturation binding with 
3




Vehicle 0.25 ± 0.05 4.6 ± 0.7 
BMS-986122 0.21 ± 0.05 5.9 ± 0.7 
Morphine 0.21 ± 0.06 4.3 ± 0.6 
Morphine + BMS-986122 0.39 ± 0.10 4.2 ± 0.5 
 
All ligands are at 10 µM. Kd and Bmax were calculated by performed saturation binding in 
membranes prepared from C6MOPr cells treated 18 h with the indicated vehicles/ligands. 
Nonspecific binding in the presence of saturating (10 µM) naloxone was subtracted before fitting 
curves using GraphPad Prism. Data shown were calculated from 3 separate saturation binding 







morphine concentrations in the presence of vehicle or 10 M BMS-986122. Overnight treatment 
with morphine cause a significant reduction in morphine-mediated GTPγ
35
S binding and this was 
reversed back to control conditions in the presence of BMS-986122 (Fig 5.1E). 
In addition to diminished functional responses, chronic exposure to MOPr agonists has 
been shown to cause downregulation of the receptor (Stafford et al., 2001; Patel et al., 2002) 
both in vitro and in vivo, and the degree of downregulation of positively correlated with ligand 
efficacy (Chakrabarti et al., 1997; Yoburn et al., 2003, 2004). However, in the C6MOPr cells 
saturation binding using the non-selective opioid antagonist 
3
H-diprenorphine revealed no 
differences in Kd or Bmax after overnight treatment with BMS-986122, morphine, or the 
combination of both (Table 5.1). 
The diminished functional response after morphine or DAMGO exposure could be a 
result of several processes including MOPr phosphorylation, arrestin binding and internalization.  
Using an antibody specific for MOPr phosphorylated at serine-375 (S375), a site known to be 
targeted by GPCR receptor kinase 2/3 (GRK2/3) as well as GRK5 (Doll et al., 2011; Just et al., 
2013; Allouche et al., 2014), we evaluated the ability of BMS-986122 to afford phosphorylation 
of this site and/or or to increase the ability of morphine to induce MOPr phosphorylation. 
C6MOPr cells were exposed to BMS-986122 (10 µM) for 10 min (peak time for agonists as 
determined by time course; data not shown) and analyzed using SDS-PAGE followed by 
Western blot to probe for phosphorylated S375. As shown in Fig 5.2, basal levels of 
phosphorylated S375-MOPr are very low, as reported (Just et al., 2013). BMS-986122 exposure 
failed to result in significant phosphorylation of this residue, while the positive control DAMGO 
(10µM) resulted in robust phosphorylation of this site. The partial agonist morphine (10 µM) 
resulted in no phosphorylation of S375, as has been previously reported (McPherson et al., 2010) 
and BMS-986122 was unable to enhance phosphorylation induced by morphine (Fig 5.2). 
To quantify the internalization of MOPr by BMS-986122, HEK293T cells were 
transiently transfected with MOPr that has a FLAG epitope on the extracellular N-terminus of 
the receptor. Following ligand treatment at 37ºC, cells were fixed and cell surface receptors were 
quantified using an alkaline phosphatase-conjugated anti-FLAG antibody. As shown in Fig 5.3, 
BMS-986122 (10 µM) alone did not cause a significant decrease in cell surface receptors, but the 










Figure 5.2: BMS-986122 does not enhance agonist-mediated phosphorylation of S375 of 
MOPr. C6MOPr were treated with 10 µM ligands (or vehicle) for ten mins and then examined 
using SDS-PAGE followed by western blot against phosphorylated S375 of MOPr. Shown is the 
mean ± SEM quantification of 3 separate experiments (A) and a representative image (B) with 
lanes as follows 1) vehicle, 2) DAMGO, 3) DAMGO + BMS-986122, 4) BMS-986122, 5) 






resulted in less internalization than DAMGO as was expected but this was unaltered in the 
presence of 10 µM BMS-986122. 
It has been previously shown that BMS-986122 does not recruit arrestin-3 alone using the 
DiscoveRx PathHunter
®
 assay (Burford et al., 2013), but does enhance the ability of orthosteric 
ligands to recruit arrestins. As BMS-986122 was unable to alter cellular desensitization and 
internalization which are events largely regulated by arrestins, we wanted to confirm that BMS-
986122 did not engage arrestin-mediated signaling. We investigated the ability of BMS-986122 
to active extracellular regulated kinase 1/2 (ERK1/2), which can be mediated by both arrestin 
and G protein pathways.  In C6MOPR cells, BMS-986122 (10 µM) alone activated ERK1/2 with 
a peak time occurring at 30 min (Fig 5.4). Using this peak time, we then performed a 
concentration response of BMS-986122 that give an EC50 of approximately 100 nM. 
Pretreatment of the cells with pertussis toxin (PTX; 100 ng/mL) for 18 h did not alter ability of 
BMS-986122 to activate ERK1/2, suggesting this pathway was not G protein mediated.  
Importantly, BMS-986122 did not stimulate ERK1/2 phosphoryation in the parental C6 glioma 




Here we report that BMS-986122, despite enhancing the efficacy of morphine to activate 
G protein, does not enhance morphine’s ability to cause MOPr desensitization, downregulation, 
phosphorylation MOPr at S375, or MOPr internalization. Furthermore, we show that BMS-
986122 can rescue agonist-mediated signaling in membranes expressing MOPr that have been 
functionally desensitized by prolonged agonist treatment. Finally, we find that BMS-986122 is 
capable of activating MOPr in the absence of orthosteric ligand in a way that leads to G protein-
independent activation of ERK1/2 indicating that BMS-986122 is a signaling biased “ago-
PAM”.  
As we have previously shown, BMS-986122 can drive active-MOPr by allosterically 
disrupting Na
+
 binding (Chapter 2; (Livingston and Traynor, 2014)) thereby forming a state of 
MOPr that is captured and stabilized by the active-state sensor nanobody 39 (Chapter 4). 















Figure 5.3: Internalization of MOPr by various ligands. As described in the methods, the 
ability of various ligands (all at 10 µM) to cause internalization of MOPr following 10 min of 
treatment was measured in HEK293T cells transiently transfected with FLAG-tagged MOPr. 
Data are presented as percent change from vehicle condition and data shown are means of 3-4 










Figure 5.4: BMS-986122 mediated ERK1/2 activation in C6MOPr cells. Shown are 
representative western blot images of the time course (A), dose response at 30 min (A) and dose 
response at 30 min following 18 h pretreatment with PTX (100 ng/mL). The numbers above A 
are minutes and C/E represents concentrations of BMS-986122 in nM. B, D, and E show the 
average quantification of 1-3 experiments for each point. Data from D and F were fitted using 
linear regression to calculate pEC50 values of Vehicle: -7.22 ± 0.35 and PTX: -7.53 ± 0.66 which 






association (Chapter 4) driven by BMS-986122 suggest that its efficacy or ability to stabilize 
active-state MOPr is low. As such, the lack of functional desensitization and MOPr 
internalization by BMS-986122 alone (Fig 5.1) is explained as these outputs are correlated with 
ligand efficacy. But, this active-state formation is responsible for the ability of BMS-986122 to 
enhance the efficacy of morphine which is exemplified by the ability of BMS-986122 to rescue 
the desensitized response. This is likely due to enhancement in the functionality of the non-
desensitized receptors and an apparent enhancement in receptor reserve.   
Given the ability of BMS-986122 to enhance the efficacy of morphine to initiate G 
protein signaling, it is surprising that we do not see enhancement of morphine-mediated 
phosphorylation of S375 as this site is phosphorylated by G protein-recruited kinases, 
specifically GRK2/3. It is true the BMS-986122 could drive phosphorylation of other residues on 








 sequences.  But, S375 is the 
initiating residue phosphorylated and is a necessary prerequisite for phosphorylation of other 
sites (e.g. S363, T376, and T379) (Just et al., 2013). In addition, morphine has been shown to 
only cause phosphorylation of S375 and only in certain cell types (Doll et al., 2011). It may be 
that BMS-986122 changes the phosphorylation ‘bar-code’ of morphine (Lau et al., 2011; Nobles 
et al., 2011), but the lack of enhancement of the initiating residue (S375) suggests this will not be 
the case. In addition, S375 has been shown to be the residue that enhances the affinity of arrestin 
to bind MOPr (El Kouhen et al., 2001).  
The lack of BMS-986122 mediated phosphorylation of S375 on its own fits with previous 
studies that showed no recruitment of arrestin-3 by BMS-986122 alone using the DiscoveRx 
PathHunter assay (Burford et al., 2013). This also explains why BMS-986122 alone did not 
cause internalization of MOPr alone (Fig 5.3). Importantly, the DiscoveRx assay only measured 
arrestin-3 recruitment and the ability of BMS-986122 to promote arrestin-2 recruitment is 
unknown. BMS-986122 has been shown to enhance endomorphin-1 mediated recruitment of 
arrestin-3 (Burford et al., 2013), suggesting that BMS-986122 can enhance arrestin recruitment 
for some ligands. It is important to note though, that the PathHunter assay measures enzyme 
complementation resulting from proximity of arrestin with MOPr and the functional 
consequence of this arrestin-receptor interaction that BMS-986122 enhanced is not known. Not 
all receptor:arrestin interactions result in receptor internalization (For review see (Shenoy and 





internalization as the arrestin data would suggest and conversely if BMS-986122 enhances 
morphine mediated arrestin-3 recruitment, which we would predict it does not as it does not 
enhance morphine driven internalization of MOPr.  
The physiological consequence of the enhancement in efficacy of morphine to active G 
protein but lack of enhancement in morphine-mediated MOPr internalization by BMS-986122 is 
unknown. Though this is seen as a lack of enhanced functional desensitization in C6MOPr cells 
(Fig 5.1), the effects on more chronic tolerance and dependence in vivo can only be speculated. 
According to studies performed using arrestin-3 knockout mice, lack of arrestin-3 resulted in 
morphine-mediated analgesia with less tolerance development as compared to wildtype controls 
(Bohn et al., 1999; Raehal and Bohn, 2011) which suggests that BMS-986122 coadminstration 
with morphine should enhance analgesia without enhancing tolerance. It is important to note that 
the arrestin-3 knockout animals would show decreased MOPr internalization but also decreased 
arrestin-mediated signaling. As BMS-986122 has no effect on internalization but does appear to 
signal through arrestin (see below), this complicates the prediction. On the other hand, the RAVE 
(relative activity versus endocytosis) theory proposed by Whistler and colleagues states that 
arrestin-mediated internalization is actually beneficial in avoiding tolerance as it enables 
recycled, resensitized receptors to return to the surface (Finn and Whistler, 2001; Martini and 
Whistler, 2007). In this theory, agonists that do not cause robust internalization cause more 
tolerance due to the accumulation of desensitized, non-functional receptors at the cell surface. 
According to this theory, the lack of enhancement of morphine-mediated MOPr internalization 
with the accompanied enhancement in the efficacy of morphine could actually enhance tolerance 
development. 
The ability of BMS-986122 to activate ERK1/2 while failing to inhibit adenylate cyclase  
(AC; up to 30 µM in the C6MOPr cells; data not shown) is indicative of a bias because opioid 
agonists, including DAMGO, are more potent at inhibition of AC as compared to ERK1/2 
activation (Clark et al., 2003) in these cells. The mechanism of ERK1/2 activation by BMS-
986122 is independent of Gαi/o proteins as shown by the insensitivity of the response to PTX 
pretreatment (Fig 5.4). While there is evidence of MOPr coupling to the PTX-insensitive Gαz 
subunit (Tso and Wong, 2000; Sánchez-Blázquez et al., 2001), C6 glioma cells have been shown 
to not express this subtype (Charpentier et al., 1993). This suggests an arrestin-mediated 





mediated ERK1/2 activation compared to faster (5-10 min) G protein mediated ERK1/2 
activation for MOPr (Clark et al., 2003). Furthermore, the lack of arrestin-3 recruitment as 
measured by the PathHunter assay (Burford et al., 2013) suggests it is not arrestin-3 mediated. 
This leaves arrestin-2, which has been shown to be less involved in regulating agonist-mediated 
internalization of MOPr. Therefore, we propose that BMS-986122 promotes ERK1/2 activation 
selectively by arrestin-2, and does not engage arrestin-3 which is why internalization of MOPr is 
not enhanced (see Chapter 6 for further discussion). A remaining question is the cellular fate of 
this activated ERK1/2 as it has been reported the arrestin-activated ERK1/2 is translocated to the 
nucleus and is responsible for alteration in gene transcription (Zheng et al., 2008). Indeed, if this 
ERK1/2 does translocate to the nucleus, then knowing the transcriptional targets would enable 
prediction of the long term consequences of BMS-986122 administration.  
Activation of ERK1/2 by BMS-986122 occurs at much lower concentrations than the 
published affinity for BMS-986122 for MOPr (2 µM; (Burford et al., 2013)) would predict. The 
reported KB was found utilizing both whole-cell and membrane based assay in various cell types, 
including the same C6MOPr cells, so this does not account for the difference. The discrepancy is 
indicative of a high level of efficacy for BMS-986122 to activating this pathway. It is unknown 
if this high efficacy of BMS-986122 to activate ERK1/2 is specific to BMS-986122 or is a more 
common feature of positive allosteric modulation of MOPr or even other opioid receptors. 
Indeed, the recently discovered PAM of the delta opioid receptor (DOPr), BMS-986187, is also 
able to activate ERK1/2 alone as well as activate G protein, inhibit AC, and trigger recruitment 
of β-arrestin ((Burford et al., 2015); Appendix B), and the cannabinoid CB1 receptor PAM, 
ORG27569, can activate ERK1/2 through a G protein-independent mechanism (Ahn et al., 
2012). 
Overall this study has investigated the effects of chronic PAM activity at MOPr and the 
consequences of enhancement of the efficacy of the gold standard opioid, morphine.  It has been 
found that while BMS-986122 can enhance acute G protein signaling, it does not enhance 
cellular desensitization, or MOPr phosphorylation and internalization or downregulation. On the 
other hand BMS-986122 does enhance agonist-mediated signaling in membranes that express 
desensitized MOPrs suggesting that a PAM may be beneficial for patients already tolerant to 
opioid medications. Finally, we have shown that BMS-986122 is actually a biased “ago-PAM” 





understanding the mechanism and consequences of BMS-986122-mediated ERK 
phosphorylation. 
 





S]GTPγS (guanosine-5’-(3-thio)triphosphate) were 
purchased from PerkinElmer. Guanosine diphosphate (GDP), p-nitrophenyl phosphate (pNPP), 
and M2 mouse anti-FLAG antibody conjugated to alkaline phosphatase were from Sigma-
Aldrich (St Louis, MO, USA). PTX was from List Biological Laboratories Inc. (Campbell, CA, 
USA). All tissue culture supplies, including Lipofectamine 2000, were from Invitrogen 
(Carlsbad, CA, USA) unless otherwise stated.  
Cell line and transfection: C6 glioma cells were stably transfected with rat MOPr as described 
previously. Cells were grown in DMEM containing 10% fetal bovine serum, 1% pen/strep, and 
100 µg/mL geneticin (G148) in a 37 ºC incubator containing 5% CO2. HEK293T cells (from 
AATC) were grown in DMEM supplemented with 10% FBS and 1% pen-strep. (Pen/strep was 
removed 24 h prior to transient transfection). For transient transfection, cDNA (FLAG-MOPr) in 
complex with Lipofectamine 2000 reagent in minimal media was added to cells in log phase of 
growth. Cells were used 48 hours following transfection. 
Membrane Preparation: Confluent C6MOPr cells were rinsed with phosphate buffered saline 
and then detached using harvesting buffer (20 mM HEPES pH 7.4, 0.68 mM EDTA, and 150 
mM NaCl). Cells were pelleted following centrifugation at 300g for 3 min at room temperature. 
Supernatant was discarded and pellet was resuspended in ice-cold 50mM Tris buffer, pH 7.4. 
Pellet was homogenized using a Tissue Tearor (company) and then centrifuged at 20000g for 20 
min at 4 ºC. The supernatant was discarded and the pellet as resuspended, homogenized, and 
centrifuged once more. The final pellet was homogenized in 50 mM Tris, pH 7.4 using a glass 
dounce homogenizer and aliquots were flash frozen and stored at -80 ºC until use in assays. 
Concentration of protein was determined using a BCA protein assay with bovine serum albumin 
as the standard.  
 
3
H-DPN Saturation Binding Assay: C6- MOPr cell membranes (5 µg/well) were incubated for 





with various concentrations of 
3
H-DPN (0.02-4.0 nM). Nonspecific binding was measured in the 




S Binding Assays: C6MOPr cell membranes (10 µg/well; prepared as described above) 
were incubated while shaking for 60 min at 25 ºC in assay buffer (50 mM Tris pH 7.4, 1 mM 
EDTA, 5 mM MgCl2, 100 mM NaCl)  containing 30 µM GDP, 0.1 nM GTPγ
35
S, orthosteric 
ligand and allosteric ligand (or vehicle). Basal binding was measured in the absence of 
orthosteric ligand and maximal binding was determined using 10 µM of the full agonist internal 
standard DAMGO. The reaction was terminated using rapid filtration onto glass GF/C fiber 
filters (Whatman) and rinsed 6-8 times using 1 mL of cold wash buffer (50 mM Tris pH 7.4, 5 
mM MgCl2, 100 mM NaCl).  The filters were dried and radioactivity was measured using liquid 
scintillation counting with EcoLume liquid scintillation cocktail (MP Biomedicals) in a Wallac 
1450 MicroBeta counter. 
 
P-ERK Assays: C6MOPr cells were plated in 24-well plates the day before the assay to reach 80-
90% confluency on the day of the assay and treated with vehicle or pertussis toxin (PTX; 100 
ng/mL). The medium was replaces with serum-free DMEM two hours prior to addition of 
vehicle or BMS-986122 at the indicated concentration. The assay was stopped by aspirating the 
medium and rinsing the cells twice with ice-cold phosphate buffered saline. Lysates were 
collected with radioimmuno-precipitation assay buffer [50 mM Tris, pH 7.4, 150 mM NaCl, 1% 
Triton X-100, 1% sodium deoxycholic acid, 0.1% SDS] plus protease inhibitor, 2mM EDTA, 
100 µM NaF, and 10 µM sodium orthovanadate. Lysates were sonicated for 30 seconds and 
centrifuged at 10000 x g at 4 °C for 10 min. Supernatant was taken and diluted into SDS sample 
buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 0.0008% bromophenol blue) and 
beta-mercaptoethanol. Samples were loaded on 12% polyacrimilade gel and subjected to SDS-
PAGE followed by transfer to PVDF nitrocellulose membranes for Western blotting. The blot 
was propped with a 1:2000 dilution of anti-phospho-p44/42 MAPK (ERK1/2) antibody and 
visualized using horseradish peroxidase (HRP) -conjugated anti-mouse IgG. To ensure equal 
loading, membranes were stripped and total ERK levels were assessed using 1:1000 dilution of 





Phosphorylation of MOPr S375 Assays: C6 MOPr cells were split into 6-well plates to reach 
90% confluency for the day of the assay. Briefly, ligand/vehicles were added to the media to 
reach the indicated concentrations. Media was aspirated at the indicated time and cells were 
quickly rinsed with ice-cold phosphate buffered saline. Lysates were collected with 
radioimmuno-precipitation assay buffer [50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 
1% sodium deoxycholic acid, 0.1% sodium dodecyl sulfate (SDS)] plus protease inhibitor, 2 mM 
EDTA, 100 µM NaF, and 10 µM sodium orthovanadate. Lysates were sonicated for 30 seconds 
and centrifuged at 10000 x g at 4 °C for 10 min. The resulting pellet was resuspended in SDS 
sample buffer and loaded onto a 10% polyacrylmaide gel and subjected to SDS-PAGE followed 
by transfer to PVDF nitrocellulose membranes for Western blotting.  The blot was incubated 
overnight at 4 °C with a 1:1000 dilution of the anti phosphor- S375 MOPr antibody and 
visualized using HRP conjugated secondary antibody. 
Internalization Assays: HEK293T cells were grown to 80% confluency prior to transient 
transfection with FLAG tagged MOPr. 24 h following transfection, cells were seeded (0.75 × 10
6
 
cells per well) onto poly-d-lysine coated 24-well plates. 24 h following splitting, the cells were 
treated with drug (or vehicle) in the presence of allosteric ligand (or vehicle) for 10 min at 37C in 
DMEM. At the end of the incubation period, the cells were fixed with 3.7% formaldehyde in 
Tris-buffered saline [(TBS), 25 mM Tris–HCl, pH 7.4, 2.7 mM KCl, 140 mM NaCl] for 5 min at 
4 °C. The cells were washed three times with TBS, blocked with 1% non-fat dry milk made up in 
TBS for 1 h at room temperature and washed two times with TBS and incubated with 
monoclonal anti-FLAG M2 alkaline phosphatase antibody for 1 h at 23 °C. Cells were washed 
five times and incubated with p-nitrophenyl phosphate for 30 min at 23 °C. 0.2 mL aliquots were 
added to 0.05 mL 3 N NaOH in a 96-well plate. Absorbance at 405 nm was measured using a 
VERSAmax tunable microplate reader (Molecular Devices, Sunnyvale, CA, USA). The 
percentage of receptors internalized was calculated using the following equation: [1 − (Drug 
O.D. − Background O.D./Control O.D. − Background O.D.) × 100], where O.D. is optical 
density. Background was defined as the absorbance of untransfected HEK293 cells and control 
as absorbance from untreated FLAG MOPr expressing cells. 
 
Data analysis: Concentration-effect curves from GTPγ
35
S binding assays and ERK1/2 activation 





determine EC50 values and maximal effects. Saturation binding data were fit to a one-site 
hyperbolic function after nonspecific binding was subtracted. Kd and Bmax values were obtained 
using GraphPad Prism 6.01. Data presented are means and SEM from at least 3 independent 

































Discussion and Future Directions 
 
Summary and significance 
Studies described in this thesis investigated allosteric modulation of the mu opioid 
receptor (MOPr) in the context of receptor:ligand interactions and cellular signaling, both acutely 
and chronically. The positive allosteric modulators (PAMs) discussed in this thesis, particularly 
BMS-986122, represent the first molecules unequivocally shown to be PAMs at MOPr.  
I have shown that BMS-986122 functions at the MOPr by allosterically disrupting the 
binding of Na
+
 ion, an endogenous negative allosteric modulator of MOPr, and that the actions 
of BMS-986122 are probe dependent, that is they are contingent on the ligand occupying the 
orthosteric binding site. Moreover this probe dependence is based on the efficacy of the 
orthosteric agonist. I have also demonstrated that this mechanism of allosteric activity is not 
unique to MOPr or to BMS-986122, and have described the non-selective positive allosteric 
ligand BMS-986187 as a PAM of both the delta opioid receptor (DOPr) and MOPr with the same 
mechanism of action at both. This work also indicates that MOPr and DOPr may share a 
common allosteric binding site capable of recognizing structurally diverse ligands. Next, I 
developed and implemented a biophysical technique to quantify intrinsic efficacy of both 
allosteric and orthosteric ligands of the MOPr in a cell-free manner and used it to verify our 
hypothesis that MOPr PAMs stabilize active state conformations of MOPr. Finally, I have 
explored the effects of chronic MOPr PAM activity in cellular models of desensitization and 
tolerance, finding that BMS-986122 selectively enhances signaling through G protein over 
enhancement of receptor desensitization. 
This work provides proof of principle of a novel way to target MOPr, one of the most 
pharmacologically important G protein-coupled receptors (GPCRs). Such an approach could lead 
to major changes in the management of pain, as a MOPr PAM could be capable of pain relief 





spatial and temporal regulation. In addition, the mechanism of allostery I have proposed is likely 
to be important for other class A GPCRs that bind to and are regulated by Na
+
 ions. Indeed, I 
have already shown this to be the case for an additional GPCR, DOPr (Chapter 3). Furthermore, 
the novel assay I present in Chapter 4 for the determination of intrinsic efficacy of orthosteric 
and allosteric ligands can readily applied to other GPCRs as a way to measure efficacy of ligands 
in preclinical settings to better predict in vivo activity. This measurement of efficacy is cell-free 
and does not depend on signaling output. Finally, work in Chapter 5 suggests that allosteric 
ligands at MOPr have the potential for signaling bias and also the potential to enhance the 
desired effects (i.e. G protein activation), but not detrimental signaling (i.e. desensitization and 
tolerance) of clinically used opioids, such as morphine. This raises the possibility of creating an 
allosteric ligand that can enhance the pain-relieving effects of currently used opioids while not 
increasing tolerance, thereby enhancing their therapeutic potential. 
  
Future directions 
 Though this body of work has answered many questions regarding the mechanisms and 
consequences of PAM activity at MOPr, it has also raises additional questions regarding 
allosteric modulation at MOPr and DOPr that should be a focus of future research. In the 
following sections, I will discuss these future directions and provide both my hypotheses and 
possible methods for addressing them. 
 
Identification of MOPr-PAM binding site 
One of the most pressing questions involves the binding site of BMS-986122 and the 
other allosteric ligands. From Chapter 4, we know that BMS-986122 and BMS-986187 bind 
directly to the receptor to modulate receptor function. They do not bind at a secondary protein or 
at the interface of the receptor with any other protein since they both show allosteric activity at 
purified MOPr reconstituted as monomers into high-density lipoproteins (rHDL).  We can make 
some provisional inferences of the binding site of BMS-986122 based on published work of 
other GPCRs.  
Several class A GPCR X-ray crystallographic structures in complex with an allosteric 
ligand have recently been solved. What stands out is that each allosteric ligand binds in a 





on any given GPCR. For instance, the free fatty acid receptor (FFAR1) structure in complex with 
the allosteric ligand TAK-875 shows the ligand binding via the lipid bilayer with extensive 
contacts in TM3, TM4, and extracellular loop 2 (ECL2) (Srivastava et al., 2014). Whereas 
FFAR1 and opioid receptors share low sequence homology and there is no support for MOPr 
PAMs binding in a similar manner, it cannot be ruled out. Indeed, all of our MOPr PAMs are  
lipophilic with several halogen groups (Burford et al., 2013; Bisignano et al., 2015; NT Burford 
et al., 2015) so they could potentially partition into the membrane bilayer. In addition, the C-C 
chemokine receptor type 5 (CCR5) in complex with the HIV drug maraviroc was recently solved 
(Tan et al., 2013). While maraviroc is allosteric and does not compete with the endogenous 
chemokine, it was observed to bind to a site analogous to the orthosteric site of MOPr (Tan et al., 
2013). However, the allosteric site on MOPr is not the orthosteric site as my work shows that 
PAMs do not displace orthosteric ligands (Burford et al., 2013; Livingston and Traynor, 2014; 
Bisignano et al., 2015).  
Presently, there is only one X-ray crystal structure of a Class A GPCR in complex with 
an allosteric ligand and an agonist: the M2 acetylcholine receptor in complex with the agonist 
iperoxo and the PAM LY2119620 (Kruse et al., 2013).  The binding site of LY2119620 may 
share some commonalities with the BMS-986122 binding site on MOPr. Indeed, recent 
molecular dynamics simulation studies performed with MOPr using BMS-986122 hypothesized 
that the MOPr PAM interacts with residues 6.58 and 7.35, analogous to those resides that 
LY2119620 interacts with in the M2R (Bartuzi et al., 2016). In addition, another group 
performed simulations using BMS-986187 at DOPr and also found that residues 6.58 and 7.35 
play a role in PAM binding (Shang et al., 2016). From Chapter 3, I hypothesize that these 
allosteric sites on MOPr and DOPr are analogous. These data support that the binding site of the 
PAMs described in this thesis may analogous to the binding site of LY2119620 on the M2R. 
Mutagenesis of residues 6.58 and 7.35 should be performed to determine the role of these 
residues in the activity of BMS-986122. 
Currently, our lab is working with collaborators to obtain a crystal structure of MOPr in 
complex with a PAM. One of the problems is the poor solubility of the current modulators and 
the low affinity they have for agonist-free receptor (µM range; Chapter 2; Chapter 3). This 
means that the structure will likely need to be a co-crystal in the presence of both an agonist and 





nM (Chapter 4) which is more amenable to crystallography. As such, we are concurrently 
working with medicinal chemists to develop novel MOPr PAMs with enhanced affinity and 
solubility more suited for both crystallography as well as in vivo work (discussed later). Also 
conceivable would be the crystallization of inactive MOPr with a SAM or NAM that would not 
depend on the presence of an agonist or G protein. Currently, the SAMs we have also have µM 
affinity and there are no known NAMs of MOPr.  
A more straightforward approach that could be done is to analyze the activity of BMS-
986187 at various species of MOPr (human, rat, mouse, etc). As most species’ opioid receptors 
bind opioid peptides (although some species have lost opioid peptide expression while retaining 
the receptors (Dores et al., 2002)), divergence arises in areas of the proteins not involved in the 
binding of orthosteric ligands- namely allosteric sites (Dreborg et al., 2008). This evolutionarily-
driven mutagenesis could yield information regarding the BMS-986122 binding site and could be 
determined by calculating KB at each of the receptor types.  
 
Identification of potential endogenous opioid receptor PAM 
Due to the ability of both MOPr and DOPr to bind the same allosteric ligands (Chapter 
3), albeit with different affinities, I hypothesize that there is an allosteric site that is somewhat 
conserved between the two receptors. Phylogenetically, it is thought that MOPr and DOPr share 
a common ancestral GPCR and that they are more similar to one another compared to the other 
opioid receptors (Dreborg et al., 2008). It is possible that the PAMs in this thesis, specifically 
BMS-986122 and BMS-986187, also bind to kappa opioid receptor (KOPr) and the 
nociceptin/orphinan FQ opioid receptor (NOPr). Preliminary work has failed to show PAM 
activity at either of these receptors (data not shown), but due to probe dependence, we may not 
have used the correct agonist. In addition, these PAMs may be silent allosteric ligands at KOPr 
and NOPr. However, due to a lack of PAMs at these receptors, it is currently impossible to test 
this theory. In the future, if PAMs for KOPr and NOPr are discovered, their reversal by BMS-
986122 and BMS-986187 could be evaluated.  
Due to this possible conservation between allosteric sites on MOPr and DOPr, it is 
tempting to speculate the existence of an endogenous allosteric modulator of MOPr and DOPr. 
Attempts to find a potential endogenous allosteric ligand could be made using metabolomics 





contains compounds with biological activity whose target proteins have not yet been identified). 
Screens could be performed looking for enhancement of signaling by the endogenous opioid 
peptides, with cooperativity being presumed but not certain. Another approach that would be 
independent of a chosen orthosteric ligand would be to look for displacement of a radiolabeled 
PAM, although to date we do not have compounds with sufficiently high affinity 
 
Identification of signaling pathway for BMS-986122 mediated activation of MAPK 
In Chapter 6, I found that BMS-986122 actives MAPK in a G protein independent 
manner and I hypothesize occurs through arrestin-2. From the initial discovery of BMS-986122, 
we know that BMS-986122 does not recruit arrestin-3 alone as measured using the DiscoveRx® 
PathHunter assay (Burford et al., 2013).  But, because the G protein independent MAPK 
activation is slow to peak and sustained, it is presumably arrestin-mediated, leaving arrestin-2 as 
the subtype capable of generating this signal. Furthermore, recent studies I have performed using 
the AlphaScreen® system (Garbison et al., 2015) have found that BMS-986122-activated 
MAPK is not cytosolic (unpublished data).  
Downstream of MOPr, G protein activated MAPK stays in the cytosol while arrestin-
activate MAPK translocates to the nucleus (Zheng et al., 2008). Furthermore, ligands that can 
internalize MOPr robustly can recruit both arrestin-2 and arrestin-3, suggesting the arrestin-3 
may play more of a role in trafficking of MOPr whereas arrestin-2 may be involved in other 
signaling, though this is speculative. From these data, I hypothesize that BMS-986122 fails to 
enhance internalization and receptor desensitization because it selectively engages arrestin-2 and 
activates MAPK. Mouse embryonic fibroblasts (MEFs) that lack arrestin-2, arrestin-3, or both 
arrestin-2/3 stably expressing MOPr can be employed to further probe the mechanism of BMS-
986122-mediated MAPK activation.  
 
Validation of MOPr-PAM activity in rodent models of antinociception 
Potential therapeutic use of the allosteric modulators is predicated by their ability to 
enhance antinociception in rodent models of acute and chronic pain.  But, this must be validated. 
BMS-986122 has recently been tested in vivo in our laboratory using rodent models of 
antinociception, particularly the hot plate assay that measures thermal latency (Woolfe and 





profile of BMS-986122 (and limited compound), BMS-986122 was administered 
intracerebroventricularly (i.c.v.) and it was found that it enhanced thermal latency on its own. 
Importantly, this enhancement was blocked by pretreatment of the animal with the opioid 
antagonist naloxone and or when using MOPr global knockout mice (Fig 6.1). As stated above, 
we are working with chemists to develop higher affinity compounds that could potentially cross 
the blood brain barrier for future studies. 
In addition to acute antinociception, the ability of a MOPr PAM to treat pain chronically 
should be evaluated. As shown in Chapter 5, BMS-986122 did not cause desensitization and 
cellular tolerance on its own nor did it enhance the ability of agonists to cause these effects. This 
suggests that BMS-986122 should not cause tolerance in vivo, but the studies I performed were 
in cultured cells that lack neuronal connections and circuitry. While tolerance does begin at the 
level of the receptor, it is hypothesized that circuit-level adaptations also occur with the 
formation of tolerance and dependence in animals and humans (Williams et al., 2001; Kosten 
and George, 2002).  
 
Investigation of abuse potential of MOPr PAMs 
Opioid agonists used in the clinic cause euphoria and therefore have an addictive liability.  
MOPr PAMs should be evaluated in rodent models of self-administration and conditioned place 
preference as well as antinociception. If BMS-986122 causes conditioned place preference or 
elicits self-administration alone in animal models, this is indicative of addictive liability 
(Cunningham et al., 2006; O’Connor et al., 2011). Ideally, a MOPr PAM would have enough 
allosteric efficacy and/or signaling bias to enhance enkephalin-mediated analgesia but not other 
effects, especially because the PAM maintains the temporal and spatial activity of the 











Figure 6.1: BMS-986122 antinociception mediated through MOPr. Pretreatment (30 min) 
with the nonselective opioid antagonist naloxone (1.0 mg/kg) blocked the antinociceptive effects 
of BMS-986122 (1.5 nmols) (n = 6 per group) (top figure). Antinociceptive effects of 1.5 nmols 
BMS-986122 are abolished in MOPr homozygous null (-/-) knockout mice (n = 8) (bottom 
figure). ** P < 0.01; *** P < 0.001 vs. vehicle control groups. NLX = naloxone; BMS = BMS-
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 As a whole, this body of works mechanistically describes the acute and chronic cellular 
and receptor-level consequences of PAM activity at the MOPr. It provides the basis for future 
preclinical studies to develop a novel method of pain management in humans and establishes a 
new method for assessing the efficacy of allosteric and orthosteric ligand for this receptor. MOPr 
PAMs can enhance the intrinsic efficacy of both endogenous opioid peptides as well as clinically 
used opioids while sparing the enhancement of tolerance and desensitization that result from 
chronic exposure. These ligands have great potential as novel therapeutics and future work will 





































Recent technological advances in biochemical methods have aided in solving x-ray 
structures of many different G protein-coupled receptors (GPCRs), proteins once thought too 
dynamic for such endeavors (for review see (Ghosh et al., 2015)).  Since the first structures of 
rhodopsin (Palczewski et al., 2000) and the β2-adrenergic receptor ((β2AR);(Cherezov et al., 
2007)) in 2000 and 2007 respectively, over 125 structures of GPCRs in both inactive and active 
states have been solved. Mechanistic insights into the binding and activation of receptors by 
agonists have been examined for both the β2AR and the M2 muscarinic acetylcholine receptor 
(M2R), with both inactive and active state crystal structures existing for both (Rasmussen, 
DeVree, et al., 2011; Haga et al., 2012; Kruse et al., 2013).  
In 2012, the crystal structure of the inactive mouse mu opioid receptor (MOPr) in 
complex with the irreversible morphinan antagonist β-funaltrexamine (β-FNA) was solved 
(Manglik et al., 2012). With this structure came the confirmation of decades of structure-activity 
and mutagenesis work concerning the crucial residues involved in ligand recognition, including 
W318
7.35
, a residue proposed to be involved with the ‘address’ portions of opioid ligands in the 
“message-address” hypothesis of opioid selectivity (Lipkowski et al., 1986). While the inactive-
state structure provides a lot of information, active-state structures give insights into 
determinants of agonist activity which would be beneficial for MOPr, one of the most 
pharmacologically targeted GPCRs in the world.  
                                                          
2
 Parts of this work were published in Nature. Huang W, Manglik A, Venkatakrishnan AJ, Laeremans T, Feinberg 
EN, Sanborn AL, Kato H, Livingston KE, Thorsen TS, Kling R, Granier S, Gmeiner P, Traynor JR, Weis WI, 
Steyaert J, Dror RO, Kobilka BK. “Structural Insights into µ-Opioid Receptor Activation.” Nature. 2015 Aug 20; 






One of the impediments in obtaining active-state structures of GPCRs is having an 
agonist capable of stabilizing an active-state receptor long enough to develop an active-state 
antigen in vivo following immunization and also to grow homogenous crystals (Steyaert and 
Kobilka, 2011). Ligands with fast kinetics of binding, particularly those with fast dissociation 
rates, are not well-suited due to the protein dynamics associated with binding and unbinding. In 
order to find a slowly dissociating ligand compatible with crystallography of active-state MOPr, 
we utilized the method of Motulsky-Mahan to measure the dissociation rates of various 
unlabelled opioid agonists (Motulsky and Mahan, 1984).   
Briefly, for this method the association rate of a radiolabeled antagonist with known 
kinetics is measured in the presence of varying concentrations of cold ligand with two basic 
phenotypes resulting (Fig A.1). For competitive ligands with dissociation rates that are faster 
than the radiolabeled ligand, all curves with be exponential with a decrease in max as the 
concentration of cold ligand increases. In contrast, if the cold ligand dissociates slower than the 
labeled ligand, the association will be exponential at first (assuming the association rates of the 
labeled and unlabelled ligands are relatively equal) but soon diminish as receptor sites are 
occupied with the slowly dissociating cold ligand, creating an ‘overshoot.’ Mathematical models 
can be used which incorporate the known kon, koff, and concentration of radioligand as well as the 
concentration of cold ligand in order to calculate the kon and koff of the cold ligand. Validity of 
the assay was confirmed by calculating Kd values from the calculated rates and comparing them 
with known affinity values for the test ligands.   
In order to choose ligands to screen, we focused on MOPr agonists that were high 
efficacy (at least 90% stimulation compared to the endogenous ligand standard), high affinity (Ki 
less than 1 nM), and molecules that were non-peptidic to minimize ligand flexibility. In addition, 
several clinical compounds known to be slowly dissociating, namely methadone and 




















Figure A.1: Protypic results from Mahan-Motulsky. The association of a radiolabelled 
antagonist over time is shown in blue. The association is altered in the presence of either a 







The β2AR-Gαs structure was solved in complex with the highly efficacious, high affinity 
agonist BI-167107 which had a dissociation half-time (t1/2) of over 30 hours (Rasmussen, 
DeVree, et al., 2011). While this was the goal for MOPr, such a slowly dissociating ligand was 
not found. After screening over a dozen ligands, the slowest ligands were: BU97008, 14-
phenylpropoxymetopon (PPOM;(Schutz et al., 2003)), BU9609,  and BU72 (Fig A.2) with t1/2 
dissociation times of approximately 231, 122, 100, and 70 min respectively. In addition, all four 
ligands were full agonists at activation of GTPγ
35
S binding in C6MOPr cell membranes with 
affinity of less than 0.5 nM (data not shown).  
Of these four ligands, only one succeeded in producing crystals that diffracted: BU72. 
BU72 is a buprenorphine analog with subnanomolar affinity and agonist activity at MOPr, delta 
opioid receptor, and kappa opioid receptor (Neilan et al., 2004; Divin et al., 2008). It is a potent 
analgesic in rodents, but has a very narrow therapeutic index with high levels of respiratory 
depression, limiting its utility as a drug. In contrast to our general hypothesis, BU72 was not the 
slowest dissociating ligand tested, emphasizing that other characteristics of the ligand are 
important for successful crystal formation and diffraction (Hassell et al., 2006).   
All of the ligands were initially screened used cell membranes prepared from C6 cells 
stably expressing rat MOPr. Once the crystals were shown to diffract and the structure was in the 
process of being resolved, the kinetics of BU72 at the purified MOPr construct used for 
crystallography were examined. Purified MOPr was reconstituted into high-density lipoproteins 
(MOPr-rHDL) and, using the Motulsky-Mahan method, the t1/2 of dissociation of BU72 from 
MOPr-rHDL was found to be 43 min (Fig A.3). For the crystal structure, the receptor was 
stabilized in the active state using camelid antibody nanobody 39 (Nb39). To understand the 
influence of Nb39 on BU72 affinity and binding kinetics, competition binding of BU72 for 3H-
diprenorphine (
3
H-DPN) was performed in the MOPr-HDL system with and without Nb39. As 
expected, Nb39 (3 µM) increased the affinity of BU72 by 10-fold from 0.8 nM (95% CI: 0.4 - 
1.6 nM) to 0.09 nM (95% CI: 0.06 - 0.13 nM) (Fig A.4). (This concentration of Nb39 was 
chosen because at higher concentrations, Nb39 inhibited 
3
H-DPN binding. Data not shown).  In 
addition, the effect of Nb39 on the dissociation kinetics of BU72 was tested. The Motulsky-
Mahan method was performed and the t1/2 of dissociation of BU72 was 140 minutes in the 





Another facet of BU72 binding that is unique is its sensitivity to Na
+
. Opioid agonist 
binding is highly dependent on the concentration of Na
+
 present (Pert and Snyder, 1976; Selley 
et al., 2000). In addition, this sensitivity to Na
+
 is correlated with the efficacy of the ligand with 
higher efficacy ligands showing greater shifts in the affinity by the addition of sodium. Using 
Ehlert’s equation, the intrinsic efficacy of BU72 is 4.7 which is the same as etorphine (Chapter 2; 
(Livingston and Traynor, 2014)). In contrast to this high efficacy, the shift in affinity of BU72 by 
the addition of Na
+
/GTP is quite small (six-fold) from 0.38 ± 0.04 nM (in 100 mM NaCl/ 10µM 
GTP) to 0.06 ± 0.02 nM (in Tris pH 7.4) as found doing competition binding in C6MOPr cells. 
As we have previously shown the sodium-insensitive ligand etorphine to also be insensitive to 
allosteric modulation by BMS-986122 (Chapter 2), we investigated if the affinity of BU72 would 
be enhanced by BMS-986122. The data matched etorphine in that BU72 was also insensitive to 
enhancement in affinity by BMS-986122 (Ki = 0.39 ± 0.02 nM with 10 µM BMS-986122). 
In addition to understanding the binding kinetics of BU72 and its cooperativity with 
Nb39, we investigated the potential to BU72 to be a biased ligand. In order to validate this, the 
ability of BU72 to active ERK1/2 in C6MOPr cells was determined by using SDS-PAGE 
followed by western analysis. BU72 (10 nM; ~10 x Kd) exposure caused robust ERK1/2 
activation that peaked at 5 min. Overnight pretreatment of the C6MOPr cells with PTX (100 
ng/mL) blocked the early phase of ERK1/2 activation, indicating that the majority of ERK1/2 
activation was caused by G proteins (Fig A.4). To validate that BU72 was also not overtly biased 
towards G protein, we assessed the ability of it to cause MOPr internalization. Utilizing an 
ELISA based internalization method, the ability of BU72 to cause MOPr internalization was 
compared to an endogenous ligand that is known to be unbiased, leucine-enkephalin (Leu-Enk) 
(McPherson et al., 2010). BU72 caused the same degree of internalization as Leu-Enk, indicating 
























Upon final refinement and solving of the crystal structure of active MOPr in complex 
with Nb39 and BU72, the relatively fast dissociation of BU72 compared to BI-167107 could be 
explained (Huang et al., 2015). The binding pocket of MOPr, even in an active state, is more 
open than compared to the β2AR and the M2R (Rasmussen, DeVree, et al., 2011; Kruse et al., 
2013). This orthosteric site, which must be large enough to accommodate the binding of the 
endogenous β-endorphin (31 amino acids), remains open even in the active state which supports 
the generally fast association and dissociation of even the highest affinity opioid agonists. In 
addition, subsequent NMR studies on BU72 association with MOPr revealed BU72 to be a 
“superagonist” that was able to stabilize active-state MOPr better than traditional full agonists 
like DAMGO (Sounier et al., 2015), indicating that this ligand may have unique properties that 
engender its ability to stabilize the MOPr-Nb39 crystal complex as compared to the other slower 
dissociating agonists BU9609 and PPOM. Overall, this study established the use of the 
Motulsky-Mahan method in a purified MOP-rHDL system to find tools to aid in the 













Figure A.3: Motulsky-Mahan experiments of BU72 in the absence or presence of Nb39. The 
dissociation half-life (t1/2) of BU72 was determined by measuring the association rate of the 
antagonist 
3
H-DPN in the presence of the indicated concentrations of BU72. The dissociation t1/2 
of BU72 is 43 min (top) and increases to 140 min in presence of Nb39 (bottom) (Figure from 















Figure A.4: Enhancement in affinity of BU72 to bind MOPr rHDL in the presence of Nb39. 
The ability of BU72 to displacement 
3
H-DPN in MOPr rHDL was measured in the absence or 
presence of 3 µM Nb39. Data shown are means ± SEM of 3 independent experiments each in 













Figure A.5: Time course of BU72 mediated ERK1/2 activation. Time course of BU72 (10 
nM) was performed in C6MOPr cells pretreated overnight with vehicle or PTX (100 ng/mL). 
Samples were analyzed using SDS-PAGE followed by western blot. A) Quantified data for 3 
separate experiments. B) Representative image showing samples loaded in the same order as the 
















Figure A.6: BU72 internalizes MOPr to the same extent as the endogenous ligand Leu-Enk. 
HEK293T cells transiently expressing FLAG tagged MOPr were used to monitor the 
internalization caused by agonist exposure for 10 minutes. Data shown are mean and SEM from 












S]GTPγS (guanosine-5’-(3-thio)triphosphate) were 
purchased from PerkinElmer. Guanosine diphosphate (GDP), p-nitrophenyl phosphate (pNPP), 
and M2 mouse anti-FLAG antibody conjugated to alkaline phosphatase were from Sigma-
Aldrich (St Louis, MO, USA). PTX was from List Biological Laboratories Inc. (Campbell, CA, 
USA). All tissue culture supplies, including Lipofectamine 2000, were from Invitrogen 
(Carlsbad, CA, USA) unless otherwise stated.  
Cell line and transfection: C6 glioma cells were stably transfected with rat MOPr as described 
previously. Cells were grown in DMEM containing 10% fetal bovine serum, 1% pen/strep, and 
100 µg/mL geneticin (G148) in a 37 ºC incubator containing 5% CO2. HEK293T cells (from 
AATC) were grown in DMEM supplemented with 10% FBS and 1% pen-strep. (Pen/strep was 
removed 24 h prior to transient transfection). For transient transfection, cDNA (FLAG-MOPr) in 
complex with Lipofectamine 2000 reagent in minimal media was added to cells in log phase of 
growth. Cells were used 48 h following transfection. 
Membrane Preparation: Confluent C6-MOPr cells were rinsed with phosphate buffered saline 
and then detached using harvesting buffer (20 mM HEPES pH 7.4, 0.68 mM EDTA, and 150 
mM NaCl). Cells were pelleted following centrifugation at 300 g for 3 min at room temperature. 
Supernatant was discarded and pellet was resuspended in ice-cold 50 mM Tris buffer, pH 7.4. 
Pellet was homogenized using a Tissue Tearor (company) and then centrifuged at 20000 g for 20 
min at 4 ºC. The supernatant was discarded and the pellet as resuspended, homogenized, and 
centrifuged once more. The final pellet was homogenized in 50 mM Tris, pH 7.4 using a glass 
dounce homogenizer and aliquots were flash frozen and stored at -80 ºC until use in assays. 
Concentration of protein was determined using a BCA protein assay with bovine serum albumin 
as the standard.  
 
Reconstitution of MOPr: Purified MOPr was reconstituted into high-density lipoprotein (HDL) 
particles comprised of the lipids POPC and POPG (Avanti Polar Lipids) in a 3:2 molar ratio as 











H-DPN) was incubated with varying concentrations of 
agonist in a binding buffer comprised of 25mM HEPES pH 7.4, 100mM NaCl, and 0.1% BSA in 
the presence or absence of 3 µM Nb39. For assays performed using cell membranes, conditions 
listed were kept the same except for exclusion of BSA and inclusion of 10µg protein per well. 
Binding reactions were incubated for 2 h at 25°C. Free radioligand was separated from bound 
radioligand by rapid filtration onto a Whatman GF/C filter pretreated with 0.1% 
polyethylenimine using a 24-well harvester (Brandel). Nonspecific binding was measured in the 
presence of 10µM naloxone, an opioid antagonist. Radioligand activity was measured by liquid 
scintillation counting using a Wallac 1450 MicroBeta counter (Perkin Elmer). Competition 
binding data were fit to a one-site model using GraphPad Prism 6.0.  
 
Mahan Motulsky Assay: Dissociation studies for BU72 were performed using the method of 
Motulsky and Mahan (Motulsky and Mahan, 1984). 
3
H-DPN was diluted in an assay buffer 
comprised of 20 mM Tris, pH 7.4, 150 mM NaCl, and 0.05% BSA containing MOPr in HDL 
particles with either vehicle or different concentrations of BU72 alone or in the presence of 
Nb39. Binding reactions were incubated at 25 °C in the dark and nonspecific binding was 
determined in the presence of 10 µM naloxone. Aliquots of this binding reaction were removed 
at specified time points over the course of 2-8 h and filtered through Whatman GF/C filters with 
the aid of a Brandel harvester. As above, radioligand activity was measured by liquid 
scintillation counting. Dissociation rates for BU72 were determined by fitting data in the 
‘kinetics of competitive binding’ program in GraphPad Prism 6.02. For K1 and K2, rates of 3H-
DPN association and dissociation were determined through independent studies following the 
same method as above. 
 
Purification of MOPr: Full length Mus musculus MOPr bearing an amino-terminal Flag epitope 
tag and a carboxy-terminal 6xHis tag was expressed in Sf9 insect cells using the BestBac 
baculovirus system (Expression Systems). A tobacco etch virus (TEV) protease recognition 
sequence was inserted after residue 51 and a rhinovirus 3C protease recognition sequence was 
inserted before residue 359 for cleavage during purification. Insect cells were infected with 





buffer comprised of 25 mM HEPES pH 7.4, 100 mM NaCl, 0.01% MNG (Anatrace), and 
0.001% cholesterol hemisuccinate (CHS), as previously described (Manglik et al., 2012). 
Purification of Nb39: Nb39 was purified as described (Huang et al., 2015). Briefly, Nb39 
bearing a carboxy-terminal His tag were expressed in the periplasm of Escherichia coli strain 
WK6 grown in Terrific Broth medium containing 0.1% glucose, 2 mM MgCl2, and 50 mg/ml 
ampicillin and induced with 0.5 mM isopropyl-b-D-thiogalactoside (IPTG). Cells were harvested 
after overnight growth at 25 °C and incubated in a buffer containing 200 mM Tris pH 8.0, 0.5 
mM EDTA, 500 mM sucrose and 0.5 mg/ml lysozyme for 1 h at 25 ºC. Bacteria were 
osmotically lysed by rapid dilution in water. The periplasmic fraction was isolated by 
centrifugation of cell debris, and was supplemented with NaCl (150 mM final) and imidazole (25 
mM final). Nb39 was isolated from the periplasmic fraction by nickel affinity chromatography, 
and subsequently purified by size-exclusion chromatography in a buffer comprised of 25 mM 
HEPES pH7.5 and 100 mM NaCl. Peak fractions were pooled and concentrated to approximately 
5mM. 
Apolipoprotein purification and biotinylation: Apolipoprotein-AI (Apo-AI) was purified as 
described previously (Whorton et al., 2007). Apo-A1 was biotinylated using NHS-PEG4-biotin 
(Pierce Biotechnology) at a 1:1 molar ratio. Following a 30-min biotinylation reaction at room 
temperature, the sample was dialysed to remove free biotin.  
P-ERK Assays: C6MOPr cells were plated in 24-well plates the day before the assay to reach 80-
90% confluency on the day of the assay and treated with vehicle or pertussis toxin (PTX; 
100ng/mL). The medium was replaces with serum-free DMEM two hours prior to addition of 
vehicle or BMS-986122 at the indicated concentration. The assay was stopped by aspirating the 
medium and rinsing the cells twice with ice-cold phosphate buffered saline. Lysates were 
collected with radioimmuno-precipitation assay buffer [50 mM Tris, pH 7.4, 150 mM NaCl, 1% 
Triton X-100, 1% sodium deoxycholic acid, 0.1% SDS] plus protease inhibitor, 2mM EDTA, 
100 µM NaF, and 10 µM sodium orthovanadate. Lysates were sonicated for 30 seconds and 
centrifuged at 10000 x g at 4 °C for 10 min. Supernatant was taken and diluted into SDS sample 
buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 0.0008% bromophenol blue) and 
beta-mercaptoethanol. Samples were loaded on 12% polyacrimilade gel and subjected to SDS-





was propped with a 1:2000 dilution of anti-phospho-p44/42 MAPK (ERK1/2) antibody and 
visualized using horseradish peroxidase (HRP) -conjugated anti-mouse IgG. To ensure equal 
loading, membranes were stripped and total ERK levels were assessed using 1:1000 dilution of 
anti-p42/44 MAPK (ERK1/2) antibody. 
Internalization Assays: HEK293T cells were grown to 80% confluency prior to transient 
transfection with FLAG tagged MOPr. 24 hours following transfection, cells were seeded 
(0.75 × 10
6
 cells per well) onto poly-d-lysine coated 24-well plates. 24 h following splitting, the 
cells were treated with drug (or vehicle) in the presence of allosteric ligand (or vehicle) for 10 
minutes at 37C in DMEM. At the end of the incubation period, the cells were fixed with 3.7% 
formaldehyde in Tris-buffered saline [(TBS), 25 mM Tris–HCl, pH 7.4, 2.7 mM KCl, 140 mM 
NaCl] for 5 min at 4 °C. The cells were washed three times with TBS, blocked with 1% non-fat 
dry milk made up in TBS for 1 h at room temperature and washed two times with TBS and 
incubated with monoclonal anti-FLAG M2 alkaline phosphatase antibody for 1 h at 23°C. Cells 
were washed five times and incubated with p-nitrophenyl phosphate for 30 min at 23°C. 0.2 mL 
aliquots were added to 0.05 mL 3 N NaOH in a 96-well plate. Absorbance at 405 nm was 
measured using a VERSAmax tunable microplate reader (Molecular Devices, Sunnyvale, CA, 
USA). The percentage of receptors internalized was calculated using the following equation: 
[1 − (Drug O.D. − Background O.D./Control O.D. − Background O.D.) × 100], where O.D. is 
optical density. Background was defined as the absorbance of untransfected HEK293 cells and 



















Discovery, Synthesis, and Molecular Pharmacology of Selective Positive Allosteric 
Modulators of the δ-Opioid Receptor3 
 
Summary 
Allosteric modulators of G protein-coupled receptors (GPCRs) have a number of 
potential advantages compared to agonists or antagonists that bind to the orthosteric site of the 
receptor. These include the potential for receptor selectivity, maintenance of the temporal and 
spatial fidelity of signaling in vivo, the ceiling effect of the allosteric cooperativity which may 
prevent overdose issues, and engendering bias by differentially modulating distinct signaling 
pathways. Here we describe the discovery, synthesis, and molecular pharmacology of δ-opioid 
receptor-selective positive allosteric modulators (δ PAMs). These δ PAMs increase the affinity 
and/or efficacy of the orthosteric agonists leu-enkephalin, SNC80 and TAN67, as measured by 
receptor binding, G protein activation, β-arrestin recruitment, adenylyl cyclase inhibition, and 
extracellular signal-regulated kinases (ERK) activation. As such, these compounds are useful 
pharmacological tools to probe the molecular pharmacology of the δ receptor and to explore the 
therapeutic potential of δ PAMs in diseases such as chronic pain and depression. 
 
Introduction 
The δ-opioid receptor is a seven transmembrane domain (7TMD) receptor that belongs to 
the class A family of G protein-coupled receptors (GPCRs). Agonists of the δ receptor have been 
shown to be antinociceptive especially in chronic pain models (Gavériaux-Ruff and Kieffer, 
2011) and to have potential as antidepressant agents (Lutz and Kieffer, 2013). The possible dual 
                                                          
3 This research was originally published in the Journal for Medicinal Chemistry. Burford NT, Livingston KE, Canals 
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Traynor J, Gerritz S, Alt A. “Discovery, Synthesis and Pharmacological Characterization of Selective Positive 
Allosteric Modulators of the δ-Opioid Receptor.” J Med Chem. 2015 May 28;58(10):4220-9.  





effects of δ receptor agonists to alleviate chronic pain and mitigate emotional disorders provide a 
particularly attractive therapeutic strategy because of the high level of comorbidity between 
chronic pain and depression. However, agonists acting directly at the δ receptor can show 
proconvulsant effects in animal models, including non-human primates. Indeed, it has been 
proposed that these seizurogenic properties of δ receptor agonists may be responsible for their 
antidepressant-like activity analogous to electroconvulsive therapy (Broom et al., 2002).
 
On the 
other hand, slowing the rate of administration of the δ receptor agonist SNC80 reduces 
seizurogenic activity but has no effect on anti-depressant-like effects (Jutkiewicz et al., 2005). 
Also, some δ receptor agonists (e.g., ADL5859) show no seizures in rat or mouse models (Le 
Bourdonnec et al., 2008). These and other findings suggest that the convulsive properties of δ 
receptor agonists can be separated from their antidepressant-like effects (Jutkiewicz et al., 2006; 
Chu Sin Chung and Kieffer, 2013; Chu Sin Chung et al., 2015). 
Allosteric modulators for GPCRs bind to a site on the receptor that is topographically 
distinct from the site that binds the orthosteric (or endogenous) agonist. Positive allosteric 
modulators (PAMs) increase the affinity and/or efficacy of bound orthosteric agonist ligands. 
The operational model of allosterism allows the quantification of allosteric effects, and as such, it 
can estimate the binding affinity of the allosteric ligand to the free receptor (pKB), the allosteric 
cooperativity factor (αβ), as well as any intrinsic agonist efficacy (τB) of the allosteric ligand. 
PAMs that have little or no intrinsic efficacy (τB) but modulate the orthosteric agonist response 
have a number of advantages over orthosteric ligands (Christopoulos and Kenakin, 2002; May, 
Leach, et al., 2007; N Burford et al., 2015). In particular, these PAMs can theoretically maintain 
the temporal and spatial fidelity of endogenous receptor activation in vivo. The allosteric 
modulator binds to the target receptor but remains effectively silent until the endogenous 
orthosteric agonist is presented to the receptor. Therefore, PAMs can amplify the effect of 
endogenous signaling molecules without disrupting normal physiological regulation of receptor 
activation and might therefore be expected to exhibit superior efficacy and side effect profiles 
compared to traditional orthosteric agonists. Studies with δ receptor selective ligands, or utilizing 
a genetic deletion of the δ receptor (Gavériaux-Ruff and Kieffer, 2011), suggest that native 
opioid peptide signaling at the δ receptor mediates an increase in pain threshold in models of 
chronic pain and modulates mood states in rodent models (Pradhan et al., 2011). Therefore, 





agonist peptides and thereby be therapeutically efficacious. In addition, the finite nature of the 
agonist potency shift (defined by the allosteric cooperativity factor), which saturates when the 
allosteric site is fully occupied, may increase the safety margin between therapeutic effect and 
possible side effects associated with overactivation of the target receptor. Finally, and pertinent 
to the δ-receptor system which is known to exhibit ligand-biased signaling (Pradhan et al., 2012), 
PAMs can modulate the signaling bias of receptor activation toward desired pathways or 
engender bias from previously unbiased ligands (Leach et al., 2010; Kenakin and Christopoulos, 
2012). Thus, δ PAMs may provide a greater therapeutic window between pain relieving and 
antidepressant-like effects and proconvulsive activity, compared with traditional δ receptor 
orthosteric agonists. 
In this study we report the synthesis and structure–activity relationships (SAR) of the first 
described δ PAMs. One of the most potent compounds identified, 3,3,6,6-tetramethyl-9-(4-((2-
methylbenzyl)oxy)phenyl)-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione (2, BMS-986187), 
was further characterized in radioligand binding assays and using a range of cellular functional 
assays. 2 was shown to positively modulate orthosteric agonist binding affinity and functional 
potency at the δ receptor and enhance the efficacy of the partial agonist TAN67. 
 
Results 
Discovery and Structure–Activity Relationship (SAR) of δ Receptor PAMs 
The δ PAM chemotype was identified from a high throughput screen (HTS) using a β-
arrestin recruitment assay in a PathHunter U2OS cell line coexpressing μ and δ receptors (U2OS-
OPRM1D1) (DiscoveRx, Fremont, CA) (Zhao et al., 2008; Bassoni et al., 2012). The screen was 
executed in PAM mode by measuring activity in the presence of an EC10 concentration of both 
endomorphin 1 (a μ-receptor-selective agonist) and leu-enkephalin which in this assay and cell 
line was a relatively selective agonist for the δ receptor (Burford et al., 2014). Typically, when 
using HTS approaches to identify PAMs, an EC20–40 concentration of orthosteric agonist is used 
(Burford et al., 2011).
 
However, in this HTS the sum of the two EC10 concentrations of agonists 
offered a compromise between the detection of both μ and δ receptor PAMs and the ability to 
maintain the overall signal window so that lower efficacy partial agonists could also be detected. 
Follow-up in vitro testing to determine structural features necessary for PAM activity was 





DiscoveRx. Concentration-response curves (CRCs) for HTS hits were determined both in agonist 
mode (in the absence of orthosteric agonist) to determine agonist activity of the test compounds, 
and in PAM mode (in the presence of an EC20 concentration of orthosteric agonist) to determine 
allosteric modulator activity using the β-arrestin recruitment assays. Compound 7 (Table B.1) 
was identified as a δ PAM, producing a robust potentiation of the response to an EC20 
concentration of leu-enkephalin. 
As shown in Scheme 1, we synthesized a series of close analogs of 7 to optimize δ PAM 
potency and selectivity. None of the compounds exhibited significant agonist activity in a β-
arrestin recruitment assay, but all of the compounds produced measurable PAM activity at the δ 
receptor. 1 with an unsubstituted benzyl ring acted as a δ PAM with an EC50 value of 0.2 μM and 




μ receptor. Introduction of a methyl group in various positions around the phenyl ring (2–4) 
suggested that ortho substitution increased δ receptor PAM activity by an order of magnitude, 
with minimal effect on μ receptor PAM activity, while meta and para substitution did not 
significantly affect δ or μ receptor PAM activity. The corresponding ortho-F analog 5 was not 
significantly more active than 1, suggesting that the increased δ receptor activity with the o-
methyl was due to a steric rather than an electronic effect. Similarly, the meta- and para-F 
analogs 6 and 7 or the ortho-Cl analog 8 did not afford an increase in δ receptor activity. 
Introduction of a second Cl group in the meta position (9) provided a modest improvement in δ 
receptor activity while maintaining selectivity. A more pronounced effect was observed with the 





observable PAM activity at the μ receptor, suggesting that 9 - (4-((2-bromobenzyl)oxy)phenyl)-
3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione (10, BMS-986188) is the 
most δ receptor-selective analog we have identified to date. The effect of ortho substitution on δ 
receptor PAM potency and selectivity appears to be restricted to small substituents. As shown 
with analogs 11–15, larger ortho sub-stituents did not improve δ PAM activity and had no effect 
on selectivity. Similarly, more drastic changes to the chemotype, such as increasing the chain 
length between the ether oxygen and the phenyl ring, or replacement of the benzyl ether with a 
phenyl amide, yielded a significant loss in δ receptor PAM activity (data not shown). The most 
potent δ PAM identified was 2, which in the presence of an EC20 of leu-enkephalin produced a β-
arrestin response with an average EC50 of 33 nM in CHO-OPRD1 cells (Table B.1). 
Representative agonist and PAM mode CRCs for 2 at the μ and δ receptor are shown in Figure 
B.1. In this example, 2 produced little or no activity in agonist mode, but in PAM mode (in the 
presence of an EC20 of leu-enkephalin (in CHO-OPRD1 cells) or endomorphin 1 (in CHO-
OPRM1 cells)) produced a response with an EC50 of 48 nM in CHO-OPRD1 cells and 2 μM in 
CHO-OPRM1 cells. 
Binding Characterization of 2 
2 (at concentrations up to 30 μM) does not inhibit binding of the orthosteric antagonist 
3
H-diprenorphine (DPN) to CHO-hDOPr cell membranes, suggesting that 2 is acting at an 
allosteric site to produce agonist and PAM activity (Figure B.2A). However, in competition 
binding experiments 10 μM 2 increased the affinity of the orthosteric agonists, leu-enkephalin 
(Fig B.2B), SNC80 (Fig B.2C), and TAN67 (Fig B.2D) to displace 
3
H-DPN. This suggests that 2 
is an affinity modulator (the α component of the cooperativity factor) in the system tested (Table 
B.2). The affinity shift with the partial agonist TAN67 is less than that seen with the full agonists 
















Figure B.1: β-Arrestin recruitment response to 2 in agonist mode (in the absence of 
orthosteric agonist) and in PAM mode (in the presence of an EC20 of orthosteric agonist) in 
PathHunter cells expressing δ receptors (CHO-OPRD1) and μ receptors (CHO-OPRM1). 
For CHO-OPRD1 cells the orthosteric agonist was leu-enkephalin, and for CHO-OPRM1 cells 
the orthosteric agonist was endomorphin 1. In PAM mode, the EC20 response of orthosteric 
agonist was normalized to 0%. 100% represents the response to a maximally effective 







Table B.1: Structure−Activity Relationship of the δ-PAM Chemotype in PathHunter CHO-




No activity was observed in agonist mode (in the absence of orthosteric agonist (data not 
shown)). In PAM mode (in the presence of an EC20 of leu-enkephalin for OPRD1 cells or an 
EC20 of endomorphin I for OPRM1 cells), robust responses were observed. The mean EC50 
values, Ymax values, and potency ratio of δ receptor activity/μ receptor activity in PAM mode are 





Functional Characterization of 2 
The PAM activity of 2 was further characterized in four different functional assays. In the 
CHO-OPRD1 PathHunter cells, 2 effects on leu-enkephalin potency and efficacy were studied in 
both β-arrestin recruitment assays and inhibition of forskolin-stimulated cAMP accumulation 
assays. Unlike the U2OS cell lines used in the HTS, where forskolin was relatively ineffective at 
stimulating adenylyl cyclase activity, the recombinant CHO PathHunter cell lines allowed us to 
investigate both β-arrestin recruitment and inhibition of forskolin-stimulated cAMP 
accumulation in the same cell line. In the β-arrestin recruitment assay, 2 alone (up to 10 μM) 
produced only marginal agonist activity (∼10% of a maximal response to leu-enkephalin) but 
produced a robust 18-fold increase in the potency of leu-enkephalin (Fig B.3A). A small increase 
in the maximal response to leu-enkephalin with 2, relative to leu-enkephalin alone, was also 
observed. This suggests that 2 is a PAM with little or no intrinsic efficacy in this system. In 
contrast, in the inhibition of forskolin-stimulated cAMP assay, 2 alone produced robust activity 
resulting in full inhibition of cAMP accumulation at concentrations above 3 μM (Fig B.3B). At 
lower concentrations, 2 increased the potency of leu-enkephalin. At a 370 nM concentration of 2 
(the highest concentration at which a potency for leu-enkephalin could be determined) the 
potency of leu-enkephalin was increased by 56-fold. Similar findings were observed using the 
small molecule orthosteric agonist SNC80 in these two assays (Table B.3). 
Similar to the findings in the cAMP functional assay, 2 was also shown to be a PAM in 
[
35
S]GTPγS binding (Fig B.4A) and in ERK1/2 phosphorylation (Fig B.4B) in CHO-hDOPr 


















Figure B.2: Effect of 2 on 3H-diprenorphine (DPN) binding (A) and the effect of 10 μM 2 
on leu-enkephalin (B), SNC80 (C), and TAN67 (D) competition binding curves in CHO-














Table B.2: Effect of 2 (10 μM) on Orthosteric Agonist Competition Binding Ki Values in 
CHO-hDOPr Cell Membranes 
 
2 had no effect on 
3
H-DPN binding (see Figure B.2) but increased the affinity of orthosteric 













Figure B.3: Effect of increasing concentrations of 2 on leu-enkephalin concentration–
response curves in β-arrestin recruitment (A) and in inhibition of forskolin-stimulated 
cAMP accumulation (B) in CHO-OPRD1 cells. Data are presented as the mean ± SEM of four 














Figure B.4: Effect of increasing concentrations of 2 on leu-enkephalin concentration–
response curves in [35S]GTPγS binding in CHO-hDOPr membranes (A) and in pERK in 
CHO-hDOPr cells (B). In the [35S]GTPγS binding assay, 0% and 100% represent the basal 
response and the maximal response produced, respectively. In the pERK assay, 0% represents 
basal activity in serum-free media and 100% represents the pERK response in the presence of 
10% serum. Data are presented as the mean ± SEM, n = 3–7. Data were fitted to the operational 
















Values for affinity, efficacy, and allosteric cooperativity for orthosteric ligands and 2 are derived 
from the operational model of allosterism. Three different orthosteric agonists were used (leu-
enkephalin, SNC80, and TAN67), across up to four functional assays (β-arrestin recruitment, 
[
35
S]GTPγS binding, cAMP inhibition, and pERK). In the model τA and τB represent the efficacy 
of the orthosteric agonist and allosteric modulator, respectively; pKA and pKB represent the 
binding affinity of the orthosteric agonist and the allosteric modulator, respectively, to the free 
receptor; and αβ represents the composite allosteric cooperativity factor. Data are presented as 
the mean ± SEM of three to seven experiments. 
*pKA is fixed to its equilibrium binding affinity, as ligand is a full agonist in all end points tested. 
**pKA of leu-enkephalin and TAN67 in end points where they are partial agonists was obtained 
from fitting their concentration response curves to the operational model of agonism to obtain a 
functional affinity in each end point tested. 
***the pKB for TAN67 in [
35
S]GTPγS binding had to be fixed to the average of the pKB obtained 
from Leu-enk and SNC80 as neither allosteric agonism or potentiation reached a limit. 
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orthosteric agonist at lower concentrations. No agonist activity to 2 was observed in the parental 
CHO cells (lacking the δ receptor) in ERK1/2 phosphorylation or in parental CHO cells in 
inhibition of cAMP accumulation assays (data not shown). 2 increased the potency of leu-
enkephalin by 16-fold in the [
35
S]GTPγS binding assay in CHO-hDOPr membranes and by 8-
fold in the ERK1/2 phosphorylation assay in CHO-hDOPr cells. Similar experiments were 
performed replacing leu-enkephalin with the orthosteric agonists SNC80 and the partial agonist 
TAN67. By use of an operational model of allosterism (Leach et al., 2007) (see Methods and 
Materials), composite cooperativity (αβ) values and pKB values (denoting the equilibrium 
dissociation binding constant for 2 at the δ receptor in the absence of orthosteric agonist, i.e., at 
the free receptor) were determined for 2 across these different assays and with different 
orthosteric agonists (Table B.3). 
The mean ± SEM pKB across all the assays for 2 was 6.02 ± 0.16 (∼1 μM). One would 
expect that the pKB values should be the same across all the cell lines, functional assays, and 
orthosteric agonists used, since the pKB represents the binding affinity of 2 to the free receptor. 
Two way ANOVA with multiple comparison test of the pKB values in Table B.3 showed no 
significant difference between the different orthosteric agonist ligands used in the same 
functional assay. For SNC80 and TAN67 there were also no significant differences in pKB values 
across the different functional pathways tested. However, for leu-enkephalin there were 
significant differences in the pKB values between β-arrestin recruitment and [
35
S]GTPγS binding 
(p < 0.01) and between β-arrestin recruitment and cAMP inhibition (p < 0.001). 
 
Discussion 
By use of a β-arrestin recruitment assay, the SAR of a δ PAM chemotype identified from 
HTS was explored, resulting in identification of compounds (1–15) with little or no agonist 
activity but which produced PAM activity at the δ and μ receptor. To compare the allosteric 
activity of the compounds, we used increasing concentrations with a single (EC20) concentration 
of orthosteric agonist and analyzed the EC50 and Ymax values of the functional curves produced. 
Although the compounds exhibited a range of Ymax values in PAM mode (Table B.1) which can 
correlate with the allosteric cooperativity, the large proportion of the analogs tested exhibited 





compounds for further study. Instead, potency of the PAM response was used and selectivity was 
determined using potency ratios between the PAM responses at the δ receptor compared to the μ  
receptor. While this procedure is useful for selecting δ receptor selective PAM candidates to 
pursue, one must bear in mind that different orthosteric agonist ligands were used in the PAM 
mode assays: leu-enkephalin for the δ receptor, and endomorphin I for the μ receptor. Since we 
currently know little about the possible probe dependence of these PAM compounds at the δ and 
μ receptor, we cannot necessarily assume that the reported selectivity will be the same with 
different orthosteric probe ligands. 
The selected data set used for multivariate statistical analysis do not allow for thorough 
cross-validation of the presented linear models, but our results suggest initial physicochemical 
properties that can be used as searching criteria for additional compounds with potential PAM 
activity at δ and μ opioid receptors. 2 was selected for further characterization, since it had the 
highest PAM mode potency at the δ receptor and showed 100-fold selectivity compared to the μ 
receptor. 
The multivariate statistical analysis initially suggested that the compounds may not be 
readily soluble in aqueous buffer at concentrations in the micromolar range. Also, nephelometry 
data (not shown) suggest that 2 and 10 show particulate matter in phosphate buffered saline 
solution at concentrations above 1 μM. When nephelometry was repeated using the specific 
buffer used for the β-arrestin recruitment assays (HBSS + 25 mM HEPES and 10% FBS) in 
Table C.1, 2 and 10 produced particulate matter above 3 μM. While the majority of responses to 
2 in cells expressing the δ receptor were maximal at 1 μM (and therefore, within the solubility 
window predicted for 2), the μ receptor responses (e.g., see Figure B.1) also showed sigmoidal 
responses (i.e., the responses were not biphasic) up to 30 μM 2, suggesting that solubility was not 
an issue in these assays in the specific buffers used. However, compound solubility should be an 
important consideration in further studies and optimization of this chemical series. 
From competition binding studies, 2 did not affect 
3
H-DPN binding to the δ receptor but 
increased the affinity of orthosteric agonists, suggesting that 2 does not bind to the orthosteric 
site of the δ receptor but can increase the affinity of orthosteric agonists binding to the receptor 
(α cooperativity). The precise mechanism for this cooperativity remains unknown. However, in 
this context it is tempting to make comparisons to recently discovered PAMs of the μ opioid 
receptor (Burford et al., 2013).
 





chlorophenyl)sulfonyl)thiazolidine (16, BMS-986122) has been found to differentially increase 
the affinity of various orthosteric agonists, and the magnitude of the affinity increase (α value) 
produced by 16 correlates with the intrinsic activity of the orthosteric ligand used (Chapter 3; 
Livingston and Traynor, 2014). The mechanism by which 16 induces this affinity modulation is 
suggested to be via reducing the affinity of Na
+
 for its binding site on the μ receptor. The precise 
binding site for 16 on the μ receptor has not been clearly established, and it is unknown whether 
the δ receptor PAMs described here bind to an analogous binding site on the δ receptor or act via 
a similar mechanism. However, several analogs of 16 were found to exhibit weak activity at δ 
receptors, and most of the δ receptor PAMs described here also exhibit some degree of activity at 
μ receptors. Therefore, it is possible that these δ receptor PAMs may be binding to a site on the δ 
receptor that is analogous to the 16 binding site on the μ receptor and may work through a similar 
mechanism. The reduced affinity shift observed with 2 for the partial agonist TAN67 compared 
with the agonists with higher intrinsic activity, leu-enkephalin and SNC80 (Fig B.2, Table B.2), 
is consistent with this hypothesis. It will be interesting to determine whether these δ PAMs 
reduce the affinity of Na
+
 for its binding site on the δ receptor. Sodium ions are known to 
stabilize a lower affinity state of the δ receptor, and the molecular basis for allosteric Na
+
 control 
of opioid receptor signaling has been elucidated recently (Fenalti et al., 2014; Shang et al., 
2014). 
While TAN67 was a partial agonist in the CHO-hDOPr cell line for [
35
S]GTPγS binding 
giving 84% of maximal SNC80 response, it had even less intrinsic activity in a C6-DOPr cell 
line at 41% of maximal SNC80 response (data not shown). In the presence of 2 (300 nM), the 
maximal stimulation by TAN67 was increased to 67% of maximal SNC80 response. This 
suggests that 2 has some allosteric efficacy cooperativity (β), as well as the affinity cooperativity 
(α) observed above. 
In all of the functional assays, 2 acted as a PAM, increasing the potency of the response 
to orthosteric agonists. No activity was observed in functional assays when 2 was added alone in 
CHO-parental cells (lacking the recombinant δ opioid receptor) in either the ERK activation 
assay or cAMP assay (data not shown). However, in cells expressing the δ receptor, 2 (when 
added alone) produced significant activity in cAMP inhibition, [
35
S]GTPγS binding, and ERK 
activation assays, suggesting that this activity is due to intrinsic efficacy of 2 at the τ receptor. 





no agonist activity in the β-arrestin recruitment assay, which measures an event proximal to 
receptor activation with limited signal amplification. The difference in observed agonist activity 
for 2 between the β-arrestin recruitment assay and the cAMP assay (Fig B.3) is likely reflective 
of a higher level of signal amplification and thus a higher receptor reserve in the cAMP assay 
compared to the β-arrestin recruitment assay in the same cell line (Ehlert, 2005; Kenakin et al., 
2012). Phosphorylation of the receptor by G protein-coupled receptor kinases (GRKs) is thought 
to be a prerequisite for β-arrestin recruitment (Pierce and Lefkowitz, 2001).
 
It would be 
interesting to see how 2 impacts δ receptor phosphorylation by GRKs and consequently 
desensitization and internalization of the receptor. 
Calculation of pKB values for 2 across the various functional assays with leu-enkephalin, 
SNC80, and TAN67, using the allosteric operational model, showed some variability. These 
differences in pKB values may result from the allosteric effect not reaching a plateau or ceiling. 
This could reflect that the allosteric effect was submaximal at concentrations below those at 
which full agonism was observed with 2 or that the highest concentrations of 2 used did not 
cause the allosteric EC50 shift to reach its ceiling. This can make accurate assessment of the 
allosteric parameters more difficult to estimate in the model. Other variables, including the use of 
different cell lines or use of a tagged receptor (in the case of the PathHunter CHO-OPRD1 cell 
line), may also contribute to the variability of values obtained in the model. 
The fact that we observed PAM effects with 2 at concentrations lower than those which 
produced agonist effects is entirely consistent with the allosteric ternary complex model because 
the former effects (PAM effects) are observed in the presence of orthosteric agonist, and hence 
the affinity of the modulator for the receptor is higher, whereas the latter effects (agonist effects) 
reflect the actions of the modulator at the free receptor and thus require higher concentrations to 
achieve the same level of fractional occupancy. Therefore, a PAM with a large cooperativity 
factor (αβ) can exhibit functional activity that is far more potent than its KB value. This has 
potential implications for PAM drug discovery programs, suggesting that it is important to track 
functional PAM activity rather than KB values when designing assays to support SAR. 
Additionally, this suggests that assays assessing target engagement may dramatically 
underestimate the relevant receptor occupancy of a PAM, since the affinity of the PAM (and 
therefore its fractional receptor occupancy) will be much higher at sites where orthosteric agonist 





vivo, they nonetheless represent the relevant receptor population, since positive allosteric 
modulation can only occur when and where orthosteric agonist is bound. 
Despite the complexities discussed above, all available data suggest that 2 is a δ PAM or 
a δ PAM-agonist. In future studies, it will be important to confirm the activity of 2 and its 
analogs in cells or tissues natively expressing δ receptors. Further, it will be of significant 
interest to determine whether compounds such as 2 also exhibit direct agonist activity in native 
systems expressing endogenous levels of δ receptors. PAMs devoid of intrinsic agonist activity 
could theoretically have therapeutic advantages over PAM-agonists, particularly in the 
maintenance of the temporal and spatial fidelity of endogenous receptor activation in vivo, as 
they would effectively be silent when bound to the receptor until orthosteric (endogenous) 
agonist is presented to the receptor. A key issue will be the determination of these effects in vivo. 
We intend to evaluate the in vivo activity of 2 and its analogs in models of acute and chronic pain 
(Vanderah, 2010), migraine (Pradhan et al., 2014), depression (Jutkiewicz, 2006) and convulsive 
activity (Broom et al., 2002) which is a known liability of δ opioid receptor agonists that has 
limited the pursuit of δ receptor agonists as potential therapeutics. 
In summary, we have identified and characterized δ receptor-selective PAMs including 
our lead compound 2. Further studies are planned to assess probe dependence and signaling bias 
for these PAMs using a variety of orthosteric opioid receptor ligands and functional assays. 
Additional research is also ongoing to determine if this new class of compounds could represent 





Analogs were purchased from external vendors (1, 3–5, 7) or synthesized according to Scheme 1 
(2, 6, 8–15). All purchased and newly synthesized analogs provided analytical data consistent 
with their assigned structures and were >95% pure based on LCMS. 
 
Synthesis of Intermediate A (Scheme 1) 
To a solution of 4-hydroxybenzaldehyde (1.5 g, 12.28 mmol) in 2-propanol (35 mL) were added 





mmol). The reaction mixture was refluxed for 1.5 h in an oil bath and then cooled to room 
temperature, forming a white precipitate. After filtration, 3 g of 9-(4-hydroxyphenyl)-3,3,6,6-
tetramethyl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione was obtained in 65% yield (98% 
purity by LCMS analysis). 
1
H NMR (400 MHz, CD3Cl) δ 7.09 (d, J = 8.6 Hz, 2H), 6.56 (d, J = 
8.6 Hz, 2H), 4.67 (s, 1H), 2.46 (s, 4H), 2.23 (s, 2H), 2.21 (s, 2H), 1.10 (s, 6H), 1.00 (s, 6H); ESI-




Synthesis of Analogs 1-15 
General Procedure  
To a solution of 9-(4-hydroxyphenyl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1H-xanthene-
1,8(2H)-dione (100 μmol, 36.6 mg) in DMF (1.2 mL) were added ArCH2Br (200 μmol) and 
Cs2CO3 (65.2 mg, 200 μmol). The reaction mixture was stirred at room temperature overnight. 
Then 10 μL of the reaction solution was taken, dissolved in MeOH (0.2 mL), and analyzed by 
LCMS. The LCMS showed that the reaction was complete and the desired product as a major 
peak was found. The product was purified via preparative LC/MS with the following conditions. 
Column: XBridge C18, 19 mm × 200 mm, 5-μm particles. Mobile phase A: 5:95 
acetonitrile/water with 10 mM ammonium acetate. Mobile phase B: 95:5 acetonitrile/water with 
10 mM ammonium acetate. Gradient: 70–100% B over 15 min, then a 5 min hold at 100% B. 
Flow: 20 mL/min. Fractions containing the desired product were combined and dried via 
centrifugal evaporation. 
Two analytical LC/MS injections were used to determine the final purity. Injection 1 conditions 
were the following. Column: Waters BEH C18, 2.0 mm × 50 mm, 1.7 μm particles. Mobile 
phase A: 5:95 acetonitrile/water with 10 mM ammonium acetate. Mobile phase B: 95:5 
acetonitrile/water with 10 mM ammonium acetate. Temperature: 50 °C. Gradient: 0% B, 0–
100% B over 3 min, then a 0.5 min hold at 100% B. Flow: 1 mL/min. Detection: UV at 220 nm. 
Injection 2 conditions were the following. Column: Waters BEH C18, 2.0 mm × 50 mm, 1.7 μm 
particles. Mobile phase A: 5:95 methanol/water with 10 mM ammonium acetate. Mobile phase 
B: 95:5 methanol/water with 10 mM ammonium acetate. Temperature: 50 °C. Gradient: 0% B, 







Proton NMR was acquired in deuterated CDCl3 or DMSO. 
3,3,6,6-Tetramethyl-9-(4-((2-methylbenzyl)oxy)phenyl)-3,4,5,6,7,9-hexahydro-1H-xanthene-
1,8(2H)-dione (2, BMS-986187)  
1
H NMR (400 MHz, chloroform-d) δ 7.51–7.35 (m, 2H), 7.26–7.18 (m, 4H), 6.89 (dd, J 
= 14.2, 8.6 Hz, 2H), 5.05 (s, 2H), 4.72 (s, 1H), 2.49 (d, J = 5.9 Hz, 4H), 2.38 (d, J = 7.8 
Hz, 4H), 2.27–2.21 (m, 3H), 1.16–1.10 (m, 6H), 1.07–1.00 (m, 6H). HRMS: calcd 
C31H35O4, 471.2530; found, 471.2538 
 
9-(4-((2-Bromobenzyl)oxy)phenyl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1H-xanthene-
1,8(2H)-dione (10, BMS-986188)  
The yield of the product was 20.6 mg, and its estimated purity by LCMS analysis was 
100%. 
1
H NMR (500 MHz, DMSO-d6) δ 7.67 (d, J = 7.7 Hz, 1H), 7.56 (d, J = 7.3 Hz, 
1H), 7.42 (t, J = 7.5 Hz, 1H), 7.31 (t, J = 7.3 Hz, 1H), 7.10 (d, J = 8.1 Hz, 2H), 6.88 (d, J 
= 8.4 Hz, 2H), 5.04 (s, 2H), 4.48 (s, 1H), 2.54 (d, J = 11.4 Hz, 4H), 2.26 (d, J = 16.1 Hz, 
2H), 2.09 (d, J = 16.1 Hz, 2H), 1.04 (s, 6H), 0.91 (s, 6H). HRMS: calcd C30H32O4Br, 
535.1478; found, 535.1478. 
 
Cell Lines 
Chinese hamster ovary (CHO) PathHunter cells expressing enzyme acceptor (EA) tagged β-
arrestin 2 and either ProLink (PK) tagged δ receptor (CHO-OPRD1) or PK-tagged μ receptor 
(CHO-OPRM1) were from DiscoveRx (Fremont, CA). PathHunter is a trademark of DiscoveRx. 
Cells were grown in F-12 media (Invitrogen 11765), containing Hyclone FBS 10%, Hygromycin 
300 μg/mL (Invitrogen 10687), G418 800 μg/mL (Invitrogen 10131) and maintained at 37 °C in 
a humidified incubator containing 5% CO2. These cells were used for β-arrestin recruitment 
assays and inhibition of forskolin-stimulated cAMP accumulation assays described below. 
FlpIn CHO cells (Invitrogen, Carlsbad, CA, USA) were grown in Dulbecco's modified Eagle 
medium (DMEM) supplemented with 10% fetal bovine serum and maintained at 37 °C in a 
humidified incubator containing 5% CO2. FlpIn CHO cells were transfected with the pOG44 
vector encoding Flp recombinase and the pDEST vector encoding the human δ receptor (hDOPr) 
at a ratio of 9:1 using polyethylenimine as transfection reagent. At 24 h after transfection the 





HygroGold as selection agent. Cells were grown and maintained in DMEM containing 20 mM 
HEPES, 5% fetal bovine serum, and 200 μg/mL Hygromycin-B. Cells were maintained at 37 °C 
in a humidified incubator containing 5% CO2. These cells were used for ERK phosphorylation 
assays, and membranes derived from these cells were used for [
35
S]GTPγS binding and 
3
H DPN 
binding studies as described below. 
 
Materials 
PathHunter detection reagents were from DiscoveRx (Fremont, CA). Cell culture media and 
supplements were from Life Technologies (Carlsbad, CA). Lance-Ultra cAMP detection 
reagents, Surefire ERK assay reagents, [
3
H]diprenorphine (DPN), and [
35
S]GTPγS (guanosine-5′-
O-(3-thio)triphosphate) were from PerkinElmer Life Sciences (Cambridge, MA). Endomorphin I 
and TAN67 were obtained from Tocris. All other chemicals, unless otherwise specified, were 
purchased from Sigma (St. Louis, MO). 
 
PathHunterβ-Arrestin Assay 
Confluent flasks of CHO-OPRM1 and CHO-OPRD1 cells were harvested with TrypLE Express 
and resuspended in F-12 media supplemented with 10% FBS and 25 mM HEPES, at a density of 
6.67 × 10 cells/mL and plated (3 μL/well) into white solid TC-treated 1536-well plates (Corning, 
NY). Plates were incubated overnight at 37 °C in a 5% CO2 humidified incubator. The next day, 
compounds (40 nL of 100 × final concentration in 100% DMSO) were added to cell plates by 
acoustic dispense using an Echo-550 (Labcyte, Sunnyvale, CA) from Echo-qualified 1536-well 
source plates (Labcyte). Next, 1 μL of assay buffer (agonist mode), or assay buffer containing a 
low concentration (∼4 × EC20) of orthosteric agonist (PAM mode), was added to assay plates. 
The orthosteric agonists used are described in the Results and Discussion. Plates were covered 
with a lid and incubated at room temperature for 90 min. Incubations were terminated by the 
addition of 2 μL of PathHunter Reagent (DiscoveRx). One hour later luminescence was detected 
using a Viewlux imaging plate reader (PerkinElmer). 
 
Inhibition of Forskolin-Stimulated cAMP Accumulation Assays 
CHO-OPRD1 cells were grown to confluence (as described above). Cells were harvested and 





Compounds (30 nL of 100 × final concentration in 100% DMSO) were added to 1536-well white 
solid NT plates by acoustic dispense using an Echo-550 (Labcyte, CA) followed by a 1 μL 
addition of cells (2000 cells/well) to all wells. Next, 1 μL of either assay buffer (for agonist 
mode) or assay buffer containing a 3 × EC20 concentration of orthosteric agonist (PAM mode) 
was added. Finally, 1 μL of 3 × forskolin (2 μM final) was added. Plates were lidded and 
incubated for 45 min at rt. Incubations were terminated by the addition of Lance-Ultra cAMP 
detection reagent (PerkinElmer) (1.5 μL of Eu-cryptate-labeled cAMP tracer in lysis buffer, 
followed by 1.5 μL of U-light conjugated anti-cAMP antibody in lysis buffer). After a 1 h 
incubation at room temperature, time-resolved fluorescence (TRF) was detected on a Viewlux or 
Envision plate reader (PerkinElmer) with excitation at 337 nm and emission reads at 615 and 665 
nm. The ratiometric data (665 nm read/615 nm read) × 10 000 were then converted to cAMP 
(nM) based on a standard curve for cAMP (replacing the cell addition step) run at the same time 
and under identical conditions to the assay. 
Characterization of δ-opioid receptor-selective PAMs in the CHO-OPRD1 cAMP assay, using 
curve-shift assays, were performed as described above using orthosteric agonists described in the 
Results and Discussion. 
 
Membrane Preparation 
Confluent cells were rinsed with phosphate buffered saline and then detached using harvesting 
buffer (0.68 mM EDTA, 0.15 M NaCl, 20 mM HEPES, pH 7.4). Cells were pelleted by 
centrifugation at 300g for 3 min, followed by resuspension in cold 50 mM Tris-HCl buffer, pH 
7.4. Pellet was rehomogenized using a Tissue Tearor and then centrifuged at 20 000g for 20 min 
at 4 °C. The supernatant was discarded, and the process was repeated for an additional 
rehomogenization and centrifugation. The supernatant was discarded, and the final pellet was 
resuspended in 50 mM Tris-HCl and flash-frozen in aliquots using liquid nitrogen. Aliquots were 
kept at −80 °C until assays. Protein concentration was determined using BCA protein assay with 
bovine serum albumin as the standard. 
 
Radioligand Binding Assay 
Cell membranes (as prepared above, 10 μg/well) were incubated in the following mixture for 90 





MgCl2, 10 μM GTPγS), various concentrations of orthosteric and allosteric ligand, and 0.35-0.45 
nM [
3
H]DPN. Nonspecific binding was determined in the presence of 10 μM naloxone. 
Reactions were terminated by rapid filtration through glass microfiber GF/C filters (Whatman) 
using a Brandell harvester and washed three times using cold 50 mM Tris-HCl buffer. Filters 
were dried in a 50 °C oven, and radioactivity was measured by liquid scintillation counting with 






CHO-hDOPr cell membranes (as prepared above, 10 μg/well) were incubated for 1 h at 30 °C in 
buffer comprising 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 5 mM MgCl2, 100 mM NaCl, 0.1 
nM [
35
S]GTPγS, and 30 μM GDP (guanosine 5-diphosphate) in a final volume of 200 μL. 
Orthosteric and allosteric ligands were also included, with SNC80 used as the maximal standard 
and assay buffer used to assess basal [
35
S]GTPγS binding. The reaction was terminated by 
filtration through glass microfiber GF/C filters (Whatman) using a Brandell harvester. The filters 
were rinsed, dried, and radioactivity was counted by liquid scintillation counting using EcoLume 
liquid scintillation cocktail (MP Biomedicals) in a Wallac 1450 MicroBeta counter 
(PerkinElmer). 
 
ERK1/2 Phosphorylation Assay 
hDOPr FlpIn CHO cells (CHO-hDOPr) were seeded into 96-well plates at a density of 50 000 
cells/well. After 5–7 h, cells were washed with phosphate buffered saline (PBS) and incubated 
overnight in serum-free DMEM. Initially, time-course experiments were conducted at least twice 
for each ligand to determine the time required to maximally promote ERK1/2 phosphorylation 
via the δ-receptor. Concentration–response experiments were performed for the orthosteric 
ligands in the absence or presence of increasing concentrations of the allosteric modulator at 37 
°C. Stimulation of the cells was terminated by removal of the media and the addition of 100 μL 
of SureFire lysis buffer (PerkinElmer) to each well. The plate was shaken for 5 min at room 
temperature before transferring 5 μL of the lysates to a white 384-well Proxiplate (PerkinElmer). 
Then 8 μL of a 240:1440:7:7 mixture of Surefire activation buffer/Surefire reaction 









For all experiments data were analyzed and EC50 or K i values determined using nonlinear 
regression analysis to fit a logistic equation using GraphPad Prism, version 6 (GraphPad, San 
Diego, CA). pKB and αβ values were determined using the “operational model of allosterism” 




Within this model, E is the pharmacological effect, KA and KB denote the equilibrium binding 
constants for the orthosteric ligand A and the allosteric ligand B at the receptor. The binding 
cooperativity factor α represents the effect of the allosteric ligand on orthosteric agonist binding 
affinity and vice versa. An activation cooperativity factor β denotes the effect the allosteric 
ligand has on orthosteric agonist efficacy. Agonism constants τA and τB represent the intrinsic 
activity of the orthosteric agonist and any intrinsic activity of the allosteric ligand, respectively, 
which is dependent on the cell context and receptor expression level of the cell system and 
intrinsic efficacy of the ligands used. The remaining parameters Em and n denote the maximal 























With the hope of discovering effective analgesics with fewer side effects, attention has 
recently shifted to allosteric modulators of the opioid receptors. In the past two years, the first 
chemotypes of positive or silent allosteric modulators (PAMs or SAMs, respectively) of μ- and 
δ-opioid receptor types have been reported in the literature. During a structure-guided lead 
optimization campaign with μ-PAMs BMS-986121 and BMS-986122 as starting compounds, we 
discovered a new chemotype that was confirmed to display μ-PAM or μ-SAM activity depending 
on the specific substitutions as assessed by endomorphin-1-stimulated β-arrestin2 recruitment 
assays in Chinese Hamster Ovary (CHO)-μ PathHunter cells. The most active μ-PAM of this 
series was analyzed further in competition binding and G-protein activation assays to understand 
its effects on ligand binding and to investigate the nature of its probe dependence. 
 
Introduction 
A prominent member of the G-protein-coupled receptor (GPCR) superfamily, the μ-
opioid receptor is the main pharmacological target for both acute and chronic pain, as well as a 
target for the treatment of alcohol abuse, drug abuse, and addiction disorders (Spetea et al., 2013; 
Pasternak, 2014). Although μ-opioid medications such as morphine and its derivatives remain 
the “gold-standard” for pain management, clinicians are rightly conservative in the  
administration of these drugs, owing to their dangerous adverse effects (e.g., respiratory 
                                                          
4 This research was originally published in the Journal of Chemical Information and Modeling. Bisignano P, Burford 
NT, Shang Y, Marlow B, Livingston KE, Fenton AM, Rockwell K, Budenholzer L, Traynor JR, Gerritz SW, Alt A, 
Filizola M. “Ligand-Based Discovery of a Novel Scaffold for Allosteric Modulation of the mu Opioid Receptor.”J. 
Chem. Inform. and Modeling. 2015 Sep 28;55(9):1836-43 





depression, nausea, tolerance, dependence, and constipation), as well as social and legal issues. 
As a result, the development of new opioid analgesics that are free from side effects represents a 
critically important research objective for 21st century medicine. 
Recent high-resolution structural information on the μ-opioid receptor (Manglik et al., 
2012), as well as novel paradigms of biased agonism (or functional selectivity) and allosterism at 
this receptor (N Burford et al., 2015; Thompson et al., 2015), may offer unprecedented 
opportunities for the discovery of opioid therapeutics with reduced adverse effects. Allosteric 
ligands are defined as binding to regions that are distinct from the site where the endogenous 
ligand binds (defined as the orthosteric binding site). Depending on whether they enhance or 
reduce the affinity and/or efficacy of the orthosteric ligand, they can be classified as positive 
allosteric modulators (PAMs) or negative allosteric modulators (NAMs), respectively. In 
principle, these ligands have several theoretical advantages over traditional orthosteric agonists 
and antagonists. First, because allosteric regions of GPCRs tend to be less evolutionarily 
conserved than orthosteric binding sites, allosteric ligands can attain improved receptor type 
selectivity, which can limit the occurrence of off-target effects (although this does not eliminate 
the possibility of on-target effects). In the case of opioid receptors, development of selective 
opioid drugs has not been a major impediment, and most of the untoward side effects of opioid 
agonists are target-mediated; therefore, this specific advantage of allosteric modulators may have 
limited applicability to opioid receptors. Another important advantage of allosteric modulators is 
that their effect is limited by their cooperativity, and therefore allosteric ligands may hold great 
potential as safer drugs with fewer on-target overdosing risks. This feature may be more 
important in the case of μ-opioid receptors, where safety risks associated with drug overdose are 
a very significant problem. Finally, another major theoretical advantage of PAMs compared to 
orthosteric agonists is that PAMs are likely to maintain the temporal and spatial fidelity of 
signaling in vivo as they only act in the presence of the endogenous ligand. Therefore, PAMs 
might be expected to produce significantly less desensitization and tolerance than direct-acting 
agonists, which continuously activate the receptor until the drug is cleared. Because tolerance 
and dependence produced by direct opioid agonists remain major issues limiting their therapeutic 
utility, this feature of PAMs may have great importance in the case of μ-opioid receptors 
specifically. Similarly, opioid PAMs may be able to avoid some of the on-target side effects 





occurring. For a more thorough review on the potential advantages of opioid PAMs, see Burford 
et al (N Burford et al., 2015). It is important to note that at present these potential advantages of 
opioid PAMs remain purely theoretical, as in vivo effects of opioid PAMs have not yet been 
reported. 
Although several GPCR allosteric modulators have shown preclinical promise in 
neurodegenerative, psychiatric, or neurobehavioral diseases (Nickols et al., 2014), the 
development and validation of drug-like allosteric modulators of the opioid receptors lags 
behind. The first opioid allosteric modulators were identified for the μ-opioid receptor from a 
recent high throughput screening campaign using a β-arrestin2 recruitment assay (Burford et al., 
2013). Specifically, this screen identified two PAMs and two silent allosteric modulators (SAMs) 
of the μ-opioid receptor. While the μ-SAMs exhibited neutral cooperativity with orthosteric 
ligands in spite of their competitive binding at the allosteric site, the two μ-PAMs BMS-986121 





ol]-enkephalin), and morphine in β-arrestin2 recruitment, G-protein activation, and adenylyl 
cyclase (AC) inhibition. Although a few PAMs of the δ-opioid receptor have also been recently 
identified (NT Burford et al., 2014; Burford et al., 2015; Appendix B), additional 
pharmacological tools are needed to investigate further the effect of allosterism on μ-opioid 
receptor signaling, and to test whether μ-opioid receptor PAMs will in fact provide the potential 
therapeutic advantages described above. 
Here, we report the discovery of a new chemotype that, depending on the specific 
substitutions, exhibits μ-PAM or μ-SAM activity as assessed by endomorphin-1-stimulated β-
arrestin2 recruitment assays in Chinese Hamster Ovary (CHO)-μ PathHunter cells. Further 
radioligand binding and G-protein activation assays were performed on the most active μ-PAM 

















Figure C.1: Clustering results of the 1336 analogs of BMS-986121 and BMS-986122 
extracted from eMolecules. The three most populated clusters 2, 4, and 7 included analogs of 






Discovery and Structure–Activity Relationship of a New μ-PAM/SAM Chemotype  
In the hunt for more active allosteric modulators of the μ-opioid receptor, we searched the 
eMolecules database for analogs of the recently identified μ-PAMs BMS-986121 and BMS-
986122 (Burford et al., 2013), including significantly different chemical scaffolds. Clustering of 
the resulting 1336 molecules led to their grouping into 7 clusters (Fig C.1). While cluster 1 
contained 2 elements and clusters 3, 5, and 6 contained 1 element only, clusters 2, 4, and 7 were 
highly populated (see Fig C.1). Specifically, clusters 4 and 7 contained 353 and 660 close 
analogs of BMS-986122 and BMS-986121, respectively, whereas the 318 molecules of cluster 2 
corresponded to a significantly different chemotype (e.g., compare MS1 to BMS-986122 and 
BMS-986121 in Fig C.1). Additional analogs of this new chemotype were retrieved through a 
chemical similarity search to MS1 in both the eMolecules and ZINC databases (see Methods for 
details). 
Twenty-eight of these compounds were purchased for experimental testing, and the 
results of a primary screen based on a PathHunter β-arrestin recruitment assay are shown in 
Table C.1. While none of these compounds displayed agonist activity alone, all of them but two 
(i.e, MS27 and MS28) displayed PAM or SAM activity in the presence of low concentration of 
endomorphin-1, a μ-opioid receptor agonist. No NAM activity (inhibition of an EC50 
concentration of endomorphin-1) was detected (data not shown). As shown in Table C.1, most 
PAMs had low potencies in the single and low double digit μM range with efficacy (Ymax) values 
below 40% compared to endomorphin-1 maximal stimulation. The exceptions were MS1, MS2, 
and MS3, which displayed a Ymax value larger than 44% in PAM mode with EC50 values in the 
single digit μM range. The Ymax activity gives an indication of the degree of cooperativity 
exhibited by these compounds suggesting that MS1, MS2, and MS3 have greater cooperativity 
compared to the other MS compounds tested. The remaining 12 compounds are either SAMs or 
weak PAMs judging from their reduced PAM activity. As expected, SAMs behave as 
competitive antagonists at the allosteric site, having little to no allosteric efficacy themselves but 
inhibiting the binding of a higher efficacy PAM to the allosteric binding site. 
For the most efficacious MS1–MS3 compounds, we assessed the KB and α values of 
cooperativity by performing full concentration–response curves of the orthosteric ligand 





Table C.1: Structure Activity Relationship of a New μ-PAM/SAM Chemotype in a 
PathHunter β-Arrestin Recruitment Assay 
 
 
sample ID R1 R2 R3 EC50, μMa PAM mode Ymax % activity 
MS1 4-Br H 3-Cl,4-MeO 6.5 85.1 PAM 
MS2 4-Br H 4-PhO 6.2 109.2 PAM 
MS3 4-Cl 3-Me 3-Cl,4-MeO 5.7 44.6 PAM 
MS4 4-Br H 3-Cl 3.9 32.4 PAM 
MS5 3-Me,4-MeO H 3-Cl,4-MeO 4.7 21 PAM 
MS6 4-Me H 3-Cl,4-MeO 5.3 21.8 PAM 
MS7 4-Br H 4-MeO 5.4 22.1 PAM 
MS8 4-Cl H 4-EtO 6.4 31.8 PAM 
MS9 4-F H 3-Cl,4-MeO 7 24 PAM 
MS10 4-Cl H 4-MeO 8.9 26.4 PAM 
MS11 4-OMe H 3-Br 14.5 33 PAM 
MS12 4-Me 4-Me 3-Cl,4-MeO 21.9 10.3 PAM 
MS13 H H 3-Br > 30 20 PAM 
MS14 H H 3-Cl,4-MeO 76.1 28.4 PAM 
MS15 H 2,4-di-Cl 3-Cl,4-MeO 6a NAb SAM 
MS16 4-Cl H 3-MeO 6.5a NAb SAM 
MS17 H 4-F 3-Cl,4-MeO 6.9a NAb SAM 
MS18 4-Me H 4-MeO 14.4a NAb SAM 
MS19 H 4-Me 3-Cl 16.2a NAb SAM 
MS20 H 4-Cl 4-MeO 16.6a NAb SAM 
MS21 H 4-Cl 3-Me 21.2a NAb SAM 
MS22 H 4-Br 4-MeO 22.7a NAb SAM 
MS23 4-Cl H 3-Cl,6-MeO 23.5a NAb SAM 
MS24 H 4-Cl 3-Cl,4-MeO 24.2a NAb SAM 
MS25 H 4-Cl 2-MeO,5-Me 27.7a NAb SAM 
MS26 4-Cl H 2-MeO,5-Me >30a NAb SAM 
MS27 H 4-Me 3-Cl,4-MeO  NAb inactive 
MS28 4-MeO H 2-CF3  NAb inactive 
      
       
a
SAM compounds were detected by incubating a serial dilution of the compound with cells in the 
presence of an EC20 of endomorphin-1 plus an EC80 of BMS-986121 PAM. Under these 
conditions, the SAM compound acts as an antagonist of PAM binding, reducing PAM activity. 
Control PAMs: BMS-986121 (EC50 2.2 μM, Ymax 86%) and BMS-986122 (EC50 16.2 μM, Ymax 
108%). 
b














Figure C.2: Allosteric EC50 shifts of endomorphin-1-stimulated β-arrestin recruitment in 
CHO-μ PathHunter cells in the presence of increasing concentrations of PAM: MS1 (A), 
MS2 (B), MS3 (C), and BMS-986121 (D). KB = calculated binding affinity of PAM to free 







arrestin recruitment assay (see Fig C.2). The results confirm the ability of these molecules to act 
as PAMs with KB and α cooperativity values slightly weaker, but comparable, to those observed 
for the previously reported BMS-986121 (Burford et al., 2013). 
The allosteric compound with the highest α value of cooperativity, MS1, was analyzed 
further in competition binding and G-protein activation assays to understand its effects on ligand  





H-DPN) was performed in cell membranes prepared from 
C6 glioma cells stably expressing rat μ-opioid receptor (Fig C.3). The Kd of 
3
H-DPN was 
unchanged in the presence of 10 μM MS1 (Kd with veh = 0.25 ± 0.10 nM; Kd with MS1 = 0.35 ± 
0.15 nM, data not shown). In contrast, MS1 was able to enhance the affinity of the agonist l-
methadone to bind μ-opioid receptor (Fig C.3A). The Ki of l-methadone in the absence or 
presence of 10 μM MS1 was enhanced by 7-fold (Ki in the presence of vehicle = 1177 ± 329 nM, 
Ki in the presence of MS1 = 161 ± 38 nM; p = 0.04). Notably, MS1 exhibited strong probe 
dependence in that it failed to alter the affinity of the agonists DAMGO, endomorphin-1, and 
morphine to bind μ-opioid receptor (Fig C.3B–D). 
In addition to binding, the ability of MS1 to alter the activity of μ-opioid receptor 
agonists was investigated using GTPγ
35
S binding in C6-μ cell membranes. Although MS1 (up to 
30 μM) failed to have any activity alone (data not shown), the presence of 10 μM MS1 enhanced 
the potency of l-methadone to activate G-protein by over 4-fold (Fig C.4A) but had no effect on 
the degree of maximal stimulation. Again, MS1 showed strong probe dependence and failed to 
alter the potency or maximal stimulation of DAMGO and endomorphin-1 to activate G-protein 
(Fig C.4B,C, respectively). However, MS1 did enhance the maximal activation by morphine to 
that of a full agonist while having no effect of morphine’s potency (Fig C.4D). The lack of effect 
of MS1 on endormorphin-1 stimulation of GTPγ
35
S binding was unexpected in view of the 
enhancement of endomorphin-1 recruitment of β-arrestin, but is in line with reports that the 
endomorphins are arrestin-biased agonists (McPherson et al., 2010; Rivero et al., 2012). 
 
Molecular Descriptors of μ-PAMs/SAM and Their Statistical Analysis  
We calculated fifty-two physicochemical properties for each of the 14 μ-PAMs and 12 μ-
SAMs reported in Table C.1. The numerical values of those descriptors that displayed nonzero  












Figure C.3: Effects of MS1 on the binding of various orthosteric μ-opioid receptor agonists. 
Displacement of 
3
H-DPN by l-methadone (A), DAMGO (B), endomorphin-1 (C), and morphine 
(D) was measured in the presence of vehicle (■) or 10 μM MS1 (□) using C6-μ cell membranes. 











Figure C.4: Effects of MS1 on the potency of various orthosteric μ-opioid receptor agonists 
to activate G-protein. Agonist-stimulated GTPγ
35
S binding was measured for l-methadone (A), 
DAMGO (B), endomorphin-1 (C), and morphine (D) in the presence of vehicle (■) or 10 μM 






combinations of up to 5 descriptors, Bayesian logistical regression analysis identified four 
descriptors that could best separate between μ-PAMs and μ-SAMs as assessed experimentally. 
Specifically, the best linear model according to AIC resulted from using the following four 
properties: the predicted central nervous system activity (CNS), the conformation-independent 
predicted aqueous solubility (CIQPlogS), the Parameterized Model Number 3 (PM3)-calculated 
electron affinity (EA.eV.), and the van der Waals surface area of polar nitrogen and oxygen 
atoms and carbonyl carbon atoms (PSA). Using this model, only four (MS12, MS13, MS14, and 
MS23) out of twenty-six compounds could not be confidently assigned the same μ-PAM or μ-
SAM activity inferred from experiments owing to their predicted effect value below or above an 
arbitrary 0.5 cutoff, respectively. The remaining 11 PAMs exhibited calculated average values of 
−0.82 ± 0.40, −7.12 ± 0.75, +1.07 ± 0.14, and +76.51 ± 3.62 for CNS, CIQPlogS, PM3, and 
EA.eV., respectively, whereas the remaining 11 SAMs had corresponding values of −0.91 ± 
0.54, −6.54 ± 0.51, +0.94 ± 0.08, and +74.04 ± 2.78. 
 
Common 3D-Pharmacophore of μ-PAMs  
We built a ligand-based 3D pharmacophore model to elaborate further on the molecular 
and structural determinants that differentiate μ-PAMs from μ-SAMs. The best 3D 
pharmacophore model of this kind (Fig C.5) includes: (i) two H-bond acceptors (i.e., the two 
oxygen atoms of the sulfur dioxide group) labeled A1 and A2 in the figure, (ii) one halogen 
substituent or hydrophobic group (i.e., R1 = Br, Cl, Me; see Table C.1) labeled Halo/Hyd in the 
figure, and (iii) the three aromatic rings R1–R3 related by the distances and angles reported in 
Tables S6 and S7 (see online), respectively. Using this model, all μ-PAMs (but MS13) could be 
separated from all μ-SAMs (but MS16 and MS23) according to an arbitrary cutoff of 1.7 for the 
pharmacophore alignment fitness scores. In the case of MS13, an optimal alignment of this 
compound to the best pharmacophore model could not be found because of competition in the 
alignment between the hydrophobic substituent on ring 3 (R3) and that of ring 1 (R1). Although 
MS16 and MS23 could indeed be successfully aligned to the pharmacophore model, the R3 
methoxy substitution at the ortho- position might interfere with the position of the ligand amide 
atoms although it is also possible that the R3 methoxy substitution at ortho- or meta- positions 













Figure C.5: Ligand-based 3D pharmacophore model built from μ-PAMs shown in Table 
C.1. The best 3D pharmacophore model that separates μ-PAMs and μ-SAMs includes two H-
bond acceptors (i.e., the two oxygen atoms of the sulfur dioxide group), one halogen substituent 
or hydrophobic group (i.e., R1 = Br, Cl, Me; see Table 1), and three aromatic rings related by 
specific distances and angles listed in Tables S6 and S7 (see online). 









Recently, attention has shifted to allosteric rather than orthosteric opioid ligands as a 
means of potentially providing effective pain relief that is free from debilitating adverse effects  
(Thompson et al., 2015). These allosteric modulators are expected to be receptor type selective, 
and to act by enhancing the antinociceptive activity of endogenous opioid ligands. Therefore, μ- 
opioid receptor PAMs may have fewer on-target side effects and overdosing risks, and may 
produce less tolerance and dependence than currently used opioid agonists. It has been suggested 
that opioid ligands that bias receptor signaling toward the G-protein mediated pathway instead of 
β-arrestin2 may be therapeutically beneficial (Raehal et al., 2011). Whether caused by the 
receptor conformational plasticity, allosterism, or dimerization/oligomerization, this G-protein-
biased agonism has been suggested to remove the on-target side effects such as drug tolerance 
associated with the μ-opioid receptor internalization (e.g., see (Thompson et al., 2015)). The 
current findings with endomorphin-1 suggest that the μ-opioid receptor PAM MS1 may promote 
signaling bias in the opposite direction (favoring β-arrestin versus G-protein activation), at least 
with this peptide. Further studies are needed in order to understand more fully both the signaling 
bias and probe-dependence of this PAM, and to determine whether these properties can be 
altered through modifications to the chemical structure. 
The only two known μ-PAMs at the time of this work, i.e., BMS-986121 and BMS-
986122, are limited in their ease of synthesis. Not only is the new allosteric modulator 
chemotype we identified easier to derivatize by synthetic chemistry, and offering an additional 
point of diversity for structure–activity relationship studies compared to previously published 
compounds, but the new scaffold increases the chemical diversity of known ligands for the 
allosteric site of the μ-opioid receptor. However, undesirable “off-target” effects may still be 
present for this scaffold, and must be evaluated before further development. 
In competition binding and G-protein activation assays, MS1 displayed marked probe 
dependence. Indeed, the largest effects of MS1 were seen with l-methadone. The prototype μ-
PAM BMS-986122 also showed the highest levels of cooperativity with methadone and its 





probe dependence may be reflective of a similar mechanism of action and/or mode of binding. In 
addition, MS1 enhanced the maximal activation of the partial agonist morphine to activate G-
protein. This again fits with the probe dependence of BMS-986122 in which the efficacy of 
partial agonists was increased. The mechanism of BMS-986122 action was found to be through 
allosteric disruption of sodium ion binding (Chapter 3; Livingston and Traynor, 2014) and it 
would be interesting to determine if this new chemotype also functions in a similar manner. 
Cheminformatics analysis of the set of newly identified μ-PAMs and μ-SAMs suggested 
that physicochemical properties such as the predicted CNS, the CIQPlogS, the EA.eV., and the 
PSA may be used as searching criteria to identify additional compounds with potential PAM 
activity at μ-opioid receptors. Specifically, our best statistical model shows that μ-PAMs have 
higher predicted values of central nervous system activity, PM3-calculated electron affinity, and 
van der Waals surface area of polar nitrogen and oxygen atoms and carbonyl carbon atoms, but 
lower calculated values of conformation-independent predicted aqueous solubility, compared to 
μ-SAMs. However, it must be kept in mind that the dataset we used is limited in number and no 
thorough cross-validation of the presented statistical models could be performed. Although the 
same limitation exists for the predicted common 3D pharmacophore model of μ-PAMs vs μ-
SAMs, the suggested model can be used as an initial criterion to either design more highly potent 
derivatives of the newly identified μ-PAM or to search for completely different chemotypes that 
retain the same pharmacophore features. These inferences can and will eventually be combined 
with structural studies using the crystal structure of the active μ-opioid receptor that has appeared 
in the literature during review of this paper (Huang et al., 2015). In the meantime, additional 
ligand-based studies are ongoing in our laboratories to optimize the newly identified chemotype 
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